Main publications since 2019

‍

2023

‍

1. Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study. Pierre-Edouard Debureaux, Nathalie Forgeard, Dikelele Elessa, Stephanie Harel, Laurent Frenzel, Bruno Royer, Alexis Talbot, Sylvain Choquet, Frederic Davi, Florence Nguyen Khac, Wendy Cuccuini, Morgane Cheminant, Clotide Bravetti, Gregory Lazarian, Sophie Kaltenbach, Olivier Hermine, Damien Roos-Weil, Marion Espeli, Karl Balabanian, and Bertrand Arnulf.
Haematologica. 2023 Aug 17. doi: 10.3324/haematol.2023.283141. Free PMC article

2. Cohen, E.; Bozonnat, A.; Battistella, M.; Calvani, J.; Vignon-Pennamen, M.-D.; Rivet, J.; Moins-Teisserenc, H.; Ta, V.-A.; Ram-Wolff, C.; Bouaziz, J.-D.; Mahevas, T.; Bagot, M.; Mourah, S.; Louveau, B.; Sicre de Fontbrune, F.; Peffault de Latour, R.; de Masson, A.; Battesti, G. Severe Relapses of Cutaneous T-Cell Lymphoma after Treatment of Chronic Graft-versus-Host Disease with Ruxolitinib. J Eur Acad Dermatol Venereol 2023.

3. de Masson, A.; Beylot-Barry, M.; Ram-Wolff, C.; Mear, J.-B.; Dalle, S.; d’Incan, M.; Ingen-Housz-Oro, S.; Orvain, C.; Abraham, J.; Dereure, O.; Charbonnier, A.; Cornillon, J.; Longvert, C.; Barete, S.; Boulinguez, S.; Wierzbicka-Hainaut, E.; Aubin, F.; Rubio, M.-T.; Bernard, M.; Schmidt-Tanguy, A.; Houot, R.; Pham-Ledard, A.; Michonneau, D.; Brice, P.; Labussière-Wallet, H.; Bouaziz, J.-D.; Grange, F.; Moins-Teisserenc, H.; Jondeau, K.; Michel, L.; Mourah, S.; Battistella, M.; Daguindau, E.; Loschi, M.; Picard, A.; Franck, N.; Maillard, N.; Huynh, A.; Nguyen, S.; Marçais, A.; Chaby, G.; Ceballos, P.; Le Corre, Y.; Maury, S.; Bay, J.-O.; Adamski, H.; Bachy, E.; Forcade, E.; Socié, G.; Bagot, M.; Chevret, S.; Peffault de Latour, R. Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score Matched Controlled Prospective Study. Lancet 2023, 401 (10392), 1941–1950. IF:198,

‍

4.Ranjbaryan, M.; Calvani, J.; Louveau, B.; Cuccuini, W.; Battesti, G.; Bozonnat, A.; Moins-Teisserenc, H.; Michonneau, D.; Bagot, M.; Ram-Wolff, C.; Dobos, G.; Mourah, S.; Battistella, M.; de Masson, A. Graft-versus-Lymphoma Effect in Skin after Allogeneic Hematopoietic Stem Cell Transplantation for Sézary Syndrome. Eur J Dermatol 2023, 33 (4), 439–440.

‍

2022

1. Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial. Dulucq S, Nicolini FE, Rea D, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Coiteux V, Lenain P, Rigal-Huguet F, Liu J, Guerci-Bresler A, Legros L, Ianotto JC, Gardembas M, Turlure P, Dubruille V, Rousselot P, Martiniuc J, Jardel H, Johnson-Ansah H, Joly B, Henni T, Cayssials E, Zunic P, Berger MG, Villemagne B, Robbesyn F, Morisset S, Mahon FX, Etienne G.Haematologica. 2022 Dec 1;107(12):2859-2869. doi: 10.3324/haematol.2022.280811.PMID: 35615931 Free PMC article. Clinical Trial.

2. Battesti, G.; Ram-Wolff, C.; Dobos, G.; Aubin, F.; Algros, M.-P.; Guenova, E.; Joly, P.; Courville, P.; Mourah, S.; Cayuela, J.-M.; Bouaziz, J.-D.; Moins-Teisserenc, H.; Battistella, M.; Vignon-Pennamen, M.-D.; Rivet, J.; Bagot, M.; de Masson, A. Granulomatous Slack Skin: Clinical Characteristics, Prognosis and Response to Therapy. A Study from the Cutaneous Lymphoma French Study Group. Br J Dermatol 2022, 187 (5), 790-793.

3. Bontoux, C.; de Masson, A.; Thonnart, N.; Ram-Wolff, C.; Caraguel, F.; Batista, L.; Carpentier, S.; Moins-Teisserenc, H.; Rivet, J.; Vignon-Pennamen, M.-D.; Marie-Cardine, A.; Bagot, M.; Battistella, M. Large-Cell Transformation Is an Independent Poor Prognostic Factor in Sézary Syndrome: Analysis of 117 Cases. Br J Dermatol 2022, 187 (5), 815–817.

‍

4. Galadari, A.; Ram-Wolff, C.; Al Hage, J.; Battistella, M.; Vignon-Pennamen, M. D.; Rivet, J.; Cayuela, J. M.; Gabison, G.; Moins-Teisserenc, H.; Mourah, S.; Ingen-Housz-Oro, S.; Le Corre, Y.; Bagot, M.; de Masson, A. Cutaneous Gamma Delta T-Cell Lymphoma with Indolent Evolution: A Series of Five Cases. J Eur Acad Dermatol Venereol 2022, 36 (9), e715–e717.

‍

5. Laurent, C.; Lefèvre, G.; Kahn, J.-E.; Staumont-Salle, D.; Felten, R.; Puget, M.; Moulinet, T.; Machelart, I.; Launay, D.; Charvet, E.; Bouaziz, J. D.; Jachiet, M.; Espitia, A.; Mahr, A.; Le Clech, C.; Malphettes, M.; Morice, C.; Mourah, S.; Moins-Teisserenc, H.; Lifermann, F.; Soulier-Guérin, K.; Villate, A.; Baillou, C.; Grados, A.; Robbins, A.; Abisror, N.; Bagot, M.; Boutboul, D.; Panel, K.; Vignon-Pennamen, M.-D.; Rivet, J.; Battistella, M.; Groh, M.; de Masson, A. Cutaneous Manifestations of Lymphoid-Variant Hypereosinophilic Syndrome. Br J Dermatol 2022, 187 (6), 1011–1013.

6. Lazaridou, I.; Calvani, J.; Annabi, E.; Moins-Teisserenc, H.; Ta, V. A.; Rivet, J.; Ram-Wolff, C.; Dumont, M.; Mahevas, T.; Vignon-Pennamen, M.-D.; Mourah, S.; Bouaziz, J.-D.; Louveau, B.; Bagot, M.; Battistella, M.; de Masson, A. Toxic Epidermal Necrolysis Possibly Associated with Mogamulizumab in a Patient with Sézary Syndrome. J Eur Acad Dermatol Venereol 2023, 37 (6), e715–e717.

7. Ta, V. A.; Battistella, M.; Zhao, L. P.; Dobos, G.; Ram-Wolff, C.; Madelaine, I.; Bories, J.-C.; Tournilhac, O.; Rouanet, J.; Veyrat-Masson, R.; Bouaziz, J.-D.; Marie-Cardine, A.; Bagot, M.; Bensussan, A.; Moins-Teisserenc, H.; De Masson, A. CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas. J Invest Dermatol 2023, 143 (7), 1329-1332.e3.

8. Wang, J., Ram‐Wolff, C., Dobos, G., Al Hage, J., Grange, F., Rivet, J., Vignon‐Pennamen, M., Moins‐Teisserenc, H., Boisson, M., Moegle, C., Sadoux, A., Mourah, S., Battistella, M., Bagot, M., & de Masson, A. (2022). Head and Neck granulomatous Rash Associated with Mogamulizumab Mimicking Mycosis Fungoides. British Journal of Dermatology.

9. Giustiniani J, Dobos G, Moins-Teisserenc H, Eustaquio T, Battistella M, Ortonne N, Ram-Wolff C, Bouaziz JD, Marie-Cardine A, Mourah S, Bagot M, Kupper TS, Clark RA, Bensussan A, de Masson A. (2022) : CCR8 is a new therapeutic target in cutaneous T-cell lymphomas. Blood Advances, 6 (11), 3507-3512.

10. Laurent C, Lefevre G, Kahn JE, Staumont-Salle D, Felten R, Puget M, Moulinet T, Machelart I, Launay D, Charvet E, Bouaziz JD, Jachiet M, Espitia A, Mahr A, Le Clech C, Malphettes M, Morice C, Mourah S, Moins-Teisserenc H, Lifermann F, Soulier-Guerin K, Villate A, Baillou C, Grados A, Robbins A, Abisror N, Bagot M, Boutboul D, Panel K, Vignon-Pennamen MD, Rivet J, Battistella M, Groh M, de Masson A. (2022) : Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome. British Journal of Dermatology.

11. Galadari A, Ram-Wolff C, Al Hage J, Battistella M, Vignon-Pennamen MD, Rivet J, Cayuela JM, Gabison G, Moins-Teisserenc H, Mourah S, Ingen-Housz-Oro S, Le Corre Y, Bagot M, de Masson A. (2022) : Cutaneous gamma delta T-Cell lymphoma with indolent evolution: a series of five cases. Journal of the European Academy of Dermatology and Venereology, 36(9), 715-717.

‍

12. M. Roelens, A. De Masson, A. Andrillon, C. Ram-Wolff, L. Biard, M. Boisson, S. Mourah, M. Battistella, A. Toubert, M. Bagot, H. Moins-Teisserenc: Mogamulizumab induces long term immune restoration and reshapes tumor heterogeneity in Sézary syndrome, (2022), doi:10.1111/bjd.21018.

‍

13. Wang, J., Ram‐Wolff, C., Dobos, G., Al Hage, J., Grange, F., Rivet, J., Vignon‐Pennamen, M., Moins‐Teisserenc, H., Boisson, M., Moegle, C., Sadoux, A., Mourah, S., Battistella, M., Bagot, M., & de Masson, A. (2022). Head and Neck granulomatous Rash Associated with Mogamulizumab Mimicking Mycosis Fungoides. British Journal of Dermatology.

‍

14. Battesti, G., Ram‐Wolff, C., Dobos, G., Aubin, F., Algros, M., Guenova, E., Joly, P., Courville, P., Mourah, S., Cayuela, J., Bouaziz, J., Moins‐Teisserenc, H., Battistella, M., Vignon‐Pennamen, M., Rivet, J., Bagot, M., & de Masson, A. (2022). Granulomatous slack skin: clinical characteristics, prognosis, and response to therapy. A study from the Cutaneous Lymphoma French Study Group. British Journal of Dermatology.

15. J. Wang, C. Ram‐Wolff, G. Dobos, J. Al Hage, F. Grange, J. Rivet, M. Vignon‐Pennamen, H. Moins‐Teisserenc, M. Boisson, C. Moegle, A. Sadoux, S. Mourah, M. Battistella, M. Bagot, A. de Masson : Head and Neck granulomatous Rash Associated with Mogamulizumab Mimicking Mycosis Fungoides, Br. J. Dermatol. (2022), doi:10.1111/bjd.21030

‍

16. M. H. Vermeer, H. Moins‐Teisserenc, M. Bagot, P. Quaglino, S. Whittaker: Flow cytometry for the assessment of blood tumour burden in cutaneous T‐cell lymphoma: towards a standardised approach, Br. J. Dermatol. (2022), doi:10.1111/bjd.21053.

‍

17. N. Leupin, P. L. Zinzani, F. Morschhauser, S. Dalle, M. Maerevoet, J. Michot, V. Ribrag, F. Offner, M. Beylot‐Barry, H. Moins‐Teisserenc, K. Zwaenepoel, K. Winne, M. Battistella, A. Hultberg, D. Gandini, M. Moshir, J. Jacobs, T. Delahaye, A. Khan, P. Zabrocki, K. Silence, L. Rompaey, C. Borg, G. Motta, F. Melle, A. Calleri, P. Pauwels, H. Haard, S. Pileri, M. Bagot: Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma, Cancer (2021), doi:10.1002/cncr.34005.

‍

18. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. GenoMed4All consortium. Lancet Haematol. 2022 Nov 24:S2352-3026(22)00323-4. doi: 10.1016/S2352-3026(22)00323-4. Online ahead of print.PMID: 36436542

19. Fusion Gene Detection and Quantification by Asymmetric Capture Sequencing (aCAP-Seq). Gricourt G, Tran Quang V, Cayuela JM, Boudali E, Tarfi S, Barathon Q, Daveau R, Joy C, Wagner-Ballon O, Bories D, Pautas C, Maury S, Rea D, Roy L, Sloma I.J Mol Diagn. 2022 Nov;24(11):1113-1127. doi: 10.1016/j.jmoldx.2022.07.004. Epub 2022 Aug 10.PMID: 35963522 Free article.

20. Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission. Dulucq S, Hayette S, Cayuela JM, Bauduer F, Chabane K, Chevallier P, Cony-Makhoul P, Flandrin-Gresta P, Jeune CL, Bris YL, Legros L, Maisonneuve H, Roy L, Mahon FX, Sloma I, Rea D, Nicolini FE.Haematologica. 2022 Dec 1;107(12):2944-2949. doi: 10.3324/haematol.2022.280740.PMID: 35924576 Free PMC article. No abstract available.

21. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML. Mekinian A, Zhao LP, Chevret S, Desseaux K, Pascal L, Comont T, Maria A, Peterlin P, Terriou L, D'Aveni Piney M, Gourin MP, Vey N, Rauzy OB, Grobost V, Bezanahary H, Dimicoli-Salazar S, Banos A, Wickenhauser S, De Renzis B, Durot E, Natarajan-Amé S, Voillat L, Chermat F, Lemaire K, Jachiet V, Himberlin C, Thépot S, Diaz JMT, Frenzel L, Gyan E, Denis G, Hirsch P, Kosmider O, Ades L, Fain O, Fenaux P.Leukemia. 2022 Nov;36(11):2739-2742. doi: 10.1038/s41375-022-01698-8. Epub 2022 Sep 14.PMID: 36104395 Clinical Trial.

22. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Kantarjian HM, Jabbour E, Deininger M, Abruzzese E, Apperley J, Cortes J, Chuah C, DeAngelo DJ, DiPersio J, Hochhaus A, Lipton J, Nicolini FE, Pinilla-Ibarz J, Rea D, Rosti G, Rousselot P, Shah NP, Talpaz M, Srivastava S, Ren X, Mauro M.Am J Hematol. 2022 Nov;97(11):1419-1426. doi: 10.1002/ajh.26686. Epub 2022 Aug 30.PMID: 36054756

23. CXCR2 intrinsically drives the maturation and function of neutrophils in mice. Delobel P, Ginter B, Rubio E, Balabanian K, Lazennec G.Front Immunol. 2022 Oct 13;13:1005551. doi: 10.3389/fimmu.2022.1005551. eCollection 2022.PMID: 36311783

24. Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study). Roy L, Chomel JC, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, Charbonnier A, Dubruille V, Huguet F, Johnson-Ansah H, Lenain P, Ame S, Etienne G, Nicolini FE, Rea D, Cony-Makhoul P, Courby S, Ianotto JC, Legros L, Machet A, Coiteux V, Hermet E, Cayssials E, Bouchet S, Mahon FX, Rousselot P, Guilhot F; French CML Group (FiLMC).Br J Haematol. 2022 Oct 10. doi: 10.1111/bjh.18486. Online ahead of print.PMID: 36214090

25. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases. Jachiet V, Ricard L, Hirsch P, Malard F, Pascal L, Beyne-Rauzy O, Peterlin P, Maria ATJ, Vey N, D'Aveni M, Gourin MP, Dimicoli-Salazar S, Banos A, Wickenhauser S, Terriou L, De Renzis B, Durot E, Natarajan-Ame S, Vekhoff A, Voillat L, Park S, Vinit J, Dieval C, Dellal A, Grobost V, Willems L, Rossignol J, Solary E, Kosmider O, Dulphy N, Zhao LP, Adès L, Fenaux P, Fain O, Mohty M, Gaugler B, Mekinian A; MINHEMON: French Network of dysimmune disorders associated with hemopathies.Clin Exp Med. 2022 Aug 11. doi: 10.1007/s10238-022-00866-5. Online ahead of print.PMID: 35953763

26. Metagenomic next-generation sequencing restores the diagnosis of a rare infectious complication of B cell depletion. Garzaro M, Zhao LP, De Castro N, Mercier-Delarue S, Camelena F, Pereyre S, Gardette M, Berçot B, Malphettes M, Bébéar C, Bouaziz JD, Le Goff J, Galicier L, Salmona M.Eur J Clin Microbiol Infect Dis. 2022 Oct;41(10):1269-1273. doi: 10.1007/s10096-022-04484-7. Epub 2022 Aug 24.PMID: 36001207

27. Clinical and Hematologic Effects of Endotoxin in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome Model Mice. Majumdar S, Gao JL, Pontejo SM, Balabanian K, Bachelerie F, Murphy PM.Immunohorizons. 2022 Jul 26;6(7):543-558. doi: 10.4049/immunohorizons.2200042.PMID: 35882421

28. Editorial: Innate Anti-Tumor Immune Responses in Solid and Hematological Malignancies: From Basic Research to Clinical Applications. Chretien AS, Dulphy N, Marcenaro E.Front Immunol. 2022 Jun 16;13:957119. doi: 10.3389/fimmu.2022.957119. eCollection 2022.PMID: 35784307

29. Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes. Rethacker L, Boy M, Bisio V, Roussin F, Denizeau J, Vincent-Salomon A, Borcoman E, Sedlik C, Piaggio E, Toubert A, Dulphy N, Caignard A.Oncoimmunology. 2022 Mar 30;11(1):2057396. doi: 10.1080/2162402X.2022.2057396. eCollection 2022.PMID: 35371620

30. Clinical, pathological, and molecular features of myelodysplasia cutis. Delaleu J, Kim R, Zhao LP, de Masson A, Vignon-Pennamen MD, Cassius C, Ram-Wolff C, Bagot M, Clappier E, Adès L, Sebert M, Bouaziz JD, Fenaux P, Battistella M.Blood. 2022 Feb 24;139(8):1251-1253. doi: 10.1182/blood.2021013967.PMID: 34788403

31. Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation. Houde N, Beuret L, Bonaud A, Fortier-Beaulieu SP, Truchon-Landry K, Aoidi R, Pic É, Alouche N, Rondeau V, Schlecht-Louf G, Balabanian K, Espéli M*, Charron J*.Cell Rep. 2022 Jan 11;38(2):110223. doi: 10.1016/j.celrep.2021.110223.PMID: 35021072 *co-senior authors

32. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. Réa D, Hughes TP.Crit Rev Oncol Hematol. 2022 Mar;171:103580. doi: 10.1016/j.critrevonc.2022.103580. Epub 2022 Jan 10.PMID: 35021069 Free article. Review.

3. Single-cell resolution of plasma cell fate programming in health and disease. Delaloy C, Schuh W, Jäck HM, Bonaud A, Espéli M.Eur J Immunol. 2022 Jan;52(1):10-23. doi: 10.1002/eji.202149216. Epub 2021 Dec 17.PMID: 34694625

2021

H. Moins-Teisserenc, D. J. Cordeiro, V. Audigier, Q. Ressaire, M. Benyamina, J. Lambert, G. Maki, L. Homyrda, A. Toubert, M. Legrand: Severe Altered Immune Status After Burn Injury Is Associated With Bacterial Infection and Septic Shock, Front. Immunol. 12 (2021), doi:10.3389/fimmu.2021.586195. IF:7,5
L. Rethacker, M. Roelens, C. Bejar, E. Maubec, H. Moins-Teisserenc, A. Caignard: Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy, Cancers (Basel). 13, 1446 (2021).
A. de Masson, D. Darbord, G. Dobos, M. Boisson, M. Roelens, C. Ram-Wolff, C. Cassius, H. Le Buanec, P. de la Grange, F. Jouenne, B. Louveau, A. Sadoux, J.-D. Bouaziz, A. Marie-Cardine, M. Bagot, H. Moins Teisserenc, S. Mourah, M. Battistella : Macrophage-derived CXCL9 and CXCL11, T-cell skin homing and disease control in mogamulizumab-treated CTCL patients, Blood (2021), doi:10.1182/blood.2021013341.
Zimmermann, M. Boisson, C. Ram‐Wolff, A. Sadoux, B. Louveau, M. ‐D. Vignon‐Pennamen, J. Rivet, J. ‐M. Cayuela, G. Dobos, H. Moins‐Teisserenc, M. Roelens, A. Gruber, C. Lebbé, M. Bagot, M. Battistella, S. Mourah, A. Masson : Diagnostic performance of high‐throughput sequencing of the T‐cell receptor beta gene for the diagnosis of cutaneous T‐cell lymphoma, Br. J. Dermatol. 185, 679–680 (2021).
J. Wang, A. de Masson, C. Ram-Wolff, G. Dobos, J. Al Hage, J. Rivet, M.-D. Vignon-Pennamen, H. Moins-Teisserenc, M. Boisson, A. Sadoux, S. Mourah, M. Battistella, M. Bagot : Granulomatous rash associated with mogamulizumab mimicking mycosis fungoides: a case series, Eur. J. Cancer 156, S49 (2021).
Bontoux, A. De Masson, C. Ram-Wolff, F. Caraguel, L. Batista, H. Moins-Teisserenc, A. Marie-Cardine, M. Bagot, M. Battistella : Large cell transformation is an independent prognostic factor in Sézary syndrome: a retrospective analysis of 117 cases, Eur. J. Cancer 156, S25 (2021).
Y. H. Kim, M. Khodadoust, A. de Masson, H. Moins-Teisserenc, T. Ito, K. Dwyer, F. Herr, M. Bagot: Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study, Eur. J. Cancer 156, S48–S49 (2021).
G. Dobos, M. Miladi, M. Roelens, C. Ram-Wolff, A. de Masson, L. Michel, M. Battistella, S. Mourah, A. Bensussan, H. Moins-Teisserenc, M. Bagot : Quantifying response to various treatments using the revisited blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker, Eur. J. Cancer 156, S6–S7 (2021).

9. Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies. Mancini SJC*, Balabanian K*, Corre I*, Gavard J*, Lazennec G*, Le Bousse-Kerdilès MC*, Louache F*, Maguer-Satta V*, Mazure NM*, Mechta-Grigoriou F*, Peyron JF*, Trichet V*, Herault O.Front Immunol. 2021 Nov 10;12:766275. doi: 10.3389/fimmu.2021.766275. eCollection 2021.PMID: 34858421 *co-first authors

10. Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms. Marcault C, Zhao LP, Maslah N, Verger E, Daltro de Oliveira R, Soret-Dulphy J, Cazaux M, Gauthier N, Roux B, Clappier E, Parquet N, Dosquet C, Réa D, Zini JM, Vainchenker W, Raffoux E, Giraudier S, Kiladjian JJ, Cassinat B, Benajiba L.Blood. 2021 Nov 25;138(21):2142-2148. doi: 10.1182/blood.2020010402.PMID: 33945619

11. The long non-coding RNA CDK6-AS1 overexpression impacts on acute myeloid leukemia differentiation and mitochondrial dynamics. Porcù E*, Benetton M*, Bisio V*, Da Ros A, Tregnago C, Borella G, Zanon C, Bordi M, Germano G, Manni S, Campello S, Rao DS, Locatelli F, Pigazzi M.iScience. 2021 Oct 26;24(11):103350. doi: 10.1016/j.isci.2021.103350. eCollection 2021 Nov 19.PMID: 34816103 *co-first authors

12. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, García-Gutiérrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bédoucha V, Hochhaus A.Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984.PMID: 34407542 Free article. Clinical Trial.

22. Mek1 and Mek2 Functional Redundancy in Erythropoiesis. Beuret L, Fortier-Beaulieu SP, Rondeau V, Roy S, Houde N, Balabanian K, Espéli M, Charron J.Front Cell Dev Biol. 2021 Jul 27;9:639022. doi: 10.3389/fcell.2021.639022. eCollection 2021.PMID: 34386488

13. Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia. Borella G, Da Ros A, Borile G, Porcù E, Tregnago C, Benetton M, Marchetti A, Bisio V, Montini B, Michielotto B, Cani A, Leszl A, Campodoni E, Sandri M, Montesi M, Bresolin S, Cairo S, Buldini B, Locatelli F, Pigazzi M.Blood. 2021 Aug 19;138(7):557-570. doi: 10.1182/blood.2020009845.PMID: 34010415

14. CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness. Lewis R, Maurer HC, Singh N, Gonzalez-Menendez I, Wirth M, Schick M, Zhang L, Isaakidis K, Scherger AK, Schulze V, Lu J, Zenz T, Steiger K, Rad R, Quintanilla-Martinez L, Espeli M, Balabanian K, Keller U, Habringer S.Leukemia. 2021 Oct;35(10):2895-2905. doi: 10.1038/s41375-021-01376-1. Epub 2021 Aug 6.PMID: 34363012

15. Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease. Zhao LP, Schell B, Sébert M, Kim R, Lemaire P, Boy M, Mathis S, Larcher L, Chauvel C, Dhouaieb MB, Bisio V, Preudhomme C, Marceau-Renaut A, Itzykson R, Mekinian A, Fain O, Toubert A, Fenaux P, Dulphy N, Clappier E, Adès L.Leukemia. 2021 Sep;35(9):2731-2733. doi: 10.1038/s41375-021-01353-8. Epub 2021 Aug 3.PMID: 34344988 No abstract available.

16. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3). Berthelet J, Michail C, Bui LC, Le Coadou L, Sirri V, Wang L, Dulphy N, Dupret JM, Chomienne C, Guidez F, Rodrigues-Lima F.Mol Pharmacol. 2021 Sep;100(3):283-294. doi: 10.1124/molpharm.121.000303. Epub 2021 Jul 15.PMID: 34266924

17. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Rousselot P, Mollica L, Guilhot J, Guerci A, Nicolini FE, Etienne G, Legros L, Charbonnier A, Coiteux V, Dartigeas C, Escoffre-Barbe M, Roy L, Cony-Makhoul P, Dubruille V, Gardembas M, Huguet F, Réa D, Cayssials E, Guilhot F, Bergeron A, Molimard M, Mahon FX, Cayuela JM, Busque L, Bouchet S.Br J Haematol. 2021 Jul;194(2):393-402. doi: 10.1111/bjh.17654. Epub 2021 Jun 30.PMID: 34195988 Clinical Trial.

18. Pivotal Role for Cxcr2 in Regulating Tumor-Associated Neutrophil in Breast Cancer. Timaxian C, Vogel CFA, Orcel C, Vetter D, Durochat C, Chinal C, NGuyen P, Aknin ML, Mercier-Nomé F, Davy M, Raymond-Letron I, Van TN, Diermeier SD, Godefroy A, Gary-Bobo M, Molina F, Balabanian K, Lazennec G.Cancers (Basel). 2021 May 25;13(11):2584. doi: 10.3390/cancers13112584.PMID: 34070438

19. Immunophenotyping of the Medullary B Cell Compartment In Mouse Models. Bonaud A, Balabanian K, Espéli M.Methods Mol Biol. 2021;2308:95-105. doi: 10.1007/978-1-0716-1425-9_8.PMID: 34057717

20. Feeder-Free Differentiation Assay for Mouse Hematopoietic Stem and Progenitor Cells. Rondeau V, Espéli M, Balabanian K.Methods Mol Biol. 2021;2308:47-58. doi: 10.1007/978-1-0716-1425-9_4.PMID: 34057713

21. Culture, Expansion and Differentiation of Mouse Bone-Derived Mesenchymal Stromal Cells. Abou Nader Z, Espéli M, Balabanian K, P Lemos J.Methods Mol Biol. 2021;2308:35-46. doi: 10.1007/978-1-0716-1425-9_3.PMID: 34057712

22. Culture, Expansion and Differentiation of Human Bone Marrow Stromal Cells. Bisio V, Espéli M, Balabanian K, Anginot A.Methods Mol Biol. 2021;2308:3-20. doi: 10.1007/978-1-0716-1425-9_1.PMID: 34057710

23. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. Chretien AS, Devillier R, Granjeaud S, Cordier C, Demerle C, Salem N, Wlosik J, Orlanducci F, Gorvel L, Fattori S, Hospital MA, Pakradouni J, Gregori E, Paul M, Rochigneux P, Pagliardini T, Morey M, Fauriat C, Dulphy N, Toubert A, Luche H, Malissen M, Blaise D, Nunès JA, Vey N, Olive D.Proc Natl Acad Sci U S A. 2021 Jun 1;118(22):e2020459118. doi: 10.1073/pnas.2020459118.PMID: 34050021

24. Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells. Ouk C, Roland L, Gachard N, Poulain S, Oblet C, Rizzo D, Saintamand A, Lemasson Q, Carrion C, Thomas M, Balabanian K, Espéli M, Parrens M, Soubeyran I, Boulin M, Faumont N, Feuillard J, Vincent-Fabert C.Front Immunol. 2021 May 4;12:641692. doi: 10.3389/fimmu.2021.641692. eCollection 2021.PMID: 34017329

25. Hematopoietic Multipotent Progenitors and Plasma Cells: Neighbors or Roommates in the Mouse Bone Marrow Ecosystem? Bonaud A, Lemos JP, Espéli M*, Balabanian K*.Front Immunol. 2021 Apr 15;12:658535. doi: 10.3389/fimmu.2021.658535. eCollection 2021.PMID: 33936091 *co-senior authors

26. Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Zhao LP, Boy M, Azoulay C, Clappier E, Sébert M, Amable L, Klibi J, Benlagha K, Espéli M, Balabanian K, Preudhomme C, Marceau-Renaut A, Benajiba L, Itzykson R, Mekinian A, Fain O, Toubert A, Fenaux P, Dulphy N, Adès L.Leukemia. 2021 Sep;35(9):2720-2724. doi: 10.1038/s41375-021-01152-1. Epub 2021 Feb 23.PMID: 33623140 No abstract available.

27. Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study. Etienne G, Rea D, Coiteux V, Guerci-Bresler A, Huguet F, Legros L, Rousselot P, Nicolini FE.Leuk Res. 2021 May;104:106541. doi: 10.1016/j.leukres.2021.106541. Epub 2021 Mar 2.PMID: 33689921 Clinical Trial. No abstract available.

28. Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler AP, Maloisel F, Rea D, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Jourdan E, Berger M, Fouillard L, Alexis M, Legros L, Rousselot P, Delmer A, Lenain P, Escoffre Barbe M, Gyan E, Bulabois CE, Dubruille V, Joly B, Pollet B, Cony-Makhoul P, Johnson-Ansah H, Mercier M, Caillot D, Charbonnier A, Kiladjian JJ, Chapiro J, Penot A, Dorvaux V, Vaida I, Santagostino A, Roy L, Zerazhi H, Deconinck E, Maisonneuve H, Plantier I, Lebon D, Arkam Y, Cambier N, Ghomari K, Miclea JM, Glaisner S, Cayuela JM, Chomel JC, Muller M, Lhermitte L, Delord M, Preudhomme C, Etienne G, Mahon FX, Nicolini FE; France Intergroupe des Leucémies Myéloïdes Chroniques, Fi-LMC.Leukemia. 2021 Aug;35(8):2332-2345. doi: 10.1038/s41375-020-01117-w. Epub 2021 Jan 22.PMID: 33483613 Clinical Trial.

29. The "French Germinal Center Club" of the French Society for Immunology: a dynamic collaboration between researchers passionate about the germinal center reaction. Amé P, Dumortier H, Espéli M, Milpied P, Fazilleau N.Eur J Immunol. 2021 Feb;51(2):270-271. doi: 10.1002/eji.202170025.PMID: 33544897

30. CXCR4 signaling controls dendritic cell location and activation at steady state and in inflammation. Gallego C, Vétillard M, Calmette J, Roriz M, Marin-Esteban V, Evrard M, Aknin ML, Pionnier N, Lefrançois M, Mercier-Nomé F, Bertrand Y, Suarez F, Donadieu J, Ng LG, Balabanian K, Bachelerie F, Schlecht-Louf G.Blood. 2021 May 20;137(20):2770-2784. doi: 10.1182/blood.2020006675.PMID: 33512478

31. Hematologic disorder-associated Cxcr4 gain-of-function mutation leads to uncontrolled extrafollicular immune response. Alouche N, Bonaud A, Rondeau V, Hussein-Agha R, Nguyen J, Bisio V, Khamyath M, Crickx E, Setterblad N, Dulphy N, Mahevas M, McDermott DH, Murphy PM, Balabanian K*, Espéli M*.Blood. 2021 Jun 3;137(22):3050-3063. doi: 10.1182/blood.2020007450.PMID: 33512437 *co-senior authors

2020

1. Authentication of Primary Murine Cell Lines by a Microfluidics-Based Lab-On-Chip System. Hong Y, Singh N, Bamopoulos S, Gjerga E, Schmalbrock LK, Balabanian K, Schick M, Keller U, Wirth M.Biomedicines. 2020 Dec 9;8(12):590. doi: 10.3390/biomedicines8120590.PMID: 33317212

2. Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors? Rea D.Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):243-247. doi: 10.1182/hematology.2020002538.PMID: 33275744 Free PMC article. Review.

3. Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. Fontana D, Ramazzotti D, Aroldi A, Redaelli S, Magistroni V, Pirola A, Niro A, Massimino L, Mastini C, Brambilla V, Bombelli S, Bungaro S, Morotti A, Rea D, Stagno F, Martino B, Campiotti L, Caocci G, Usala E, Merli M, Onida F, Bregni M, Elli EM, Fumagalli M, Ciceri F, Perego RA, Pagni F, Mologni L, Piazza R, Gambacorti-Passerini C.Hemasphere. 2020 Nov 6;4(6):e497. doi: 10.1097/HS9.0000000000000497. eCollection 2020 Dec.PMID: 33196013 Free PMC article.

4. ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. Fontana D, Mauri M, Renso R, Docci M, Crespiatico I, Røst LM, Jang M, Niro A, D'Aliberti D, Massimino L, Bertagna M, Zambrotta G, Bossi M, Citterio S, Crescenzi B, Fanelli F, Cassina V, Corti R, Salerno D, Nardo L, Chinello C, Mantegazza F, Mecucci C, Magni F, Cavaletti G, Bruheim P, Rea D, Larsen S, Gambacorti-Passerini C, Piazza R.Nat Commun. 2020 Nov 23;11(1):5938. doi: 10.1038/s41467-020-19721-w.PMID: 33230096 Free PMC

5. Dynamic regulation of hypoxia-inducible factor-1α activity is essential for normal B cell development. Burrows N, Bashford-Rogers RJM, Bhute VJ, Peñalver A, Ferdinand JR, Stewart BJ, Smith JEG, Deobagkar-Lele M, Giudice G, Connor TM, Inaba A, Bergamaschi L, Smith S, Tran MGB, Petsalaki E, Lyons PA, Espeli M, Huntly BJP, Smith KGC, Cornall RJ, Clatworthy MR, Maxwell PH.Nat Immunol. 2020 Nov;21(11):1408-1420. doi: 10.1038/s41590-020-0772-8. Epub 2020 Aug 31.PMID: 32868930

6. Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors? Rea D.Blood Adv. 2020 Nov 10;4(21):5589-5594. doi: 10.1182/bloodadvances.2020002538.PMID: 33170936 Free PMC article.

7. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Hochhaus A, Breccia M, Saglio G, García-Gutiérrez V, Réa D, Janssen J, Apperley J.Leukemia. 2020 Jun;34(6):1495-1502. doi: 10.1038/s41375-020-0842-9. Epub 2020 May 4.PMID: 32366938 Free PMC article. Review.

8. Leupaxin Expression Is Dispensable for B Cell Immune Responses. Bonaud A, Clare S, Bisio V, Sowerby JM, Yao S, Ostergaard H, Balabanian K, Smith KGC, Espéli M.Front Immunol. 2020 Mar 25;11:466. doi: 10.3389/fimmu.2020.00466. eCollection 2020.PMID: 32269569

9. The health status alters the pituitary function and reproduction of mice in a Cxcr2-dependent manner. Timaxian C, Raymond-Letron I, Bouclier C, Gulliver L, Le Corre L, Chébli K, Guillou A, Mollard P, Balabanian K, Lazennec G.Life Sci Alliance. 2020 Feb 10;3(3):e201900599. doi: 10.26508/lsa.201900599. Print 2020 Mar.PMID: 32041848

10. Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report. Debureaux PE, Brignier A, Soret-Dulphy J, Réa D, Michonneau D, Peffault de Latour R, Sicre de Fontbrune F, Pagliuca S, Parquet N, Prata HP, Marouf A, Xhaard A, Kiladjian JJ, Socié G, Robin M.Ann Hematol. 2020 Apr;99(4):897-898. doi: 10.1007/s00277-020-03948-0. Epub 2020 Feb 7.PMID: 32030449 No abstract available.

11. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson S, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Pane F, Nicolini FE, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH.Leuk Lymphoma. 2020 Mar;61(3):650-659. doi: 10.1080/10428194.2019.1675879. Epub 2019 Oct 24.PMID: 31647335 Clinical Trial.

12. L. Gerard, T. Goulenok, M.Bahuaud, C. Francois, P. Aucouturier, H.Moins-Teisserenc, F. Batteux, T. Papo, K. Sacre : Serum IgG2 levelspredict long-term protection following pneumococcal vaccination in systemiclupus erythematosus (SLE), Vaccine (2020), doi:10.1016/j.vaccine.2020.08.065.

13. L.Giannoni, F. Morin, M. Robin, M. Peyneau, M. H. Schlageter, D. Desmier, S.Pagliuca, A. S. D. Galy, F. S. de Fontbrune, A. Xhaard, N. Dhedin, H. Moins-Teisserenc, R. P. de Latour,G. Socie, D. Michonneau : Human-derived alpha1-antitrypsin is stillefficacious in heavily pretreated patients with steroid-resistantgastrointestinal graft-versus-host disease, Biol Blood Marrow Transpl. (2020), doi:10.1016/j.bbmt.2020.05.014

14. M. Roelens, A. de Masson, C.Ram-Wolff, M. Bagot, H. Moins-Teisserenc:Letter to the editor with regard to the article entitled “Sézary syndrome andmycosis fungoides: An overview, including the role of immunophenotyping,”Cytom. Part B Clin. Cytom. 100,139–140 (2020).

15. Dangien, C. Ram-Wolff, P. Brice,M. Battistella, M. Roelens, H.Moins-Teisserenc, R. P. de Latour, S. Mourah, J. D. Bouaziz, C. Lebbe, M.Bagot, A. de Masson : Ifosfamide and etoposide in advanced-stage, relapsedor refractory primary cutaneous T-cell lymphomas, Br J Dermatol (2020),doi:10.1111/bjd.19220.

16. Frazao, L. Rethacker, G. Jeudy, M.Colombo, E. Pasmant, M. F. Avril, A. Toubert, H. Moins-Teisserenc, M. Roelens, S. Dalac, E. Maubec, A. Caignard:BRAF inhibitor resistance of melanoma cells triggers increased susceptibilityto natural killer cell-mediated lysis, J. Immunother. Cancer (2020),doi:10.1136/jitc-2019-000275.

17. M. Roelens, A. de Masson, C.Ram-Wolff, G. Maki, J. M. Cayuela, A. Marie-Cardine, A. Bensussan, A. Toubert,M. Bagot, H. Moins-Teisserenc:Revisiting the initial diagnosis and blood staging of mycosis fungoides andSezary syndrome with the KIR3DL2 marker, Br J Dermatol 182, 1415–1422 (2020).

‍

2019

1. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW.N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.PMID: 31826340 Free PMC article. Clinical Trial.

2. Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia. Rabian F, Lengline E, Rea D.Curr Hematol Malig Rep. 2019 Dec;14(6):492-500. doi: 10.1007/s11899-019-00546-4.PMID: 31760572 Free PMC article. Review.

3. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, O'Hare T, Druker BJ, Deininger MW.Cancer Cell. 2019 Oct 14;36(4):431-443.e5. doi: 10.1016/j.ccell.2019.08.004. Epub 2019 Sep 19.PMID: 31543464 Free PMC article.

4. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients. Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Rea D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX.Clin Cancer Res. 2019 Nov 15;25(22):6606-6613. doi: 10.1158/1078-0432.CCR-18-3373. Epub 2019 Jul 10.PMID: 31292142 Clinical Trial.

5. Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission. Dumas PY, Bérard E, Bréal C, Dulucq S, Réa D, Nicolini F, Forcade E, Dufossée M, Pasquet JM, Turcq B, Bidet A, Milpied N, Déchanet-Merville J, Lafarge X, Etienne G, Mahon FX; French Intergroup in Chronic Myeloid Leukemia.Cancer Med. 2019 Sep;8(11):4976-4985. doi: 10.1002/cam4.2371. Epub 2019 Jul 9.PMID: 31287239 Free PMC article.

6. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. Berger MG, Pereira B, Rousselot P, Cony-Makhoul P, Gardembas M, Legros L, Escoffre-Barbe M, Nicolini FE, Saugues S, Lambert C, Réa D, Guerci-Bresler A, Giraudier S, Guilhot J, Saussele S, Mahon FX; (France Intergroupe des Leucémies Myéloïdes Chroniques).Br J Haematol. 2019 Nov;187(3):337-346. doi: 10.1111/bjh.16083. Epub 2019 Jul 4.PMID: 31271217

7. Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. Bidet A, Dulucq S, Smol T, Marceau-Renaut A, Morisset S, Coiteux V, Noël-Walter MP, Nicolini FE, Tigaud I, Luquet I, Struski S, Gaillard B, Penther D, Tondeur S, Nadal N, Hermet E, Véronèse L, Réa D, Gervais C, Theisen O, Terré C, Cony-Makhoul P, Lefebvre C, Gaillard JB, Radford I, Vervaeke AL, Barin C, Chapiro E, Nguyen-Khac F, Etienne G, Preudhomme C, Mahon FX, Roche-Lestienne C; Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Intergroup of Chronic Myeloid Leukemia (Fi-LMC).Haematologica. 2019 Jun;104(6):1150-1155. doi: 10.3324/haematol.2018.208801. Epub 2018 Dec 20.PMID: 30573507 Free PMC article.

8. A chemotaxis model to explain WHIM neutrophil accumulation in the bone marrow of WHIM mouse model. Yip AK, Balachander A, Tan LDL, Liong KH, Tan RZ, Balabanian K, Bachelerie F, Ng LG, Chiam KH.Blood Sci. 2019 Sep 17;1(1):102-112. doi: 10.1097/BS9.0000000000000019. eCollection 2019 Aug.PMID: 35402788

9. B Cell Fcγ Receptor IIb Modulates Atherosclerosis in Male and Female Mice by Controlling Adaptive Germinal Center and Innate B-1-Cell Responses. Bagchi-Chakraborty J, Francis A, Bray T, Masters L, Tsiantoulas D, Nus M, Harrison J, Broekhuizen M, Leggat J, Clatworthy MR, Espéli M, Smith KGC, Binder CJ, Mallat Z, Sage AP.Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1379-1389. doi: 10.1161/ATVBAHA.118.312272. Epub 2019 May 16.PMID: 31092015

10. Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia. Zhao LP, Sicre De Fontbrune F, Contejean A, Abraham J, Terriou L, Chabrot C, Charbonnier A, Lengline E, Socié G, Peffault de Latour R.Bone Marrow Transplant. 2019 Jul;54(7):1161-1163. doi: 10.1038/s41409-019-0452-1. Epub 2019 Jan 22.PMID: 30670823

11. Atypical Chemokine Receptor 3 (ACKR3): A Comprehensive Overview of its Expression and Potential Roles in the Immune System. Koenen J, Bachelerie F, Balabanian K, Schlecht-Louf G, Gallego C.Mol Pharmacol. 2019 Dec;96(6):809-818. doi: 10.1124/mol.118.115329. Epub 2019 Apr 30.PMID: 31040166 Review.

12. FcγRIIb differentially regulates pre-immune and germinal center B cell tolerance in mouse and human. Espéli M*, Bashford-Rogers R, Sowerby JM, Alouche N, Wong L, Denton AE, Linterman MA, Smith KGC.Nat Commun. 2019 Apr 29;10(1):1970. doi: 10.1038/s41467-019-09434-0.PMID: 31036800 * corresponding author

13. NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment. Frazao A, Rethacker L, Messaoudene M, Avril MF, Toubert A, Dulphy N, Caignard A.Front Immunol. 2019 Mar 29;10:661. doi: 10.3389/fimmu.2019.00661. eCollection 2019.PMID: 30984204

14. A Neutrophil Timer Coordinates Immune Defense and Vascular Protection. Adrover JM, Del Fresno C, Crainiciuc G, Cuartero MI, Casanova-Acebes M, Weiss LA, Huerga-Encabo H, Silvestre-Roig C, Rossaint J, Cossío I, Lechuga-Vieco AV, García-Prieto J, Gómez-Parrizas M, Quintana JA, Ballesteros I, Martin-Salamanca S, Aroca-Crevillen A, Chong SZ, Evrard M, Balabanian K, López J, Bidzhekov K, Bachelerie F, Abad-Santos F, Muñoz-Calleja C, Zarbock A, Soehnlein O, Weber C, Ng LG, Lopez-Rodriguez C, Sancho D, Moro MA, Ibáñez B, Hidalgo A.Immunity. 2019 Feb 19;50(2):390-402.e10. doi: 10.1016/j.immuni.2019.01.002. Epub 2019 Jan 29.PMID: 30709741

15. Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis. Lorscheider M, Tsapis N, Ur-Rehman M, Gaudin F, Stolfa I, Abreu S, Mura S, Chaminade P, Espeli M, Fattal E.J Control Release. 2019 Feb 28;296:179-189. doi: 10.1016/j.jconrel.2019.01.015. Epub 2019 Jan 16.PMID: 30659904

16. CD16⁺NKG2A^high Natural Killer Cells Infiltrate Breast Cancer-Draining Lymph Nodes. Frazao A, Messaoudene M, Nunez N, Dulphy N, Roussin F, Sedlik C, Zitvogel L, Piaggio E, Toubert A, Caignard A.Cancer Immunol Res. 2019 Feb;7(2):208-218. doi: 10.1158/2326-6066.CIR-18-0085. Epub 2018 Dec 4.PMID: 30514793

17. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Cortes J, Rea D, Lipton JH.Am J Hematol. 2019 Mar;94(3):346-357. doi: 10.1002/ajh.25342. Epub 2018 Nov 25.PMID: 30394563 Free PMC article. Review.

18. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE.Haematologica. 2019 Jan;104(1):93-101. doi: 10.3324/haematol.2018.188987. Epub 2018 Aug 9.PMID: 30093398 Free PMC article. Clinical Trial.

19. M. Dumont, C. Ram-Wolff, M. Roelens, P. Brice,R. P. de Latour, M. Battistella, I. Madelaine, J. Delyon, F. Herms, J. D.Bouaziz, H. Moins-Teisserenc, C.Lebbe, M. Bagot, A. de Masson: Efficacy and safety of brentuximab vedotin plusbendamustine in advanced-stage primary cutaneous T-cell lymphomas, Br. J.Dermatol. 181, 1315–1317 (2019).

20. H. M. Delagreverie, L. Gerard, A.Chaillon, M. Roelens, L. Djerroudi,M. Salmonaa, J. Larghero, L. Galicier, F.Simona, E. Oksenhendler, H.Moins-Teisserenc, C. Delaugerre: Reconstitution of HIV-1 reservoirfollowing high-dose chemotherapy/autologous stem cell transplantation forlymphoma, Aids 33, 247–257 (2019).

21. P. Bonnet, M. Battistella, M.Roelens, C. Ram-Wolff, F. Herms, L. Frumholtz, J. D. Bouaziz, P. Brice, H. Moins-Teisserenc, M. Bagot, A. deMasson: Association of autoimmunity and long-term complete remission inpatients with Sezary syndrome treated with mogamulizumab, Br J Dermatol 180,419–420 (2019).

22. Brunet-Possenti, C. Charpentier,Y. Bouhnik, L. Deschamps, D. Descamps, H.Moins-Teisserenc, V. Descamps : Occurrence of Extensive CutaneousHuman Papillomavirus Infection After Initiation of Tofacitinib Therapy, JamaDermatology 155, 629–631 (2019).

23. M. Delville, F. Touzot, C. Couzin,I. Hmitou, L. Djerroudi, A. Ouedrani, F. Lefrere, C. Tuchman-Durand, C. Mollet,J. R. Fabreguettes, N. Ferry, L. Laganier, A. Magnani, E. Magrin, V. Jolaine,A. Saez-Cirion, O. Wolstein, G. Symonds, P. Frange, H. Moins-Teisserenc, M. L. Chaix-Baudier, A. Toubert, J. Larghero,N. Parquet, A. C. Brignier, F. Barre-Sinoussi, E. Oksenhendler, M.Cavazzana : Safety of CD34(+) Hematopoietic Stem Cells and CD4(+) TLymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-RiskLymphoma, Mol. Ther. Clin. Dev. 13, 303–309 (2019).

‍

2018

1. Galectin-8 Favors the Presentation of Surface-Tethered Antigens by Stabilizing the B Cell Immune Synapse. Obino D, Fetler L, Soza A, Malbec O, Saez JJ, Labarca M, Oyanadel C, Del Valle Batalla F, Goles N, Chikina A, Lankar D, Segovia-Miranda F, Garcia C, Léger T, Gonzalez A, Espéli M, Lennon-Duménil AM*, Yuseff MI*.Cell Rep. 2018 Dec 11;25(11):3110-3122.e6. doi: 10.1016/j.celrep.2018.11.052.PMID: 30540943 * co-senior author

2. Eruptive melanocytic nevi associated with ponatinib. Devred I, Arnault JP, Adas A, Rea D, Lombart F, Sevestre H, Trudel S, Lok C, Chaby G.JAAD Case Rep. 2018 Nov 12;4(10):1052-1054. doi: 10.1016/j.jdcr.2018.07.010. eCollection 2018 Nov.PMID: 30456285 Free PMC article. No abstract available.

3. AHR: leukemic countermeasure against NK cells. Dulphy N.Blood. 2018 Oct 25;132(17):1733-1734. doi: 10.1182/blood-2018-09-873570.PMID: 30361461

4. A three-miRNA-based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) RUNX1-RUNX1T1 acute myeloid leukaemia. Zampini M, Bisio V, Leszl A, Putti MC, Menna G, Rizzari C, Pession A, Locatelli F, Basso G, Tregnago C, Pigazzi M.Br J Haematol. 2018 Oct;183(2):298-301. doi: 10.1111/bjh.14950. Epub 2017 Sep 29.PMID: 28961307

5. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE.Exp Hematol. 2018 Nov;67:41-48. doi: 10.1016/j.exphem.2018.08.006. Epub 2018 Sep 5.PMID: 30195076 Free article.

6. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. Racil Z, Koritakova E, Sacha T, Klamova H, Belohlavkova P, Faber E, Rea D, Malaskova L, Prochazkova J, Zackova D, Voglova J, Wącław J, Cetkovsky P, Zak P, Mayer J.Am J Hematol. 2018 Oct;93(10):E342-E345. doi: 10.1002/ajh.25232. Epub 2018 Aug 31.PMID: 30054949 Free article. No abstract available.

7. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Piazza R, Magistroni V, Redaelli S, Mauri M, Massimino L, Sessa A, Peronaci M, Lalowski M, Soliymani R, Mezzatesta C, Pirola A, Banfi F, Rubio A, Rea D, Stagno F, Usala E, Martino B, Campiotti L, Merli M, Passamonti F, Onida F, Morotti A, Pavesi F, Bregni M, Broccoli V, Baumann M, Gambacorti-Passerini C.Nat Commun. 2018 Jun 6;9(1):2192. doi: 10.1038/s41467-018-04462-8.PMID: 29875417 Free PMC article.

8. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators.Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4.PMID: 29735299 Clinical Trial.

9. Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML. Zampini M, Tregnago C, Bisio V, Simula L, Borella G, Manara E, Zanon C, Zonta F, Serafin V, Accordi B, Campello S, Buldini B, Pession A, Locatelli F, Basso G, Pigazzi M.Leukemia. 2018 May;32(5):1124-1134. doi: 10.1038/s41375-017-0003-y. Epub 2018 Feb 2.PMID: 29472719

10. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX; French Chronic Myeloid Leukemia Study Group.Cancer. 2018 Jul 15;124(14):2956-2963. doi: 10.1002/cncr.31411. Epub 2018 May 3.PMID: 29723417 Free article.

11. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22.PMID: 29567798 Free PMC article. Clinical Trial.

12. Developmental Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions. Evrard M, Kwok IWH, Chong SZ, Teng KWW, Becht E, Chen J, Sieow JL, Penny HL, Ching GC, Devi S, Adrover JM, Li JLY, Liong KH, Tan L, Poon Z, Foo S, Chua JW, Su IH, Balabanian K, Bachelerie F, Biswas SK, Larbi A, Hwang WYK, Madan V, Koeffler HP, Wong SC, Newell EW, Hidalgo A, Ginhoux F, Ng LG.Immunity. 2018 Feb 20;48(2):364-379.e8. doi: 10.1016/j.immuni.2018.02.002.PMID: 29466759

13. How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy. Rea D, Mahon FX.Br J Haematol. 2018 Jan;180(1):24-32. doi: 10.1111/bjh.14973. Epub 2017 Oct 19.PMID: 29048128 Review.

14. L. C. M. Arruda, K. C. R.Malmegrim, J. R. Lima, E. Clave, J. B. E. Dias, D. A. Moraes, C. Douay, I.Fournier, H. Moins-Teisserenc, A. J.Alberdi, D. T. Covas, B. P. Simoes, P. Lansiaux, A. Toubert, M. C. Oliveira:Immune rebound associates with a favorable clinical response to autologous HSCTin systemic sclerosis patients, Blood Adv. 2, 126–141 (2018).

15. K. Sacre, T. Goulenok, M. Bahuaud,C. Francois, M. C. Van der Haegen, J. F. Alexandra, P. Aucouturier, M.Hurtado-Nedelec, H. Moins-Teisserenc,F. Batteux, T. Papo : Impaired long-term immune protection followingpneumococcal 13-valent/23-valent polysaccharide vaccine in systemic lupuserythematosus (SLE), Ann. Rheum. Dis. 77, 1540-+ (2018).

16. L. C. M. Arruda, J. R.Lima-Junior, E. Clave, D. A. Moraes, C. Douay, I. Fournier, H. Moins-Teisserenc, D. T. Covas, B. P.Simoes, D. Farge, A. Toubert, K. C. R. Malmegrim, M. C. Oliveira: Homeostaticproliferation leads to telomere attrition and increased PD-1 expression afterautologous hematopoietic SCT for systemic sclerosis, Bone Marrow Transplant. 53,1319–1327 (2018).

‍

2017

1. What is treatment free remission in chronic myeloid leukemia? Rea D, Etienne G, Mahon FX.Oncotarget. 2017 Dec 18;9(4):4279. doi: 10.18632/oncotarget.23398. eCollection 2018 Jan 12.PMID: 29435101 Free PMC article. No abstract available.

2. Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. Müller MC, Cervantes F, Hjorth-Hansen H, Janssen JJWM, Milojkovic D, Rea D, Rosti G.Crit Rev Oncol Hematol. 2017 Dec;120:52-59. doi: 10.1016/j.critrevonc.2017.10.002. Epub 2017 Oct 8.PMID: 29198338 Free article. Review.

3. Expression of CD94 by ex vivo-differentiated NK cells correlates with the in vitro and in vivo acquisition of cytotoxic features. Hasmim M, Khalife N, Zhang Y, Doldur M, Visentin G, Terry S, Giron-Michel J, Tang R, Delhommeau F, Dulphy N, Bourhis JH, Louache F, Chouaib S.Oncoimmunology. 2017 Jul 18;6(10):e1346763. doi: 10.1080/2162402X.2017.1346763. eCollection 2017.PMID: 29123958

4. Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs). Aggoune D, Sorel N, Bonnet ML, Goujon JM, Tarte K, Hérault O, Domenech J, Réa D, Legros L, Johnson-Ansa H, Rousselot P, Cayssials E, Guerci-Bresler A, Bennaceur-Griscelli A, Chomel JC, Turhan AG.Leuk Res. 2017 Sep;60:94-102. doi: 10.1016/j.leukres.2017.07.007. Epub 2017 Jul 26.PMID: 28772207

5. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, Guerci-Bresler A, Huguet F, Gardembas M, Escoffre M, Ianotto JC, Noël MP, Varet BR, Pagliardini T, Touitou I, Morisset S, Mahon FX; French Intergroup for Chronic Myeloid Leukemias.Cancer. 2017 Nov 15;123(22):4403-4410. doi: 10.1002/cncr.30885. Epub 2017 Jul 25.PMID: 28743166 Free article.

6. Treatment-free remission in patients with chronic myeloid leukemia. Rea D, Cayuela JM.Int J Hematol. 2018 Oct;108(4):355-364. doi: 10.1007/s12185-017-2295-0. Epub 2017 Jul 8.PMID: 28689264 Review.

7. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31.PMID: 28364360 Free PMC article. Clinical Trial.

8. Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. Hochhaus A, Mahon FX, le Coutre P, Petrov L, Janssen JJWM, Cross NCP, Rea D, Castagnetti F, Hellmann A, Rosti G, Gattermann N, Coronel MLP, Gutierrez MAE, Garcia-Gutierrez V, Vincenzi B, Dezzani L, Giles FJ.J Cancer Res Clin Oncol. 2017 Jul;143(7):1225-1233. doi: 10.1007/s00432-017-2359-9. Epub 2017 Feb 21.PMID: 28224300 Free PMC article. Clinical Trial.

9. Molecular and Functional Characterization of Lymphoid Progenitor Subsets Reveals a Bipartite Architecture of Human Lymphopoiesis. Alhaj Hussen K, Vu Manh TP, Guimiot F, Nelson E, Chabaane E, Delord M, Barbier M, Berthault C, Dulphy N, Alberdi AJ, Burlen-Defranoux O, Socié G, Bories JC, Larghero J, Vanneaux V, Verhoeyen E, Wirth T, Dalod M, Gluckman JC, Cumano A, Canque B.Immunity. 2017 Oct 17;47(4):680-696.e8. doi: 10.1016/j.immuni.2017.09.009.PMID: 29045900

10. NBEAL2 is required for neutrophil and NK cell function and pathogen defense. Sowerby JM, Thomas DC, Clare S, Espéli M, Guerrero JA, Hoenderdos K, Harcourt K, Marsden M, Abdul-Karim J, Clement M, Antrobus R, Umrania Y, Barton PR, Flint SM, Juss JK, Condliffe AM, Lyons PA, Humphreys IR, Chilvers ER, Ouwehand WH, Dougan G, Smith KG.J Clin Invest. 2017 Sep 1;127(9):3521-3526. doi: 10.1172/JCI91684. Epub 2017 Aug 7.PMID: 28783043

11. Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. Messaoudene M, Frazao A, Gavlovsky PJ, Toubert A, Dulphy N, Caignard A.Front Immunol. 2017 Jun 12;8:683. doi: 10.3389/fimmu.2017.00683. eCollection 2017.PMID: 28659921

12. Lymphoid differentiation of hematopoietic stem cells requires efficient Cxcr4 desensitization. Freitas C, Wittner M, Nguyen J, Rondeau V, Biajoux V, Aknin ML, Gaudin F, Beaussant-Cohen S, Bertrand Y, Bellanné-Chantelot C, Donadieu J, Bachelerie F, Espéli M, Dalloul A, Louache F*, Balabanian K*.J Exp Med. 2017 Jul 3;214(7):2023-2040. doi: 10.1084/jem.20160806. Epub 2017 May 26.PMID: 28550161 *co-senior authors

13. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, Gardembas M, Dubruille V, Guerci-Bresler A, Charbonnier A, Maloisel F, Ianotto JC, Villemagne B, Mahon FX, Moins-Teisserenc H, Dulphy N, Toubert A.Haematologica. 2017 Aug;102(8):1368-1377. doi: 10.3324/haematol.2017.165001. Epub 2017 May 18.PMID: 28522576

14. Eros is a novel transmembrane protein that controls the phagocyte respiratory burst and is essential for innate immunity. Thomas DC, Clare S, Sowerby JM, Pardo M, Juss JK, Goulding DA, van der Weyden L, Storisteanu D, Prakash A, Espéli M, Flint S, Lee JC, Hoenderdos K, Kane L, Harcourt K, Mukhopadhyay S, Umrania Y, Antrobus R, Nathan JA, Adams DJ, Bateman A, Choudhary JS, Lyons PA, Condliffe AM, Chilvers ER, Dougan G, Smith KG.J Exp Med. 2017 Apr 3;214(4):1111-1128. doi: 10.1084/jem.20161382. Epub 2017 Mar 28.PMID: 28351984

15. NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group. Bisio V, Zampini M, Tregnago C, Manara E, Salsi V, Di Meglio A, Masetti R, Togni M, Di Giacomo D, Minuzzo S, Leszl A, Zappavigna V, Rondelli R, Mecucci C, Pession A, Locatelli F, Basso G, Pigazzi M.Leukemia. 2017 Apr;31(4):974-977. doi: 10.1038/leu.2016.361. Epub 2016 Nov 28.PMID: 27890935

16. Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Manara E, Basso G, Zampini M, Buldini B, Tregnago C, Rondelli R, Masetti R, Bisio V, Frison M, Polato K, Cazzaniga G, Menna G, Fagioli F, Merli P, Biondi A, Pession A, Locatelli F, Pigazzi M.Leukemia. 2017 Jan;31(1):18-25. doi: 10.1038/leu.2016.177. Epub 2016 Jun 28.PMID: 27416911

17. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carré M, Guilhot F, Rousselot P, Mahon FX.J Clin Oncol. 2017 Jan 20;35(3):298-305. doi: 10.1200/JCO.2016.68.2914. Epub 2016 Oct 31.PMID: 28095277

18. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX; France Intergroupe des Leucémies Myéloïdes Chroniques.Blood. 2017 Feb 16;129(7):846-854. doi: 10.1182/blood-2016-09-742205. Epub 2016 Dec 8.PMID: 27932374

19. Hurabielle, F. Sicre de Fontbrune,H. Moins-Teisserenc, M. Robin, M.Jachiet, T. Coman, C. Cassius, F. Chasset, A. de Masson, D. Michonneau, M.Bagot, A. Bergeron, G. Socie, R. Peffault de Latour, J. D. Bouaziz: Efficacyand tolerance of ruxolitinib in refractory sclerodermatous chronicGraft-Versus-Host Disease, Br J Dermatol (2017), doi:10.1111/bjd.15593.

20. Farge, L. C. M. Arruda, F.Brigant, E. Clave, C. Douay, Z. Marjanovic, C. Deligny, G. Maki, E. Gluckman,A. Toubert, H. Moins-Teisserenc:Long-term immune reconstitution and T cell repertoire analysis after autologoushematopoietic stem cell transplantation in systemic sclerosis patients, J.Hematol. Oncol. 10 (2017), doi:10.1186/s13045-016-0388-5.

21. Rea, G. Henry, Z. Khaznadar, G.Etienne, F. Guilhot, F. Nicolini, J. Guilhot, P. Rousselot, F. Huguet, L.Legros, M. Gardembas, V. Dubruille, A. Guerci-Bresler, A. Charbonnier, F.Maloisel, J. C. Ianotto, B. Villemagne, F. X. Mahon, H. Moins-Teisserenc, N. Dulphy, A. Toubert: Natural killer-cellcounts are associated with molecular relapse-free survival after imatinibdiscontinuation in chronic myeloid leukemia: the IMMUNOSTIM study,Haematologica 102, 1368–1377 (2017).

22. M. Roelens, M. Delord, C.Ram-Wolff, A. Marie-Cardine, A. Alberdi, G. Maki, L. Homyrda, A. Bensussan, M.Bagot, A. Toubert, H. Moins-Teisserenc:Circulating and skin-derived Sezary cells: clonal but with phenotypicplasticity, Blood 130, 1468–1471 (2017).

‍

Presentation in congres

2022 :

‍

-Balabanian K. CXCR4 signaling, a gatekeeper orchestrating the specification of hematopoietic multipotent progenitors and skeletal stromal cells. Institut de Recherche Saint-Louis, Club IRSL (seminar series), Paris, 25/03/2022.

-Balabanian K. CXCR4 signaling, a gatekeeper orchestrating the specification of hematopoietic multipotent progenitors and skeletal stromal cells. INSERM U1132-BIOSCAR, Lariboisière hospital (seminar series), Paris, 15/03/2022.

-Balabanian K. Chimiokines, niches lymphoïdes et maladies immuno-hématologiques. 2ème Journée Médicale du DMU d’hématologie et immunologie Paris Nord, Paris, 21/01/2022.

-Dulphy N. Bone Marrow Microenvironment-induced NK-cell Defects in Myelodysplastic Syndromes. OPALE Carnot Institute 2^nd Scientific Meeting, Presqu’Ile de Giens, France, 10-12/10/2022

-Dulphy N. Intrinsic and Extrinsic Defects for NK-cell-mediated Immunosurveillance in Myelodysplastic Syndromes. CRCINA INSERM UMR1307 (seminar series), Nantes, France, 29/09/2022

-Dulphy N. Extrinsic and intrinsic defects for NK-cell-mediated immunosurveillance in Myelodysplastic syndromes. 14^th days of the French-speaking Group for Myelodysplasia, Nantes, France, 23-24/06/2022

-Bisio V. NK-cell immunoediting by mesenchymal stromal cells in MDS. 28ème congres of CHO 2022. Presqu’île de Giens, France.

-Bisio V. NK-cell immunoediting by mesenchymal stromal cells in MDS. FSTM, French Society of Tumor Microenvironment. 2022. Fréjus, France.

-Zhao LP. Myeloproliferative neoplasms clonal evolution landscape and its impact on patients’ prognosis. American Society of Hematology 2022.

-Abou Nader Z. Role of Cxcr4 desensitization in the dialogue between Skeletal Stromal Cells and Lymphoid Progenitors in the bone marrow. Congrès annuel de la Société Française d’Hématologie 2022

-Abou Nader Z. Role of Cxcr4 desensitization in the dialogue between Skeletal Stromal Cells and Lymphoid Progenitors in the bone marrow. Journées Françaises de Biologie des Tissus Minéralisés 2022

-Abou Nader Z. Role of Cxcr4 desensitization in the dialogue between Skeletal Stromal Cells and Lymphoid Progenitors in the bone marrow. 28ème congres of CHO 2022. Presqu’île de Giens, France.

-Khamyath M. "Association of MyD88 and CXCR4 gain of function mutations exacerbates “Waldenstrom-like” malignant transformation and plasma cell survival in a mouse model." 4th Germinal Center Workshop 2022, Marseille, France

-Bonaud A. Plasma cell maintenance and antibody secretion are under the control of Sec22b-mediated regulation of organelle dynamics. Session Jeune Chercheur du “French Club of Young Immunologists”, online meeting, 01-02-2022

2021 :

‍

-Boy M. TET2 mutations in myelodysplastic syndrome patients disrupts natural killer cell’s biology European Hematology Association (EHA) Congress 2021

-Zhao LP. MDS/CMML with TET2 or IDH mutations are associated with Systemic Inflammatory and Autoimmune Diseases (SIAD) and T Cell Dysregulation. European School of Haematology 2021.

-Bonaud A. CXCR4 desensitization control plasma cell fate in the bone marrow 17 decembre 2021. 6e congrès du GDR 3697 MICRONIT«Microenvironnement des Niches Tumorales »

-Dulphy N. MDS-associated TET2/IDH mutations in Natural Killer cells disrupt their anti-tumor activity. OPALE Carnot Institute 1^st Scientific Meeting, Lyon, France, 25-26/10/2021

-Bonaud A. SNARE mediated regulation of germinal centre and plasma cells. 3^ème workshop du « French Germinal Center Club », online meeting, 08-06-2021.

-Balabanian K. CXCR4 signaling, a gatekeeper orchestrating the fate of multipotent progenitors in the BM. IRCM CEA – Fontenay-Roses (external seminar series), online meeting, 22/04/2021.

2020 :

‍

-Bisio V. Mesenchymal stromal cell and natural killer cell cross-talk in malignant bone marrow microenvironment. 5e congrès du GDR 3697 MICRONIT«Microenvironnement des Niches Tumorales » 23-25 November 2020 e-congress.

-Zhao LP. Lymphocytes Chemokine receptors expression in patients with Myelodysplastic syndromes. Société Française d’Hématologie 2020.

-Zhao LP. MDS/CMML with TET2 or IDH mutations are associated with Systemic Inflammatory and Autoimmune Diseases (SIAD) and T Cell Dysregulation. American Society of Hematology 2020.

2019 :

‍

-Boy M. Cytotoxic and helper T and innate lymphoid cells subsets in MDS. GDR Micronit Congress 2019 Le Croisic, France

-Rondeau V. Maintenance and differentiation of adult skeletal mesenchymal stromal elements and hematopoietic multipotent progenitors require efficient CXCR4 desensitization. Annual meeting of European Chemokine & Cell Migration Conference 2019 Salamanca, Spain

-Bonaud A. Analysis of SNARE-mediated regulation of plasma cell biology. 52^ème congrès de la Société Française d’Immunologie, Nantes, 12-11-2019.

-Balabanian K. CXCR4 signaling at the crossroad between bone marrow lymphoid and stromal cells. Cellular Ecology Center/Pitié-Salpétrière - seminar series, Paris, 10/11/2019.

-Espéli M. Cxcr4-mediated regulation of plasma cell biology. IMVA-HB seminar series - Le Kremlin-Bicêtre, France 2019

2018 :

‍

-Balabanian K. Homeostatic and Pathological Chemokine-Regulated Interplays between Lymphocytes and their Microenvironment. Third annual congress of GDR 3697 Micronit « Microenvironnement des Niches Tumorales », Marseille, 31/01 to 02/02/2018

-Dulphy N. Innate lymphoid cells and bone marrow microenvironment in myelodysplastic syndromes. Third annual congress of GDR 3697 Micronit « Microenvironnement des Niches Tumorales », Marseille, 31/01 to 02/02/2018

-Dulphy N. Myelodysplastic Syndromes and Dysimmune Anomalies: Cause or Consequence. 2^nd days of Internal Medicine of the Saint-Antoine Hospital. Paris, France 16/03/2018

-Dulphy N. GvH and GvL Physiopathology in Allogeneic Hematopoietic Stem Cell Transplantation. XXII^nd Educational Days SFHI-EFI. Amiens, France 04-05/10/2018.

-Dulphy N. Role for the Natural Killer lymphocytes in controlling Chronic Myeloid Leukemia. Experts’ Meeting about the Chronic Myeloid Leukemia. Paris, France. 11/10/2018

-Espéli M. Regulation of plasma cell biology in health and disease. CRIBL seminar series – Limoges, France 2018

-Espéli M. Cxcr4 desensitization controls plasma cell differentiation and trafficking. CRCINA seminar series – Nantes, France 2018

2017 :

‍

-Balabanian K. Homeostatic and Pathological Chemokine-Regulated Interplays between Lymphocytes and their Microenvironment. Trafficking journey-CIRI, Lyon, 18/04/2018

-Dulphy N. The role of the immunity in MDS progression and treatment. Chronic Malignancy Working Party of the EBMT. MDS Educational session. New insight into pathogenesis and treatment of MDS. Paris, 21/01/2017

Poster

2022 :

‍

-Bisio V, Schell B, Zhao LP, Lereclus E, Boy M, Bonaud A, Caignard A, Toubert A, Fenaux P, Espeli M, Balabanian K, Ades L, Dulphy N. Immuno-édition des cellules Natural Killer par les Cellules Stromales/Souches Mésenchymateuses médullaires dans les Syndromes Myélodysplasiques. 42° Congress of SFH 2021. March 30-1 April 2022. Paris

-Bisio V, Schell B, Zhao LP, Lereclus E, Boy M, Bonaud A, Caignard A, Toubert A, Fenaux P, Espeli M, Balabanian K, Ades L, Dulphy N. Immuno-édition des cellules Natural Killer par les Cellules Stromales/Souches Mésenchymateuses médullaires dans les Syndromes Myélodysplasiques. 14° Journées du GFM, 23-24 juin 2022. Nantes.

-Bisio V, Schell B, Zhao LP, Lereclus E, Boy M, Bonaud A, Caignard A, Toubert A, Fenaux P, Espeli M, Balabanian K, Ades L, Dulphy N. NK-cell immunoediting by mesenchymal stromal cells in MDS. EHA. June 9-17 2022. Hybrid-Vienna

- Lin Pierre Zhao, Valeria Bisio, Berenice Schell, Camille Vaganay, Mélanie Khamyath, Camille Kergaravat, Maxime Boy, Rathana Kim, Emilie Lereclus, Lise Larcher, Emmanuelle Clappier, Antoine Toubert, Pierre Fenaux, Nina Fenouille, Alexandre Puissant, Marion Espéli, Karl Balabanian, Lionel Adès and Nicolas Dulphy. Impact of TET2 mutations on NK lymphopoiesis. 1^st French Society of Tumor Microenvironment annual meeting 2022

- Arsene Mekinian, Lin Pierre Zhao, Sylvie Chevret, Kristell Desseaux, Laurent Pascal, Thibaut Comont, Alexandre Maria, Pierre Peterlin, Louis Terriou, Maud D'Aveni Piney, Marie-Pierre Gourin, Norbert Vey, Odile Beyne Rauzy, Vincent Grobost, Holy Bezanahary, Sophie Dimicoli-Salazar, Anne Banos, Stefan Wickenhauser, Benoit De Renzis, Eric Durot, Shanti Natarajan-Amé, Laurent Voillat, Fatiha Chermat, Karine Lemaire, Vincent Jachiet, Chantal Himberlin, Sylvain Thépot, Jose Miguel Torregrosa Diaz, Laurent Frenzel, Emmanuel Gyan, Guillaume Denis, Sylvie Chevret, Pierre Hirsch, Olivier Kosmider, Lionel Ades, Olivier Fain, Pierre Fenaux, on behalf MINHEMON, GFM and French VEXAS groups. A phase II study of the efficacy and tolerance of Azacytidine in Steroid Dependent/refractory Systemic Autoimmune and Inflammatory Disorders (SAID) associated with MDS or CMML : GFM-AZA-SAID trial. American Society of Hematology 2022.

- Zeina Abou Nader, Vincent Rondeau, Maria Kalogéraki, Amélie Bonaud, Vanessa Gourhand, Gwendal Lazennec, Michel Aurrand-Lions, Claudine Blin-Wakkach, Stéphane Mancini, Nicolas Dulphy, Martine Cohen-Solal, Matthieu Rouleau, Marion Espéli and Karl Balabanian. Role of Cxcr4 desensitization in the dialogue between Skeletal Stromal Cells and Lymphoid Progenitors in the bone marrow. 1^st French Society of Tumor Microenvironment annual meeting 2022

-Mélanie Khamyath, Amélie Bonaud, Lilian Roland, Gwendal Lazennec, Nicolas Dulphy, Jean Feuillard, Christelle Vincent-Fabert, Karl Balabanian, Marion Espéli. Association of MyD88 and CXCR4 gain of function mutations exacerbates the “Waldenstrom-like” phenotype in mice. 11th International Workshop on Waldenström’s Macroglobulinemia 2022 (Madrid, Espagne).

-Mélanie Khamyath, Amélie Bonaud, Lilian Roland, Gwendal Lazennec, Nicolas Dulphy, Jean Feuillard, Christelle Vincent-Fabert, Karl Balabanian, Marion Espéli. Association of MyD88 and CXCR4 gain of function mutations exacerbates the “Waldenstrom-like” phenotype in mice. 1^st French Society of Tumor Microenvironment annual meeting 2022

-Berenice Schell, Valeria Bisio, Lin Pierre Zhao, Emilie Lereclus, Camille Kergaravat, Emmanuel Clave, Antoine Toubert, Pierre Fenaux, Marion Espéli, Karl Balabanian, Lionel Adès and Nicolas Dulphy. Modeling of NK-cell immunosurveillance in normal and pathological BM microenvironnement. Journées Ouvertes en Bioinformatique 2022, Rennes, France

2020 :

‍

- Lin-Pierre Zhao MD, Rafael Daltro de Oliveira MD, Clémence Marcault MD, Juliette Soret-Dulphy MD, Nicolas Gauthier MD, Emmanuelle Verger PhD, Nabih Maslah PharmD, Blandine Roux MSc, Nathalie Parquet MD, Christine Dosquet MD, Delphine Réa MD PhD, Jean-Marc Zini MD, William Vainchenker MD PhD, Emmanuel Raffoux MD, Stéphane Giraudier MD PhD, Bruno Cassinat PharmD PhD, Jean-Jacques Kiladjian MD PhD, Lina Benajiba MD PhD. SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN). American Society of Hematology 2020.

- V. Rondeau, A. Bonaud, J. Nguyen, Z. Abou-Nader, J. Lemos, M. Delord, D. Haferssas, C. Kappel, L. Vogg, D. McDermott, P.M. Murphy, M. Aurrand-Lions, S. Mancini, A. Anginot, M. Espéli et K. Balabanian. Rôle de la désensibilisation de CXCR4 dans la spécification lympho-myéloïde des progéniteurs hématopoïétiques multipotents. Congrès annuel de la Société Française d’Hématologie (Paris, France)

-V. Rondeau, A. Bonaud, Z. Abou-Nader, C. Kappel, D. Haferssas, L. Vogg, D.H. McDermott, P.M. Murphy, M. Aurrand-Lions, S.J.C. Mancini, M. Espéli et K. Balabanian. Rôle de la désensibilisation de CXCR4 dans la spécification lympho-myéloïde des progéniteurs hématopoïétiques multipotents. Journée Jeunes&Chercheurs de la Ligue Nationale contre le Cancer (Paris, France)

2019 :

‍

-Boy M, Azoulay C, Villemonteix J, Henry G, Amable L, Comba L, Klibi J, Lim A-I, Yssel H, Caignard A, Benlagha K, Di Santo J, Fenaux P, Adès L, Toubert A and Dulphy N. Altered T-cell subsets in MDS associated with autoimmune disorders. Congrès de la Société Française d’Immunologie 2019 (Nantes, France)

- V. Rondeau, J. Nguyen, A. Bonaud, A. Boutin, N. Alouche, M. Aurrand-Lions, S. Mancini, C. Blin-Wakkach, A. Anginot, M. Espéli, M. Rouleau and K. Balabanian. Maintenance and differentiation of adult skeletal mesenchymal stromal elements and hematopoietic multipotent progenitors require efficient CXCR4 desensitization. Congrès annuel de la Société Française d’Immunologie (Nantes, France)

2018 :

‍

- Boy M, Azoulay C, Villemonteix J, Henry G, Amable L, Comba L, Klibi J, Lim A-I, Yssel H, Caignard A, Benlagha K, Di Santo J, Fenaux P, Adès L, Toubert A and Dulphy N. Cytotoxic and helper T and innate lymphoid cells subsets in MDS. 5th European Congress of Immunology (ECI) 2018 (Amsterdam, Netherlands)

Proceedings/Recueil des communications

1) CXCR4 Drives Lympho-Myeloid Fate of Hematopoietic Progenitors Via mTOR and Mitochondrial Metabolic Pathways

Rondeau, V [1] , [2] ; Bonaud, A [2] ; Abou-Nader, Z [2] ; Lemos, J [2] ; Gourhand, V [2] ; Delord, M [3] ; Bidaut, G [4] ; Anginot, A [2] ; Mazure, N [5] ; McDermott, DH [6] ; Parietti-Montcuquet, V [7] ; Setterblad, N [8] ; Dulphy, N [2] ; Bachelerie, F [9] ; Stockholm, D [10] ; Aurrand-Lions, M [4] ; Murphy, PM; Espeli, M; Mancini, S [4] , [11] ; Balabanian, K

Blood, Volume138, Supplement1, Meeting Abstract2150

DOI10.1182/blood-2021-149312, PublishedNOV 23 2021, Indexed2022-09-01

2) Prevalence of VEXAS Syndrome in MDS/CMML Patients with Systemic Inflammatory and Auto-Immune Disease

Zhao, LP [1] , [2] ; Schell, B [2] , [3] ; Kim, R [3] ; Sebert, M [1] , [4] ; Lemaire, P [3] ; Boy, M [2] ; Mathis, S [3] ; Larcher, L [3] , [4] ; Chauvel, C [3] ; Dhouaieb, MB [3] ; Bisio, V [2] ; Preudhomme, C [5] , [6] ; Marceau-Renaut, A [5] , [6] ; Itzykson, R [1] , [4] ; Mekinian, A [7] , [8] ; Fain, O [7] , [8] ; Toubert, A [2] , [9] ; Fenaux, P [1] ; Dulphy, N [2] , [9] ; Clappier, E [3] , [4] ; Ades, L

Clinical lymphoma, myeloma and leukemia, Volume21, PageS337-S338, Supplement1, Meeting Abstract MDS-029

Published SEP 2021, Indexed2021-09-19

3) Sec22b is indispensable for plasma cell maintenance and antibody secretion

Espeli, M [1] , [2] ; Bonaud, A [1] , [2] ; Poncet, L [3] ; Gilbert, SM [4] ; Herrerias, PC [5] ; Barbier, J [6] ; Hill, D [7] ; Aloatti, A [8] ; Gilet, D [6] ; Stockholm, D [9] ; Amigorena, S [8] ; Smith, KG [4] ; Bruhns, P [5] ; Balabanian, K [1] , [2] ; Linterman, MA [7] ; Peden, AA

European Journal of Immunology, Volume51, Page9-9, Supplement1, Meeting Abstract S1.1

Published AUG 2021, Indexed 2022-03-05

4) Characterization of human innate lymphoid cell subsets in healthy lymph nodes

Rethacker, L [1] ; Boy, M [1] ; Roussin, F [2] ; Toubert, A [1] ; Dulphy, N [1] ; Caignard, A [1]

European Journal of Immunology, Volume51, Page36-36, Supplement1, Meeting Abstract OP-035

PublishedAUG 2021, Indexed2022-03-05

5) TET2/IDH mutations in myelodysplastic syndrome patients disrupts Natural Killer cells biology

Boy, M [1] ; Bisio, V [1] ; Zhao, LP [1] ; Lereclus, E [1] ; Guidez, F [2] ; Retiere, C [3] ; Clappier, E [4] ; Balabanian, K [1] ; Toubert, A [1] ; Fenaux, P [5] ; Ades, L [5] ; Dulphy, N

European Journal of Immunology, Volume51, Page44-44, Supplement1, Meeting AbstractOP-063

Published AUG 2021, Indexed 2022-03-05

6) MDS/CMML with TET2 or IDH mutation Are Associated with Systemic Inflammatory and Autoimmune Diseases (SIAD) and T Cell Dysregulation

Zhao, LP ; Boy, M ; Clappier, E ; Sebert, M ; Amable, L ; Klibi, J ; Benlagha, K ; Espeli, M ; Balabanian, K ; Preudhomme, C ; Marceau, A ; Itzykson, R ; Mekinian, A ; Fain, O ; Toubert, A ; Fenaux, P ; Dulphy, N ; Ades, L

Blood, Volume136, Supplement1, DOI10.1182/blood-2020-141228

PublishedNOV 5 2020, Indexed2021-02-17, Meeting Abstract

7) How Many Patients Have Congenital Neutropenia? a Population-Based Estimation from the Nationwide French Severe Chronic Neutropenia Registry

Donadieu, J; Beaupain, B ; Lapillonne, H; Fenneteau, O; De Fontbrune, FS; Bertrand, Y ; Aladjidi, N; Barlogis, V ; Abou Chahla, W; Lamy, T; Autrel, AM; Fieschi, C; Leblanc, T; Moshous, D ; Soulier, J; Beaussant, SC; Delhommeau, F; Cave, H; Paillard, C; Gouache, E; Mitri, FB; Bonnet, D ; Faivre, LO; Labrune, P; Pasquet, M; Gandemer, V; Mahlaoui, N; Balabanian, K; Bachelerie, F ; Bellanne-Chantelot, C

Blood, Volume136, Supplement1, DOI10.1182/blood-2020-135912

Published NOV 5 2020, Indexed 2021-02-22

8) Activated CXCR4 signaling accelerates TCL-1 driven lymphomagenesis

Lewis, R [1] ; Habringer, S [2] ; Maurer, HC [1] ; Singh, N [1] , [2] ; Espeli, M [3] ; Balabanian, K [3] ; Keller, U [2]

Oncology Research and treatment, Volume42, Page158-159, Supplement4

Meeting AbstractV604, Published2019, Indexed2020-09-29

9) Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

Vey, N; Dumas, PY; Recher, C; Gastaud, L; Lioure, B; Bulabois, CE; Pautas, C; Marolleau, JP; Lepretre, S; Raffoux, E; Thomas, X; Hicheri, Y; Bonmati, C; Quesnel, B; Rousselot, P; Castaigne, S; Jourdan, E; Malfuson, JV; Guillerm, G; Bouhris, JH; Ojeda, M (Ojeda, Mario) ; Hunault, M; Ifrah, N; Gardin, C; Delannoy, A; Beautier, L; Paturel, C; Andre, P; Zerbib, R; Preudhomme, C; Toubert, A; Dulphy, N; Olive, D; Pigneux, A; Dombret, H

Blood, Volume130, Supplement1, Meeting Abstract889

Published DEC 7 2017, Indexed 2018-07-13

Conference 59th Annual Meeting of the American-Society-of-Hematology (ASH)

Atlanta, GA, DEC 09-12, 2017

10) Efficient lymphoid differentiation of hematopoietic stem cells requires cxcr4 desensitization

Freitas, C [1] ; Wittner, M [2] ; Nguyen, J [1] ; Rondeau, V [1] ; Donadieu, J [3] ; Bachelerie, F [1] ; Espeli, M [1] ; Louache, F [2] ; Balabanian, K

Haematologica, Volume102, Page453-453, Supplement2

Meeting AbstractE1102, PublishedJUN 26 2017, Indexed2017-07-12

Meeting Abstract

Conference : 22nd Congress of the European-Hematology-Association

Madrid, SPAIN, JUN 22-25, 2017

‍

Ouvrage (y compris édition critique et traduction)

Karl Balabanian and Marion Espéli : Invited editors for Methods in Molecular Biology (2020): “Bone marrow environment” (ISBN 978-1-0716-1424-2)

Chapitre d'ouvrage

Rethacker L., Dulphy N., and A. Caignard. (2021). Challenges for NK cell-based therapies: What can we learn from lymph nodes? “Successes And Challenges Of NK Immunotherapy. Breaking Tolerance To Cancer Resistance”. Ed. Elsevier Academic Press (ISBN 978-0-12-824375-6)

Article de blog scientifique

Inserm, le Magazine #49 Avril 2021 :

Marion Espéli et Karl Balabanian : Quand la réponse humorale extrafolliculaire s’emballe

Communication Inserm Ile de France Mars 2021:

Marion Espéli et Karl Balabanian : La signalisation de CXCR4, un rhéostat de la réponse humorale extrafolliculaire

Brevet

“New Method to Obtain Lymphoid Progenitors” Patent WO/2018/177971 (PCT/EP2018/057580) registered in 2018

Authors: Christelle Freitas, Vincent Rondeau and Karl Balabanian

"T cells modified to express mutated CXCR4 or partially deleted and uses thereof” Patent WO/2021/069593 (PCT/EP2020/078283) registered in 2021

Authors: Mélanie Wencker, Sophia Djebali, Jacqueline Marvel and Karl Balabanian

“Development of an in vitro co-culture model between primary stromal cells and MPP4”

Patenting started the 25/04/2022 with Inserm Transfer (N/REF : EB22198)

Authors: Zeina Abou Nader, Marion Espéli and Karl Balabanian

Autre publication

Schell B. and N. Dulphy. (2022) La cellule NK : fonctions et dysfonctions. Correspondances en Onco-Hématologie. 17(6):334-338

Houde N, Espéli M, Charron J. (2022). Involvement of MEK1 and MEK2 kinases in the maturation of the mouse immune system. Médecine/Sciences. 38(6-7):529-532.

Toubert A., Turhan A, Guerci-Bresler A., Dulphy N., and D. Réa. (2018). Lymphocytes NK : un rôle majeur dans le contrôle immunologique de la leucémie myéloïde chronique. Médecine/Sciences. 34:540-6.

Documents non publiés

Pré-publication, document de travail

Anginot A, Nguyen J, Abou Nader Z, Rondeau V, Bonaud A, Kalogeraki M, Boutin A, Lemos J, Bisio V, Koenen J, Sakr L, Marty C, Coudert A, Provot S, Dulphy N, Aurrand-Lions M, Mancini SJC, Lazennec G, McDermott DH, Guidez F, Blin-Wakkach C, Murphy PM, Cohen-Solal M, Espéli M, Rouleau M, and Balabanian K. 2023. WHIM Syndrome-linked CXCR4 mutations drive osteoporosis. Nature Communications, in press

Bonaud A, Gargowitsch L, Gilbert SM, Rajan E, Canales-Herrerias P, Stockholm D, Rahman NF, Collins MO, Taskiran H, Hill DL, Alloatti A, Alouche N, Balor S, Soldan V, Gillet D, Barbier J, Bachelerie F, Smith KGC, Jellusova J, Bruhns P, Amigorena S, Balabanian K, Linterman MA, Peden AA, Espéli M. 2023. Sec22b is a critical and nonredundant regulator of plasma cell maintenance. Proc Natl Acad Sci U S A. 2023 Jan 10;120(2):e2213056120. doi: 10.1073/pnas.2213056120

Bonaud A, Khamyath M and Espéli M. 2023. The cellular Biology of plasma cells: Unmet need and opportunities. Immunology Letters. 2023 Feb;254:6-12. doi: 10.1016/j.imlet.2023.01.005. Epub 2023 Jan 13.

Khamyath M, Bonaud A, Balabanian K* and Espéli M*. 2023. La signalisation de Cxcr4, un rhéostat de la réponse immune à médiation humorale. Médecine/Sciences. 2023 Jan;39(1):23-30. doi: 10.1051/medsci/2022192. Epub 2023 Jan 24. *co-senior authors

Boy M, Bisio V, Zhao LP, Guidez F, Schell B, Lereclus E, Henry G, Villemonteix J, Rodrigues-Lima F, Gagne K, Retiere C, Larcher L, Kim R, Clappier E, Sebert M, Mekinian A, Fain O, Caignard A, Espeli M, Balabanian K, Toubert A, Fenaux P, Ades L, and Dulphy N. 2023. Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation. Nature Communications. 2023 Feb 3;14(1):588. doi: 10.1038/s41467-023-36193-w.

Rapport

N/A

Travaux universitaires

Thèses

Jessica Natt : 2017 «Plasmocytes et désordres immunitaires : impacts des chimiokines et de leurs récepteurs sur la biologie des cellules sécrétrices d’anticorps dans le syndrome WHIM et le lupus systémique»

Université Paris-Saclay

Nagham Alouche : 2018 «Impact of a gain of function of Cxcr4 on plasma cell biology»

Université Paris-Saclay

Julie Nguyen : 2018 «Rôle de la désensibilisation de Cxcr4 dans l’homéostasie médullaire chez la souris»

Université Paris-Saclay

Joyce Koenen : 2019 «Rôle de ACKR3/CXCR7 dans l’homéostasie de l'écosystème médullaire chez la souris»

Université Paris-Saclay

Vincent Rondeau : 2020 «Rôle de la désensibilisation de CXCR4 dans la spécification lympho-myéloïde des progéniteurs hématopoïétiques multipotents»

Université Paris-Saclay

Maxime Boy : 2021 «Impact des mutations TET2/IDH sur les populations lymphocytaires dans les Syndromes Myélodysplasiques»

Université Paris-Cité

HDR

Marion Espéli : 2017 « Analysis of B cell biology in health and disease »

Université Paris-Saclay

Cours

N. Dulphy. 2021. “Lymphoid cells of innate immunity: Natural Killer cells and ILCs”. Repository UE13 Immunology. DFGSM2 Medical Studies, Faculté de Santé, Université Paris Cité.

‍

Team pour Hélène Moins

‍

2022

1. Predictive value of vascular endothelialgrowth factor polymorphisms for maintenance bevacizumab efficacy in metastaticcolorectal cancer: an ancillary study of the PRODIGE 9 phase III trial. deRauglaudre B, Sibertin-Blanc C, Fabre A, Le Malicot K, Bennouna J, GhiringhelliF, Taïeb J, Boige V, Bouché O, Chatellier T, Faroux R, François E, Jacquot S,Genet D, Mulot C, Olschwang S, Seitz JF, Aparicio T, Dahan L.Ther Adv Med Oncol.2022 Dec 26;14:17588359221141307. doi: 10.1177/17588359221141307. eCollection2022.PMID: 36601631 Free PMC article.

2. Risk of SARS-CoV-2 infection inhealthcare workers with inflammatory bowel disease: a case-control study. Amiot A, Bourrier A, Gornet JM, Dewit O, Nancey S, Altwegg R, AbitbolV, Laharie D, Reenaers C, Gagnière C, Buisson A, Nachury M, Viennot S, VuittonL, Stefanescu C, Marteau P, Bouguen G, Seksik P; GETAID-INFOPRO study group.InfectPrev Pract. 2023 Mar;5(1):100267. doi: 10.1016/j.infpip.2022.100267. Epub 2022Dec 30.PMID: 36601289 Free PMCarticle.

3. Reply to Danese et al. Jung CFM, Hallit R, Müller-Dornieden A,Calmels M, Goere D, Chaput U, Camus M, Gonzalez JM,Barthet M, Jacques J, Legros R, Barrioz T, Kück F, Seif Amir Hosseini A,Ghadimi M, Kunsch S, Ellenrieder V, Wedi E, Barret M.Endoscopy.2023 Jan;55(1):101. doi: 10.1055/a-1901-8750. Epub 2022 Dec 20.PMID: 36538923 No abstract available.

4. Autologous organoid co-culture modelreveals T cell-driven epithelial cell death in Crohn's Disease. Hammoudi N, Hamoudi S, Bonnereau J, BottoisH, Pérez K, Bezault M, Hassid D, Chardiny V, Grand C, Gergaud B, Bonnet J,Chedouba L, Tran Minh ML, Gornet JM, Baudry C, Corte H, Maggiori L, ToubertA, McBride J, Brochier C, Neighbors M, Le Bourhis L, Allez M.FrontImmunol. 2022 Nov 10;13:1008456. doi: 10.3389/fimmu.2022.1008456. eCollection2022.PMID: 36439157 Free PMCarticle.

5. A Two-Step Frailty Assessment Strategyin Older Patients With Solid Tumors: A Decision Curve Analysis. González Serrano A, Laurent M, Barnay T,Martínez-Tapia C, Audureau E, Boudou-Rouquette P, Aparicio T, Rollot-Trad F, Soubeyran P, Bellera C,Caillet P, Paillaud E, Canouï-Poitrine F.JClin Oncol. 2023 Feb 1;41(4):826-834. doi: 10.1200/JCO.22.01118. Epub 2022 Oct28.PMID: 36306481 Free PMCarticle.

6. Epigenetic master regulators HDAC1 andHDAC5 control pathobiont Enterobacteria colonization in ileal mucosa of Crohn'sdisease patients.ChervyM, Sivignon A, Dambrine F, Buisson A, Sauvanet P, Godfraind C, Allez M, Le Bourhis L, The Remind Group, Barnich N, DenizotJ.Gut Microbes. 2022 Jan-Dec;14(1):2127444. doi:10.1080/19490976.2022.2127444.PMID: 36175163 Free PMCarticle.

7. Comparison of the risk of Crohn'sdisease postoperative recurrence between modified Rutgeerts score i2a and i2bcategories: an individual patient data meta-analysis. Rivière P, Pekow J, Hammoudi N, Wils P,De Cruz P, Wang CP, Mañosa M, Ollech J, Allez M, Nachury M, Kamm MA, Ahanori M,Ferrante M, Buisson A, Singh S, Laharie D, Diouf M, Fumery M.JCrohns Colitis. 2022 Sep 18:jjac137. doi: 10.1093/ecco-jcc/jjac137. Onlineahead of print.PMID: 36124813

8. Phase II INTERACT-ION study: ezabenlimab(BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed bychemoradiotherapy in patients with Stage III squamous cell anal carcinoma. Kim S, Boustani J, Vernerey D, VendrelyV, Evesque L, Francois E, Quero L, Ghiringhelli F, de la Fouchardière C,Dahan L, Bouché O, Chibaudel B, Hajbi FE, Vernet C, Rebucci-Peixoto M,Feuersinger A, Maritaz C, Borg C.FrontOncol. 2022 Aug 24;12:918499. doi: 10.3389/fonc.2022.918499. eCollection 2022.PMID: 36119522 Free PMCarticle.

9. Preliminary tolerance analysis ofadjuvant chemotherapy in older patients after resection of stage III coloncancer from the PRODIGE 34-FFCD randomized trial. Aparicio T, Bouché O, Etienne PL, Barbier E,Mineur L, Desgrippes R, Guérin-Meyer V, Hocine F, Martin J, Le Brun-Ly V,Cretin J, Desramé J, Rinaldi Y, Cany L, Falandry C, Lefevre LB, Marous M,Terrebonne E, Mosser L, Turpin J, Turpin A, Bauguion L, Reichling C, Van denEynde M, Carola E, Hiret S.Dig Liver Dis. 2022 Sep14:S1590-8658(22)00662-4. doi: 10.1016/j.dld.2022.08.036. Online ahead ofprint.PMID: 36115817 Freearticle.

10. Recurrence-free survival versus overallsurvival as a primary endpoint for studies of resected colorectal livermetastasis: a retrospective study and meta-analysis. Ecker BL, Lee J, Saadat LV, Aparicio T, Buisman FE, Balachandran VP, DrebinJA, Hasegawa K, Jarnagin WR, Kemeny NE, Kingham TP, Groot Koerkamp B, Kokudo N,Matsuyama Y, Portier G, Saltz LB, Soares KC, Wei AC, Gonen M, D'Angelica MI.LancetOncol. 2022 Oct;23(10):1332-1342. doi: 10.1016/S1470-2045(22)00506-X. Epub 2022Sep 1.PMID: 36058227

11. Large-scale sequencing identifiesmultiple genes and rare variants associated with Crohn's diseasesusceptibility. Sazonovs A, Stevens CR, Venkataraman GR,Yuan K, Avila B, Abreu MT, Ahmad T, Allez M, Ananthakrishnan AN, Atzmon G, Baras A,Barrett JC, Barzilai N, Beaugerie L, Beecham A, Bernstein CN, Bitton A,Bokemeyer B, Chan A, Chung D, Cleynen I, Cosnes J, Cutler DJ, Daly A, Damas OM,Datta LW, Dawany N, Devoto M, Dodge S, Ellinghaus E, Fachal L, Farkkila M,Faubion W, Ferreira M, Franchimont D, Gabriel SB, Ge T, Georges M, Gettler K,Giri M, Glaser B, Goerg S, Goyette P, Graham D, Hämäläinen E, Haritunians T,Heap GA, Hiltunen M, Hoeppner M, Horowitz JE, Irving P, Iyer V, Jalas C, KelsenJ, Khalili H, Kirschner BS, Kontula K, Koskela JT, Kugathasan S, Kupcinskas J,Lamb CA, Laudes M, Lévesque C, Levine AP, Lewis JD, Liefferinckx C, LoescherBS, Louis E, Mansfield J, May S, McCauley JL, Mengesha E, Mni M, Moayyedi P,Moran CJ, Newberry RD, O'Charoen S, Okou DT, Oldenburg B, Ostrer H, Palotie A,Paquette J, Pekow J, Peter I, Pierik MJ, Ponsioen CY, Pontikos N, Prescott N,Pulver AE, Rahmouni S, Rice DL, Saavalainen P, Sands B, Sartor RB, Schiff ER,Schreiber S, Schumm LP, Segal AW, Seksik P, Shawky R, Sheikh SZ, Silverberg MS,Simmons A, Skeiceviciene J, Sokol H, Solomonson M, Somineni H, Sun D, Targan S,Turner D, Uhlig HH, van der Meulen AE, Vermeire S, Verstockt S, Voskuil MD,Winter HS, Young J; Belgium IBD Consortium; Cedars-Sinai IBD; International IBDGenetics Consortium; NIDDK IBD Genetics Consortium; NIHR IBD BioResource;Regeneron Genetics Center; Consortium;SPARC IBD Network; UK IBD Genetics Consortium; Duerr RH, Franke A, Brant SR,Cho J, Weersma RK, Parkes M, Xavier RJ, Rivas MA, Rioux JD, McGovern DPB, HuangH, Anderson CA, Daly MJ.Nat Genet. 2022 Sep;54(9):1275-1283.doi: 10.1038/s41588-022-01156-2. Epub 2022 Aug 29.PMID: 36038634 Free PMCarticle.

12. Distinct blood protein profilesassociated with the risk of short-term and mid/long-term clinical relapse inpatients with Crohn's disease stopping infliximab: when the remission statehides different types of residual disease activity. Pierre N, Huynh-Thu VA, Marichal T, AllezM, Bouhnik Y, Laharie D,Bourreille A, Colombel JF, Meuwis MA, Louis E; GETAID (Groupe d’EtudeThérapeutique des Affections Inflammatoires du tube Digestif).Gut. 2023 Mar;72(3):443-450. doi: 10.1136/gutjnl-2022-327321. Epub2022 Aug 25.PMID: 36008101 Freearticle.

13. Efficacy and Safety of InfliximabRetreatment in Crohn's Disease: A Multicentre, Prospective, ObservationalCohort (REGAIN) Study from the GETAID. Boschetti G, Nachury M, Laharie D, Roblin X, GillettaC, Aubourg A, Bourreille A, Zallot C, Hebuterne X, Buisson A, Grimaud JC,Bouhnik Y, Allez M, Altwegg R, Viennot S, Vuitton L,Carbonnel F, Paul S, Desseaux K, Lambert J, Peyrin-Biroulet L.AmJ Gastroenterol. 2022 Sep 1;117(9):1482-1490. doi:10.14309/ajg.0000000000001842. Epub 2022 Jun 2.PMID: 35973142

14. Neoadjuvant Nivolumab Plus Ipilimumab andAdjuvant Nivolumab in Localized Deficient Mismatch Repair/MicrosatelliteInstability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCORNEONIPIGA Phase II Study. André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C,Adenis A, Jary M, Tournigand C, Aparicio T,Desrame J, Lièvre A, Garcia-Larnicol ML, Pudlarz T, Cohen R, Memmi S, VernereyD, Henriques J, Lefevre JH, Svrcek M.J Clin Oncol. 2023 Jan 10;41(2):255-265. doi:10.1200/JCO.22.00686. Epub 2022 Aug 15.PMID: 35969830 Free PMCarticle. Clinical Trial.

15. ELANE neutropenia and solid tumors: Fourcases from the French severe chronic neutropenia registry. Donadieu J, Bou Mitri F, Beaupain B,Alajidi N, Viallard JF, Paih JL, Yacoub M, Leblanc T, Quero L, Rouland A, Labbe L, Deback C,Bellanne-Chantelot C, Emile JF.PediatrBlood Cancer. 2022 Nov;69(11):e29923. doi: 10.1002/pbc.29923. Epub 2022 Aug 15.PMID: 35969146

16. Genetic Diagnosis Guides Treatment ofAutoimmune Enteropathy.Charbit-HenrionF, Haas M, Chaussade S, Cellier C, Cerf-Bensussan N, Malamut G; Contributorsfrom the AUTOIMMUNE ENTEROPATHY WORKING GROUP; Khater S, Khiat A, Cording S,Parlato M, Dragon-Durey MA, Beuvon F, Brousse N, Terris B, Picard C, Fusaro M,Rieux-Laucat F, Stolzenberg MC, Jannot AS, Mathian A, Allez M, Malphettes M, Fieschi C, Aubourg A,Zallot C, Roblin X, Abitbol V, Belle A, Wils P, Cheminant M, Matysiak-Budnik T,Vuitton L, Pouderoux P, Abramowitz L, Castelle M, Suarez F, Hermine O, RuemmeleF, Mouthon L.Clin Gastroenterol Hepatol. 2022 Aug6:S1542-3565(22)00730-3. doi: 10.1016/j.cgh.2022.07.030. Online ahead of print.PMID: 35944833 Freearticle. No abstract available.

17. What should be done in terms offertility preservation for patients with cancer? The French 2021 guidelines. Rives N, Courbière B, Almont T, KassabD, Berger C, Grynberg M, Papaxanthos A, Decanter C, Elefant E, Dhedin N,Barraud-Lange V, Béranger MC, Demoor-Goldschmidt C, Frédérique N, Bergère M,Gabrel L, Duperray M, Vermel C, Hoog-Labouret N, Pibarot M, Provansal M, Quéro L, Lejeune H, Methorst C, Saias J,Véronique-Baudin J, Giscard d'Estaing S, Farsi F, Poirot C, Huyghe É.EurJ Cancer. 2022 Sep;173:146-166. doi: 10.1016/j.ejca.2022.05.013. Epub 2022 Aug3.PMID: 35932626 Review.

18. A CEACAM5-derived Peptide Activating CD8⁺ Regulatory T Cells: A Future Option forRestoring Mucosal Homeostasis in Crohn's Disease? Allez M.Gastroenterology.2022 Oct;163(4):822-824. doi: 10.1053/j.gastro.2022.07.070. Epub 2022 Aug 2.PMID: 35931106 No abstract available.

19. Immunotherapy in MSI/dMMR tumors in theperioperative setting: The IMHOTEP trial. Coutzac C, Bibeau F, Ben Abdelghani M, Aparicio T, Cohen R, Coquan E, Dubreuil O, EvesqueL, Ghiringhelli F, Kim S, Lesourd S, Neuzillet C, Phelip JM, Piessen G,Rochigneux P, Samalin E, Soularue E, Touchefeu Y, Tougeron D, Zaanan A, de laFouchardière C.Dig Liver Dis. 2022Oct;54(10):1335-1341. doi: 10.1016/j.dld.2022.07.008. Epub 2022 Jul 28.PMID: 35907691 Freearticle. Clinical Trial.

20. Cutaneous manifestations oflymphoid-variant hypereosinophilic syndrome. Laurent C, Lefèvre G, Kahn JE, Staumont-Salle D,Felten R, Puget M, Moulinet T, Machelart I, Launay D, Charvet E, Bouaziz JD,Jachiet M, Espitia A, Mahr A, Le Clech C, Malphettes M, Morice C, Mourah S, Moins-TeisserencH, Lifermann F, Soulier-Guérin K, Villate A, Baillou C,Grados A, Robbins A, Abisror N, Bagot M, Boutboul D, Panel K, Vignon-PennamenMD, Rivet J, Battistella M, Groh M, de Masson A; CEREO network.BrJ Dermatol. 2022 Dec;187(6):1011-1013. doi: 10.1111/bjd.21782. Epub 2022 Aug12.PMID: 35862277 No abstract available.

21. Comparative real-world effectiveness ofvedolizumab and ustekinumab for patients with ulcerative colitis: a GETAIDmulticentre cohort study. Meyer A, Fumery M, Peyrin-Biroulet L,Filippi J, Altwegg R, Bouhnik Y, Serrero M, Laharie D, Roblin X, Nachury M,Abitbol V, Cadiot G, Nancey S, Allez M, Gilletta C, Vuitton L, Savoye G, NahonS, Bourrier A, Buisson A, Bouguen G, Bourreille A, Viennot S, Carbonnel F,Amiot A.Scand J Gastroenterol. 2022 Dec;57(12):1454-1462. doi:10.1080/00365521.2022.2095668. Epub 2022 Jul 12.PMID: 35819361

22. Autologous T cell responses to primaryhuman colorectal cancer spheroids are enhanced by ectonucleotidase inhibition. Bonnereau J, Courau T, Asesio N, SalfatiD, Bouhidel F, Corte H, Hamoudi S, Hammoudi N, Lavolé J, Vivier-Chicoteau J,Chardiny V, Maggiori L, Blery M, Remark R, Bonnafous C, Cattan P, Toubert A,Bhat P, Allez M, Aparicio T, Le BourhisL.Gut. 2022 Jul 8:gutjnl-2021-326553. doi:10.1136/gutjnl-2021-326553. Online ahead of print.PMID: 35803702

23. Large-cell transformation is anindependent poor prognostic factor in Sézary syndrome: analysis of 117 cases. Bontoux C, de Masson A, Thonnart N,Ram-Wolff C, Caraguel F, Batista L, Carpentier S, Moins-TeisserencH, Rivet J, Vignon-Pennamen MD, Marie-Cardine A, BagotM, Battistella M.Br J Dermatol. 2022 Nov;187(5):815-817.doi: 10.1111/bjd.21738. Epub 2022 Aug 2.PMID: 35791764 Free PMCarticle. No abstract available.

24. Predictive factors for the success ofendoscopic dilation of esophageal caustic stricture: the experience of a Frenchtertiary reference center. Hammoudi N, Giaoui A, Lambert J, DhoogeM, Corte H, Tran-Minh ML, Cattan P, Gornet JM.SurgEndosc. 2022 Aug;36(8):5660-5668. doi: 10.1007/s00464-021-08781-8. Epub 2022Jul 5.PMID: 35790591

25. CORE-IBD: A MultidisciplinaryInternational Consensus Initiative to Develop a Core Outcome Set for RandomizedControlled Trials in Inflammatory Bowel Disease. CORE-IBD Collaborators; Ma C, Hanzel J, Panaccione R,Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, Bernstein CN, Bossuyt P, BresslerB, Bryant RV, Cohen B, Colombel JF, Danese S, Dignass A, Dubinsky MC, FleshnerPR, Gearry RB, Hanauer SB, Hart A, Kotze PG, Kucharzik T, Lakatos PL, Leong RW,Magro F, Panés J, Peyrin-Biroulet L, Ran Z, Regueiro M, Singh S, Spinelli A,Steinhart AH, Travis SP, van der Woude CJ, Yacyshyn B, Yamamoto T, Allez M, Bemelman WA, Lightner AL, Louis E, RubinDT, Scherl EJ, Siegel CA, Silverberg MS, Vermeire S, Parker CE, McFarlane SC,Guizzetti L, Smith MI, Vande Casteele N, Feagan BG, Jairath V.Gastroenterology.2022 Oct;163(4):950-964. doi: 10.1053/j.gastro.2022.06.068. Epub 2022 Jul 3.PMID: 35788348

26. A Genetic Association Test Accountingfor Skewed X-Inactivation With Application to Biotherapy Immunogenicity inPatients With Autoimmune Diseases. Hässler S, Camilleri-Broët S, Allez M, Deisenhammer F, Fogdell-Hahn A,Mariette X, Pallardy M, Broët P.FrontMed (Lausanne). 2022 Jun 1;9:856917. doi: 10.3389/fmed.2022.856917. eCollection2022.PMID: 35721087 Free PMCarticle.

27. [Immunotherapy and radiotherapy: Anoften-winning combination]. Blanchet-Deverly S, Quéro L.BullCancer. 2022 Jul-Aug;109(7-8):748-750. doi: 10.1016/j.bulcan.2022.05.001. Epub2022 Jun 15.PMID: 35717221 French. No abstract available.

28. Ustekinumab versus adalimumab forinduction and maintenance therapy in biologic-naive patients with moderately toseverely active Crohn's disease: a multicentre, randomised, double-blind,parallel-group, phase 3b trial. Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V,Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E,Shchukina OB, Sandborn WJ; SEAVUE Study Group.Lancet.2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2.PMID: 35691323 ClinicalTrial.

29. Granulomatous slack skin: clinicalcharacteristics, prognosis and response to therapy. A study from the CutaneousLymphoma French Study Group. Battesti G, Ram-Wolff C, Dobos G, AubinF, Algros MP, Guenova E, Joly P, Courville P, Mourah S, Cayuela JM, Bouaziz JD, Moins-TeisserencH, Battistella M, Vignon-Pennamen MD, Rivet J, Bagot M,de Masson A; Cutaneous Lymphoma French Study Group.BrJ Dermatol. 2022 Nov;187(5):790-793. doi: 10.1111/bjd.21699. Epub 2022 Jul 4.PMID: 35661348 Free PMCarticle. No abstract available.

30. Emergency computed tomography evaluationof caustic ingestion. Assalino M, Resche-Rigon M, Corte H, Maggiori L, Zagdanski AM, GoereD, Sarfati E, Cattan P,Chirica M.DisEsophagus. 2022 Nov 15;35(11):doac032. doi: 10.1093/dote/doac032.PMID: 35649393

31. Fecal microbiota and bile acids in IBDpatients undergoing screening for colorectal cancer. Lavelle A, Nancey S, Reimund JM, LaharieD, Marteau P, Treton X, Allez M, Roblin X, Malamut G, Oeuvray C,Rolhion N, Dray X, Rainteau D, Lamaziere A, Gauliard E, Kirchgesner J, BeaugerieL, Seksik P, Peyrin-Biroulet L, Sokol H.GutMicrobes. 2022 Jan-Dec;14(1):2078620. doi: 10.1080/19490976.2022.2078620.PMID: 35638103 Free PMCarticle.

32. Safety of FOLFIRI + Durvalumab +/-Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A SafetyRun-In from the Randomized Phase II Study DURIGAST PRODIGE 59. Evrard C, Aparicio T, Soularue E, Le Malicot K, Desramé J,Botsen D, El Hajbi F, Gonzalez D, Lepage C, Bouché O, Tougeron D, On Behalf OfThe Durigast-Prodige Investigators/Collaborators.Biomedicines.2022 May 23;10(5):1211. doi: 10.3390/biomedicines10051211.PMID: 35625947 Free PMCarticle.

33. FFCD 1709-SIRTCI phase II trial:Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumabin liver-dominant metastatic colorectal cancer. Randrian V, Pernot S, Le Malicot K, Catena V,Baumgaertner I, Tacher V, Forestier J, Hautefeuille V, Tabouret-Viaud C,Gagnaire A, Mitry E, Guiu B, Aparicio T, Smith D, Dhomps A, Tasu JP, PerdrisotR, Edeline J, Capron C, Cheze-Le Rest C, Emile JF, Laurent-Puig P,Bejan-Angoulvant T, Sokol H, Lepage C, Taieb J, Tougeron D.DigLiver Dis. 2022 Jul;54(7):857-863. doi: 10.1016/j.dld.2022.04.024. Epub 2022May 21.PMID: 35610167 Freearticle. Clinical Trial.

34. Prevalence of anti-TNF contraindicationsin Crohn's disease: A cross-sectional survey from the GETAID. Amiot A, Seksik P, Reimund JM, NachuryM, Altwegg R, Bourreille A, Viennot S, Fumery M, Roblin X, Serrero M, Allez M, Painchart C, Chanteloup E, Vuitton L,Fotsing G, Buisson A, Coulibaly B, Nancey S, Gilletta C, Plastaras L, AbitbolV, Guillo L, Simon M, Nahon S, Laharie D, Peyrin-Biroulet L, Bouguen G;anti-TNF contraindication study group.DigLiver Dis. 2022 Oct;54(10):1350-1357. doi: 10.1016/j.dld.2022.04.011. Epub 2022May 14.PMID: 35577685 Freearticle.

35. Epidemiology, Risk Factors and Diagnosisof Small Bowel Adenocarcinoma. Aparicio T, Pachev A, Laurent-Puig P, Svrcek M.Cancers (Basel). 2022May 2;14(9):2268. doi: 10.3390/cancers14092268. PMID: 35565398 Free PMCarticle. Review.

36. Heterogeneity of Mismatch Repair Statusand Microsatellite Instability between Primary Tumour and Metastasis and ItsImplications for Immunotherapy in Colorectal Cancers. Evrard C, Messina S, Sefrioui D, FrouinÉ, Auriault ML, Chautard R, Zaanan A, Jaffrelot M, De La Fouchardière C, Aparicio T, Coriat R, Godet J, Silvain C, RandrianV, Sabourin JC, Guimbaud R, Miquelestorena-Standley E, Lecomte T, Moulin V,Karayan-Tapon L, Tachon G, Tougeron D.IntJ Mol Sci. 2022 Apr 17;23(8):4427. doi: 10.3390/ijms23084427.PMID: 35457245 Free PMCarticle.

37. The Role of Radiotherapy in TreatingKaposi's Sarcoma in HIV Infected Patients. Quéro L, Palich R, Valantin MA, On Behalf OfCancervih Working Group.Cancers (Basel). 2022 Apr 10;14(8):1915.doi: 10.3390/cancers14081915.PMID: 35454820 Free PMCarticle. Review.

38. Prognosis and chemosensitivity ofnon-colorectal alimentary tract cancers with microsatellite instability. Boyer C, Sefrioui D, Cohen R, ChautardR, Perrier M, Lebrun H, Goujon G, Hautefeuille V, Dior M, Walter T, Mary F,Manfredi S, Caroli-Bosc FX, Cervantes B, Coriat R, Deluche E, Zaanan A, OlivierR, Bouché O, Piessen G, Lecomte T, Louvet C, Michel P, Aparicio T, André T, Taieb J, Randrian V, TougeronD.Dig Liver Dis. 2023 Jan;55(1):123-130. doi:10.1016/j.dld.2022.03.011. Epub 2022 Apr 6.PMID: 35397988

39. Innate lymphoid cells: NK and cytotoxicILC3 subsets infiltrate metastatic breast cancer lymph nodes. Rethacker L, Boy M, Bisio V, Roussin F,Denizeau J, Vincent-Salomon A, Borcoman E, Sedlik C, Piaggio E, Toubert A,Dulphy N, Caignard A.Oncoimmunology.2022 Mar 30;11(1):2057396. doi: 10.1080/2162402X.2022.2057396. eCollection2022.PMID: 35371620 Free PMCarticle.

40. Role of adherent and invasive Escherichiacoli in Crohn's disease: lessons from thepostoperative recurrence model. Buisson A, Sokol H, Hammoudi N, Nancey S, Treton X, Nachury M, Fumery M,Hébuterne X, Rodrigues M, Hugot JP, Boschetti G, Stefanescu C, Wils P, SeksikP, Le Bourhis L, Bezault M, Sauvanet P, Pereira B, Allez M, Barnich N; Remind study group.Gut.2023 Jan;72(1):39-48. doi: 10.1136/gutjnl-2021-325971. Epub 2022 Mar 31.PMID: 35361684 ClinicalTrial.

41. SOCRATE-PRODIGE 55 trial: A randomizedphase II study to evaluate second-line ramucirumab alone or with paclitaxel inolder patients with advanced gastric cancer. Boisteau E, François E, Aparicio T, Le Malicot K, Boulahssass R, LecomteT, Laurent-Puig P, Guiu B, Paillaud E, Galais MP, Lopez-Trabada Ataz D,Tougeron D, Dourthe LM, Guimbaud R, Samalin E, Moreau M, Louvet C, Lepage C,Lièvre A.Dig Liver Dis. 2022 Jun;54(6):747-754. doi:10.1016/j.dld.2022.03.001. Epub 2022 Mar 26.PMID: 35351371 ClinicalTrial.

42. Overall Survival and Prognostic Factorsamong Older Patients with Metastatic Pancreatic Cancer: A RetrospectiveAnalysis Using a Hospital Database. Conti C, Pamoukdjian F, Aparicio T, Mebarki S, Poisson J, Manceau G, TaiebJ, Rance B, Katsahian S, Charles-Nelson A, Paillaud E.Cancers(Basel). 2022 Feb 22;14(5):1105. doi: 10.3390/cancers14051105.PMID: 35267412 Free PMCarticle.

43. Prevalence of Self-Reported VenousThromboembolism and Cardiovascular Risk Factors in Patients with UlcerativeColitis: The GETAID FOCUS Study. Guillo L, Amiot A, Serrero M, Altwegg R, Roblin X, Atanasiu C, BuissonA, Le Berre C, Reenaers C, Gornet JM, Laharie D, Abitbol V, Biron A, CaronB, Nancey S, Chupin A, Blain A, Vuitton L, Caillo L, Kirchgesner J, Nachury M, Peyrin-BirouletL; FOCUS Study Group.Dig Dis Sci. 2022 Sep;67(9):4525-4532.doi: 10.1007/s10620-022-07445-4. Epub 2022 Mar 4.PMID: 35246801

44. Impact of the Ileal Microbiota onSurgical Site Infections in Crohn's Disease: A Nationwide Prospective Cohort. Julien C, Anakok E, Treton X, Nachury M,Nancey S, Buisson A, Fumery M, Filippi J, Maggiori L, Panis Y, Zerbib P,François Y, Dubois A, Sabbagh C, Rahili A, Seksik P, Allez M, Lefevre JH; REMIND Study GroupInvestigators; Le Corff S, Bonnet A, Beyer-Berjot L, Sokol H.JCrohns Colitis. 2022 Aug 30;16(8):1211-1221. doi: 10.1093/ecco-jcc/jjac026.PMID: 35218661

45. CCR8 is a new therapeutic target incutaneous T-cell lymphomas. Giustiniani J, Dobos G, Moins-TeisserencH, Eustaquio T, Battistella M, Ortonne N, Ram-Wolff C,Bouaziz JD, Marie-Cardine A, Mourah S, Bagot M, Kupper TS, Clark RA, BensussanA, de Masson A.Blood Adv. 2022 Jun 14;6(11):3507-3512.doi: 10.1182/bloodadvances.2021006512.PMID: 35201316 Free PMCarticle. No abstract available.

46. IOIBD Recommendations for ClinicalTrials in Ulcerative Proctitis: The PROCTRIAL Consensus. Caron B, Abreu MT, Siegel CA, PanaccioneR, Sands BE, Dignass A, Turner D, Dotan I, Hart AL, Ahuja V, Allez M, Ananthakrishnan AN, Ghosh S, GriffithsAM, Halfvarson J, Kaser A, Kotze PG, Koutroubakis IE, Lakatos PL, Levine A,Lewis JD, Magro F, Mantzaris GJ, O'Morain C, Ran Z, Reinisch W, Rogler G, SacharDB, Siegmund B, Silverberg MS, Sood A, Spinelli A, Steinwurz F, Tysk C,Yamamoto-Furusho JK, Schreiber S, Rubin DT, Sandborn WJ, Danese S,Peyrin-Biroulet L.Clin Gastroenterol Hepatol. 2022Nov;20(11):2619-2627.e1. doi: 10.1016/j.cgh.2022.02.032. Epub 2022 Feb 19.PMID: 35189386 Review.

47. [Major advance in the preoperativetreatment of rectal cancer]. Blanchet-Deverly S, Quéro L.BullCancer. 2022 Apr;109(4):393-395. doi: 10.1016/j.bulcan.2021.12.012. Epub 2022Feb 16.PMID: 35181062 French. No abstract available.

48. Flow cytometry for the assessment ofblood tumour burden in cutaneous T-cell lymphoma: towards a standardizedapproach. Vermeer MH, Moins-TeisserencH, Bagot M, Quaglino P, Whittaker S.BrJ Dermatol. 2022 Jul;187(1):21-28. doi: 10.1111/bjd.21053. Epub 2022 May 3.PMID: 35157307 Free PMCarticle. Review.

49. Endoscopic management of anastomoticleak after esophageal or gastric resection for malignancy: a multicenterexperience. Hallit R, Calmels M, Chaput U, LorenzoD, Becq A, Camus M, Dray X, Gonzalez JM, Barthet M, Jacques J, Barrioz T,Legros R, Belle A, Chaussade S, Coriat R, Cattan P, Prat F, Goere D, Barret M.TherapAdv Gastroenterol. 2021 Jul 23;14:17562848211032823. doi: 10.1177/17562848211032823.eCollection 2021.PMID: 35154387 Free PMCarticle.

50. Identification of Gene ExpressionProfiles Associated with an Increased Risk of Post-Operative Recurrence inCrohn's Disease. Ngollo M, Perez K, Hammoudi N, GorelikY, Delord M, Auzolle C, Bottois H, Cazals-Hatem D, Bezault M, Nancey S, NachuryM, Treton X, Fumery M, Buisson A, Barnich N, Seksik P; REMIND Study GroupInvestigators; Shen-Orr SS, Le Bourhis L, Allez M.JCrohns Colitis. 2022 Aug 30;16(8):1269-1280. doi: 10.1093/ecco-jcc/jjac021.PMID: 35143619

51. Head and neck granulomatous rashassociated with mogamulizumab mimicking mycosis fungoides. Wang J, Ram-Wolff C, Dobos G, Al Hage J,Grange F, Rivet J, Vignon-Pennamen MD, Moins-TeisserencH, Boisson M, Moegle C, Sadoux A, Mourah S, BattistellaM, Bagot M, de Masson A.Br J Dermatol. 2022 Jul;187(1):129-131.doi: 10.1111/bjd.21030. Epub 2022 Apr 7.PMID: 35083741 No abstract available.

52. Endpoints for extraintestinalmanifestations in inflammatory bowel disease trials: the EXTRA consensus fromthe International Organization for the Study of Inflammatory Bowel Diseases. GuilloL, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B,Ahuja V, Ali SA, Allez M,Ananthakrishnan AN, Bhattacharya A, Dubinsky M, Griffiths A, Hart A, KorelitzB, Kotze PG, Koutroubakis IE, Lakatos PL, Lindsay JO, Magro F, Mantzaris GJ, NgSC, O'Morain C, Panés J, Parigi T, Ran Z, Rogler G, Rubin DT, Sachar DB,Siegmund B, Steinwurz F, Tysk C, Vavricka S, Verstraete SG, Brezin AP, HaemelAK, Dignass A, Sands BE, Danese S, Peyrin-Biroulet L.Lancet GastroenterolHepatol. 2022 Mar;7(3):254-261. doi: 10.1016/S2468-1253(21)00297-1. Epub 2022Jan 17.PMID: 35051383

53. Mogamulizumab induces long-term immunerestoration and reshapes tumour heterogeneity in Sézary syndrome. Roelens M, de Masson A, Andrillon A,Ram-Wolff C, Biard L, Boisson M, Mourah S, Battistella M, Toubert A, Bagot M, Moins-TeisserencH.Br J Dermatol. 2022 Jun;186(6):1010-1025. doi:10.1111/bjd.21018.PMID: 35041763

54. The Pre-Operative GRADE Score IsAssociated with 5-Year Survival among Older Patients with Cancer UndergoingSurgery. WindP, Ap Thomas Z, Laurent M, Aparicio T,Siebert M, Audureau E, Paillaud E, Bousquet G, Pamoukdjian F.Cancers (Basel). 2021Dec 27;14(1):117. doi: 10.3390/cancers14010117.PMID: 35008281 Free PMCarticle.

55. Chemotherapy (doublet or triplet) plustargeted therapy by RAS status as conversion therapy in colorectal cancerpatients with initially unresectable liver-only metastases. The UNICANCERPRODIGE-14 randomised clinical trial. Ychou M, Rivoire M, Thezenas S, Guimbaud R,Ghiringhelli F, Mercier-Blas A, Mineur L, Francois E, Khemissa F, Chauvenet M,Kianmanesh R, Fonck M, Houyau P, Aparicio T, Galais MP, Audemar F, Assenat E,Lopez-Crapez E, Jouffroy C, Adenis A, Adam R, Bouché O.BrJ Cancer. 2022 May;126(9):1264-1270. doi: 10.1038/s41416-021-01644-y. Epub 2022Jan 6.PMID: 34992255 Free PMCarticle. Clinical Trial.

56. Ten-Year Outcomes of HypofractionatedPostmastectomy Radiation Therapy of 26 Gy in 6 Fractions. Mignot F, Quero L, Guillerm S, Benadon B, Labidi M,Cuvier C, Giacchetti S, Lorphelin H, Cahen-Doidy L, Teixeira L, Espie M,Hennequin C.Int J Radiat Oncol Biol Phys. 2022 Apr1;112(5):1105-1114. doi: 10.1016/j.ijrobp.2021.12.154. Epub 2021 Dec 26.PMID: 34963557

57. Meta-Analysis of IBD Gut Samples GeneExpression Identifies Specific Markers of Ileal and Colonic Diseases. Perez K, Ngollo M, Rabinowitz K, HammoudiN, Seksik P, Xavier RJ, Daly MJ, Dotan I, Le Bourhis L, Allez M.InflammBowel Dis. 2022 May 4;28(5):775-782. doi: 10.1093/ibd/izab311.PMID: 34928348

58. Macrophage-derived CXCL9 and CXCL11,T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients. deMasson A, Darbord D, Dobos G, Boisson M, Roelens M, Ram-Wolff C, Cassius C, LeBuanec H, de la Grange P, Jouenne F, Louveau B, Sadoux A, Bouaziz JD,Marie-Cardine A, Bagot M, Moins-Teisserenc H,Mourah S, Battistella M.Blood.2022 Mar 24;139(12):1820-1832. doi: 10.1182/blood.2021013341.PMID: 34905599

59. Is There a Benefit of Oxaliplatin inCombination with Neoadjuvant Chemoradiotherapy for Locally Advanced RectalCancer? An Updated Meta-Analysis. Des Guetz G, Landre T, Bollet MA, Mathonnet M, QuéroL.Cancers (Basel). 2021Nov 30;13(23):6035. doi: 10.3390/cancers13236035.PMID: 34885147 Free PMCarticle. Review.

60. Outcomes Associated With CausticIngestion Among Adults in a National Prospective Database in France. Challine A, Maggiori L, Katsahian S,Corté H, Goere D, Lazzati A, Cattan P, Chirica M.JAMASurg. 2022 Feb 1;157(2):112-119. doi: 10.1001/jamasurg.2021.6368.PMID: 34878529 Free PMCarticle.

61. Kidney function monitoring ininflammatory bowel disease: The MONITORED consensus. Guillo L, Delanaye P, Flamant M,Figueres L, Karam S, Lemoine S, Benezech A, Pelletier AL, Amiot A, Caron B,Stefanescu C, Boschetti G, Bouguen G, Rahier JF, Gornet JM, Hugot JP, Bonnet J, Vuitton L, NachuryM, Vidon M, Uzzan M, Serrero M, Dib N, Seksik P, Hebuterne X, Bertocchio JP,Mariat C, Peyrin-Biroulet L.Dig Liver Dis. 2022 Mar;54(3):309-315.doi: 10.1016/j.dld.2021.11.008. Epub 2021 Dec 2.PMID: 34866011 Freearticle. Review.

62. Steroid-Free Deep Remission at One YearDoes Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIXTrial. Laharie D, D'Haens G, Nachury M,Lambrecht G, Bossuyt P, Bouhnik Y, Louis E, Janneke van der Woude C, Buisson A,Van Hootegem P, Allez M, Filippi J, Brixi H, Gilletta C, PiconL, Baert F, Vermeire S, Duveau N, Peyrin-Biroulet L.ClinGastroenterol Hepatol. 2022 Sep;20(9):2074-2082. doi:10.1016/j.cgh.2021.11.030. Epub 2021 Nov 26.PMID: 34843987 ClinicalTrial.

63. Appendiceal tumors and pseudomyxomaperitonei: French Intergroup Clinical Practice Guidelines for diagnosis,treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER,SFCD, SFED, SFRO, ACHBT, SFR). Delhorme JB, Villeneuve L, Bouché O, Averous G, Dohan A, Gornet JM, You B, Bibeau F, Dartigues P, Eveno C,Fontaine J, Kepenekian V, Pocard M, Rousset P, Quenet F, Mariani P, Glehen O, Goéré D.DigLiver Dis. 2022 Jan;54(1):30-39. doi: 10.1016/j.dld.2021.10.005. Epub 2021 Nov20.PMID: 34815194

64. Etrolizumab as induction and maintenancetherapy for ulcerative colitis in patients previously treated with tumournecrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Peyrin-Biroulet L, Hart A, Bossuyt P,Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr,Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, SandbornWJ; HICKORY Study Group.Lancet Gastroenterol Hepatol. 2022Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17.PMID: 34798039 ClinicalTrial.

65. MyelodysplasticSyndrome associated TET2 mutations affect NK cell function and genomemethylation.

Boy M,Bisio V, Zhao LP, Guidez F, Schell B, Lereclus E, Henry G, Villemonteix J,Rodrigues-Lima F, Gagne K, Retiere C, Larcher L, Kim R, Clappier E, Sebert M,Mekinian A, Fain O, Caignard A, Espeli M, Balabanian K, Toubert A,Fenaux P, Ades L, Dulphy N.NatCommun. 2023 Feb 3;14(1):588. doi: 10.1038/s41467-023-36193-w.PMID: 36737440 Free PMC article.

2021

66. Faster and less invasive tools toidentify patients with ileal colonization by adherent-invasive E. coli inCrohn's disease. Buisson A, Vazeille E, Fumery M,Pariente B, Nancey S, Seksik P, Peyrin-Biroulet L, Allez M, Ballet N, Filippi J, Yzet C, NachuryM, Boschetti G, Billard E, Dubois A, Rodriguez S, Chevarin C, Goutte M,Bommelaer G, Pereira B, Hebuterne X, Barnich N; CEALIVE & REMIND studygroup.United European Gastroenterol J. 2021Nov;9(9):1007-1018. doi: 10.1002/ueg2.12161.PMID: 34791806 Free PMCarticle.

67. Cusatuzumab for treatment ofCD70-positive relapsed or refractory cutaneous T-cell lymphoma. Leupin N, Zinzani PL, Morschhauser F,Dalle S, Maerevoet M, Michot JM, Ribrag V, Offner F, Beylot-Barry M, Moins-TeisserencH, Zwaenepoel K, de Winne K, Battistella M, Hultberg A,Gandini D, Moshir M, Jacobs J, Delahaye T, Khan A, Zabrocki P, Silence K, vanRompaey L, Borg C, Motta G, Melle F, Calleri A, Pauwels P, de Haard H, PileriS, Bagot M.Cancer. 2022 Mar 1;128(5):1004-1014. doi:10.1002/cncr.34005. Epub 2021 Nov 2.PMID: 34726773 Freearticle. Clinical Trial.

68. Radiotherapy for gastricmucosa-associated lymphoid tissue lymphoma. Quéro L, Labidi M, Bollet M, Bommier C,Guillerm S, Hennequin C, Thieblemont C.WorldJ Gastrointest Oncol. 2021 Oct 15;13(10):1453-1465. doi:10.4251/wjgo.v13.i10.1453.PMID: 34721777 Free PMCarticle. Review.

69. Impactde la COVID-19 sur l’initiation des prescriptions des biothérapies dansles maladies inflammatoires chroniques. Richette P, Allez M,Descamps V, Perray L, Pilet S, Latourte A, Maravic M.Rev Rhum Ed Fr. 2022 May;89(3):313-314. doi:10.1016/j.rhum.2021.10.560. Epub 2021 Oct 21.PMID: 34697532 Free PMCarticle. French. No abstract available.

70. Effect of lockdown on digestive systemcancer care amongst older patients during the first wave of COVID-19: TheCADIGCOVAGE multicentre cohort study. Aparicio T, Layese R, Hemery F, Tournigand C,Paillaud E, De Angelis N, Quero L, Ganne N, Prat F, Pachev A, Galula G,Benderra MA, Canouï-Poitrine F; Clinical Data Warehouse of Greater ParisUniversity Hospitals / Inserm COVID-19 research collaboration and Cancer AP-HPGroup.Dig Liver Dis. 2022 Jan;54(1):10-18. doi:10.1016/j.dld.2021.09.017. Epub 2021 Oct 4.PMID: 34654679 Free PMCarticle.

71. Quantifying response to varioustreatments using the revisited blood staging of mycosis fungoides and Sézarysyndrome with the KIR3DL2 marker. Dobos G, Miladi M, Roelens M, Ram-Wolff C, de Masson A, Michel L,Battistella M, Mourah S, Bensussan A, Moins-TeisserencH, Bagot M.EurJ Cancer. 2021 Oct;156 Suppl 1:S6-S7. doi: 10.1016/S0959-8049(21)00638-9.PMID: 34649664 No abstract available.

72. Granulomatous rash associated withmogamulizumab mimicking mycosis fungoides: a case series. Wang J, de Masson A, Ram-Wolff C, DobosG, Al Hage J, Rivet J, Vignon-Pennamen MD, Moins-TeisserencH, Boisson M, Sadoux A, Mourah S, Battistella M, BagotM.Eur J Cancer. 2021 Oct;156 Suppl 1:S49. doi:10.1016/S0959-8049(21)00716-4.PMID: 34649659 No abstract available.

73. Patient characteristics of long-termresponders to mogamulizumab: results from the MAVORIC study. Kim YH, Khodadoust M, de Masson A, Moins-TeisserencH, Ito T, Dwyer K, Herr F, Bagot M.EurJ Cancer. 2021 Oct;156 Suppl 1:S48-S49. doi: 10.1016/S0959-8049(21)00715-2.PMID: 34649658 No abstract available.

74. Large cell transformation is anindependent prognostic factor in Sézary syndrome: a retrospective analysis of117 cases. BontouxC, De Masson A, Ram-Wolff C, Caraguel F, Batista L, Moins-TeisserencH, Marie-Cardine A, BagotM, Battistella M.EurJ Cancer. 2021 Oct;156 Suppl 1:S25. doi:10.1016/S0959-8049(21)00671-7.PMID: 34649650 No abstract available.

75. Effectiveness and predictors of responseto somatostatin analogues in patients with gastrointestinal angiodysplasias: asystematic review and individual patient data meta-analysis. Goltstein LCMJ, Grooteman KV, Rocco A,Holleran G, Frago S, Salgueiro PS, Aparicio T, Scaglione G, Chetcuti Zammit S,Prados-Manzano R, Benamouzig R, Nardone G, McNamara D, Benallaoua M,Michopoulos S, Sidhu R, Kievit W, Drenth JPH, van Geenen EJM.LancetGastroenterol Hepatol. 2021 Nov;6(11):922-932. doi:10.1016/S2468-1253(21)00262-4. Epub 2021 Sep 9.PMID: 34508668

76. Gastrointestinal bleeding in criticallyill immunocompromised patients. Catano J, Sacleux SC, Gornet JM, Camus M, Bigé N, Saliba F, Azoulay E,Dumas G, Zafrani L.Ann Intensive Care. 2021 Aug21;11(1):130. doi: 10.1186/s13613-021-00913-6.PMID: 34420114 Free PMCarticle.

77. Half of Postoperative Deaths AfterCytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Could bePreventable: A French Root Cause Analysis on 5562 Patients. Houlzé-Laroye C, Glehen O, Sgarbura O,Gayat E, Sourrouille I, Tuech JJ, Delhorme JB, Dumont F, Ceribelli C, Amroun K,Arvieux C, Moszkowicz D, Pirro N, Lefevre JH, Courvosier-Clement T, Paquette B,Mariani P, Pezet D, Sabbagh C, Tessier W, Celerier B, Guilloit JM, Taibi A,Quenet F, Bakrin N, Pocard M, Goéré D, Brigand C, Piessen G, Eveno C.AnnSurg. 2021 Nov 1;274(5):797-804. doi: 10.1097/SLA.0000000000005101.PMID: 34334647

78. Impact of COVID-19 on initiation ofbiologic therapy prescriptions for chronic inflammatory diseases. Richette P, Allez M, Descamps V, Perray L, Pilet S,Latourte A, Maravic M.Joint Bone Spine. 2022 Jan;89(1):105253.doi: 10.1016/j.jbspin.2021.105253. Epub 2021 Jul 24.PMID: 34314887 Free PMCarticle. No abstract available.

79. Effectiveness and safety of ustekinumabmaintenance therapy in 103 patients with ulcerative colitis: a GETAID cohortstudy. Fumery M, Filippi J, Abitbol V, Biron A,Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-Biroulet L, Gilletta C,Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet JM, Nahon S, Bouguen G, Viennot S, NachuryM, Amiot A.Aliment Pharmacol Ther. 2021 Oct;54(7):944-951. doi:10.1111/apt.16544. Epub 2021 Jul 23.PMID: 34296456

80. Randomized Phase II Trial Evaluating TwoSequential Treatments in First Line of Metastatic Pancreatic Cancer: Results ofthe PANOPTIMOX-PRODIGE 35 Trial. Dahan L, Williet N, Le Malicot K, Phelip JM, Desrame J, Bouché O,Petorin C, Malka D, Rebischung C, Aparicio T, Lecaille C, Rinaldi Y, Turpin A, BignonAL, Bachet JB, Seitz JF, Lepage C, François E; PRODIGE 35Investigators/Collaborators.J Clin Oncol. 2021 Oct10;39(29):3242-3250. doi: 10.1200/JCO.20.03329. Epub 2021 Jul 21.PMID: 34288696 ClinicalTrial.

81. Prognostic value of the PrP^C-ILK-IDO1axis in the mesenchymal colorectal cancer subtype. Ghazi A, Le Corre D, Pilati C, Taieb J, Aparicio T, Didelot A, Dedhar S, Mulot C, LeMalicot K, Djouadi F, de Reynies A, Launay JM, Laurent-Puig P, Mouillet-RichardS.Oncoimmunology. 2021 Jun 28;10(1):1940674. doi:10.1080/2162402X.2021.1940674. eCollection 2021.PMID: 34249475 Free PMCarticle.

82. Intraoperative Radiotherapy for BreastCancer in Elderly Women. Guillerm SO, Bourstyn E, Itti R,Cahen-Doidy L, Quéro L, Labidi M, Marchand E, Lorphelin H,Giacchetti S, Cuvier C, Espié M, Teixeira L, Hennequin C.ClinBreast Cancer. 2022 Jan;22(1):e109-e113. doi: 10.1016/j.clbc.2021.05.002. Epub2021 May 15.PMID: 34154928

83. Locoregional relapses in the ACCORD12/0405-PRODIGE 02 study: Dosimetric study and risk factors. Meillan N, Orthuon A, Chauchat P, AtlaniD, Bouche O, Chaulin B, David C, Deberne M, Debrigode C, Kao W, Keller A,Laharie H, Lamezec B, Lemanski C, Magné N, Mahé MA, Mere P, Moureau-Zabotto L,Peiffert D, Pointreau Y, Quéro L, Racadot S, Roca S, Sargos P, ServagiS, Tang E, Vendrely V, Doyen J, Huguet F.RadiotherOncol. 2021 Aug;161:198-204. doi: 10.1016/j.radonc.2021.06.006. Epub 2021 Jun16.PMID: 34144078

84. Predictive factors of severe earlytreatment-related toxicity in patients receiving first-line treatment formetastatic colorectal cancer: Pooled analysis of 2190 patients enrolled inFédération Francophone de Cancérologie Digestive (FFCD) trials. BretonC, Aparicio T,Le Malicot K, Ducreux M, Lecomte T, Bachet JB, Taieb J, Legoux JL, De GramontA, Bennouna J, Bouché O, Boussari O, Manfredi S, GornetJM.EurJ Cancer. 2021 Aug;153:40-50. doi: 10.1016/j.ejca.2021.04.040.Epub 2021 Jun 12.PMID: 34130228

85. Haemorrhagic shock secondary to adiffuse ulcerative enteritis after Ipilimumab and Nivolumab treatment formetastatic melanoma: a case report. Trystram N, Laly P, Bertheau P, Baroudjian B, Aparicio T, Gornet JM.AnnPalliat Med. 2022 Feb;11(2):837-842. doi: 10.21037/apm-21-58. Epub 2021 Jun 2.PMID: 34118829 Freearticle.

86. Multicystic peritoneal mesotheliomatreated with cytoreductive surgery followed or not by hyperthermicintraperitoneal chemotherapy: results from a large multicentric cohort. Kepenekian V, Péron J, Goéré D, Sgarbura O, Delhorme JB, Eveno C,Benzerdjeb N, Bonnefoy I, Villeneuve L, Rousset P, Abboud K, Pocard M, GlehenO; On Behalf RENAPE (French Network for Rare Peritoneal Malignancies).IntJ Hyperthermia. 2021;38(1):805-814. doi: 10.1080/02656736.2021.1903585.PMID: 34039244 Freearticle.

87. The impact of PRODIGE 7 on the currentworldwide practice of CRS-HIPEC for colorectal peritoneal metastases: Aweb-based survey and 2021 statement by Peritoneal Surface Oncology GroupInternational (PSOGI). van de Vlasakker VCJ, Lurvink RJ, CashinPH, Ceelen W, Deraco M, Goéré D, González-Moreno S, Lehmann K, Li Y,Moran B, Morris DL, Piso P, Quadros CA, Rau B, Somashekhar SP, Sommariva A, vander Speeten K, Spiliotis J, Sugarbaker PH, Teo MCC, Verwaal VJ, Yonemura Y,Glehen O, de Hingh IHJT.Eur J Surg Oncol. 2021 Nov;47(11):2888-2892.doi: 10.1016/j.ejso.2021.05.023. Epub 2021 May 13.PMID: 34020808

88. The Landmark Series: Surgical Treatmentof Colorectal Cancer Peritoneal Metastases. Bijelic L, Ramos I, Goeré D.AnnSurg Oncol. 2021 Aug;28(8):4140-4150. doi: 10.1245/s10434-021-10049-3. Epub2021 May 9.PMID: 33969466 Review.

89. Severe acute respiratory syndromecoronavirus 2 vaccination for patients with solid cancer: Review and point ofview of a French oncology intergroup (GCO, TNCD, UNICANCER). TougeronD, Hentzien M, Seitz-Polski B, Bani-Sadr F, Bourhis J, Ducreux M, Gaujoux S,Gorphe P, Guiu B, Hoang-Xuan K, Huguet F, Lecomte T, Lièvre A, Louvet C,Maggiori L, Mansi L, Mariani P, Michel P, Servettaz A, Thariat J, Westeel V, AparicioT, Blay JY, Bouché O; forThésaurus National de Cancérologie Digestive (TNCD); réseau de GroupesCoopérateurs en Oncologie (GCO); Fédération Nationale des Centres de LutteContre le Cancer (UNICANCER); Association de Chirurgie Hépato-Bilio-Pancréatiqueet Transplantation (ACHBT); Association de Recherche sur les CancersGynécologiques-Groupes d'Investigateurs Nationaux pour l'étude des CancersOvariens et du Sein (ARCAGY-GINECO); Fédération Francophone de CancérologieDigestive (FFCD); Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR);Groupe d'Oncologie Radiothérapie Tête et Cou-Intergroupe ORL(GORTEC-Intergroupe ORL); Intergroupe Francophone de Cancérologie Thoracique(IFCT); InterGroupe Coopérateur de Neuro-Oncologie/Association desNeuro-Oncologues d’Expression Française (IGCNO-ANOCEF); Société Française deChirurgie Digestive (SFCD); Société Française d’Endoscopie Digestive (SFED);Société Française de Radiothérapie Oncologique (SFRO); Société Française deRadiologie (SFR); Société Nationale Française de Colo-Proctologie (SNFCP);Société Nationale Française de Gastroentérologie (SNFGE).Eur J Cancer. 2021 Jun;150:232-239. doi:10.1016/j.ejca.2021.03.030. Epub 2021 Apr 1.PMID: 33934060 Free PMCarticle. Review.

90. Limitations of the PRODIGE 7 trial -Authors' reply. Quénet F, Roca L, de Forges H, Gléhen O, GoéréD.Lancet Oncol. 2021May;22(5):e179-e180. doi: 10.1016/S1470-2045(21)00192-3.PMID: 33932377 No abstract available.

91. Chronic pouchitis and Crohn's disease ofthe pouch after ileal pouch-anal anastomosis: Incidence and risk factors. Bresteau C, Amiot A, Kirchgesner J,de'Angelis N, Lefevre JH, Bouhnik Y, Panis Y, Beaugerie L, Allez M, Brouquet A, Carbonnel F, Meyer A.DigLiver Dis. 2021 Sep;53(9):1128-1135. doi: 10.1016/j.dld.2021.03.027. Epub 2021Apr 27.PMID: 33931341

92. [Vaccination against COVID-19 inpatients with solid cancer: Review and point of view from a French oncologyinter-group (CGO, TNCD, UNICANCER)]. TougeronD, Seitz-Polski B, Hentzien M, Bani-Sadr F, Bourhis J, Ducreux M, Gaujoux S,Gorphe P, Guiu B, Hardy-Bessard AC, Hoang Xuan K, Huguet F, Lecomte T, LièvreA, Louvet C, Maggiori L, Mariani P, Michel P, Servettaz A, Thariat J, WesteelV, Aparicio T,Blay JY, Bouché O; Thésaurus national de cancérologie digestive (TNCD); réseaude groupes coopérateurs en oncologie (GCO); Fédération nationale des centres delutte contre le cancer (UNICANCER); association de chirurgiehépato-bilio-pancréatique et transplantation (ACHBT); association de recherchesur les cancers gynecologiques-groupes d’investigateurs nationaux pour l’étudedes cancers ovariens et du sein (ARCAGY-GINECO); Fédération francophone decancérologie digestive (FFCD), groupe coopérateur multidisciplinaire enoncologie (GERCOR), groupe d’oncologie radiothérapie tête et cou-intergroupeORL (GORTEC-Intergroupe ORL); intergroupe francophone de cancérologiethoracique (IFCT); intergroupe coopérateur de neuro-oncologie association desneuro-oncologues d’expression française (IGCNO-ANOCEF); Société française dechirurgie digestive (SFCD); Société française d’endoscopie digestive (SFED);Société française de radiothérapie oncologique (SFRO); Société française deradiologie (SFR); Société nationale française de colo-proctologie (SNFCP);Société nationale française de gastroentérologie (SNFGE).Bull Cancer. 2021 Jun;108(6):614-626. doi:10.1016/j.bulcan.2021.03.009. Epub 2021 Apr 12.PMID: 33902918 Free PMCarticle. Review. French.

93. What is the optimal treatment for T1N0anal squamous cell carcinoma? Analysis of current practices in the prospectiveFrench FFCD ANABASE cohort. Bacci M, Quero L, Barbier E, Parrot L, Juguet F, PommierP, Bazire L, Etienney I, Baba-Hamed N, Spindler L, François E, Ronchin P, CampoERD, Lemanski C, Lièvre A, Siproudhis L, Abramowitz L, Lepage C, Vendrely V.DigLiver Dis. 2021 Jun;53(6):776-784. doi: 10.1016/j.dld.2021.03.015. Epub 2021Apr 16.PMID: 33867291

94. Prevalence and prognosis ofmicrosatellite instability in oesogastric adenocarcinoma, NORDICAP 16-01. Tran-Minh ML, Lehmann-Che J, Lambert J,Theou-Anton N, Poté N, Dior M, Mary F, Goujon G, Gardair C, Schischmanoff O,Kaci R, Cucherousset N, Bertheau P, Couvelard A, Aparicio T; for NORDICAP.ClinRes Hepatol Gastroenterol. 2021 Jul;45(4):101691. doi:10.1016/j.clinre.2021.101691. Epub 2021 Apr 20.PMID: 33852952

95. The Activity of Crizotinib inChemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Resultsfrom the AcSé-Crizotinib Program. Aparicio T, Cozic N, de la Fouchardière C, Meriaux E, Plaza J,Mineur L, Guimbaud R, Samalin E, Mary F, Lecomte T, Gomez-Roca C, Haineaux PA,Gratet A, Selves J, Menu Y, Colignon N, Johnson L, Legrand F, Vassal G.TargetOncol. 2021 May;16(3):381-388. doi: 10.1007/s11523-021-00811-8. Epub 2021 Apr13.PMID: 33847874 Free PMCarticle.

96. Bevacizumab as maintenance therapy inpatients with metastatic colorectal cancer: A meta-analysis of individualpatients' data from 3 phase III studies. Salvatore L, Bria E, Sperduti I, Hinke A,Hegewisch-Becker S, Aparicio T, Le Malicot K, Boige V, Koeberle D,Baertschi D, Dietrich D, Tortora G, Arnold D.CancerTreat Rev. 2021 Jun;97:102202. doi: 10.1016/j.ctrv.2021.102202. Epub 2021 Mar30.PMID: 33838596 Freearticle. Review.

97. Determinants of IBD-related disability:a cross-sectional survey from the GETAID. Tannoury J, Nachury M, Martins C, Serrero M, FilippiJ, Roblin X, Bourrier A, Bouguen G, Franchimont D, Savoye G, Buisson A, LouisE, Nancey S, Abitbol V, Reimund JM, DeWitt O, Vuitton L, Mathieu N,Peyrin-Biroulet L, Gilletta C, Allez M, Viennot S, Trang-Poisson C, Laharie D,Amiot A; GETAID-Patient Experience Study Group.AlimentPharmacol Ther. 2021 May;53(10):1098-1107. doi: 10.1111/apt.16353. Epub 2021Apr 5.PMID: 33817819 Freearticle.

98. Specific Patterns of Blood ILCs inMetastatic Melanoma Patients and Their Modulations in Response toImmunotherapy. Rethacker L, Roelens M, Bejar C, MaubecE, Moins-Teisserenc H, Caignard A.Cancers(Basel). 2021 Mar 22;13(6):1446. doi: 10.3390/cancers13061446.PMID: 33810032 Free PMCarticle.

99. Practices and expectations on the use ofcirculating tumor DNA in colorectal cancer patients: A bi-nationalAGEO/AIOM/GERCOR/FFCD/FRENCH survey. Basile D, Gallois C, Puglisi F, Cohen R, Goere D, Aprile G, Lepage C, Laurent-Puig P, DiMaio M, Lecomte T, Pernot S, Zaanan A, Taieb J.ClinRes Hepatol Gastroenterol. 2021 May;45(3):101681. doi: 10.1016/j.clinre.2021.101681.Epub 2021 Mar 27.PMID: 33785445 Freearticle.

100. Hepatocellular carcinoma: FrenchIntergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE,FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). BlancJF, Debaillon-Vesque A, Roth G, Barbare JC, Baumann AS, Boige V, Boudjema K,Bouattour M, Crehange G, Dauvois B, Decaens T, Dewaele F, Farges O, Guiu B,Hollebecque A, Merle P, Selves J, AparicioT, Ruiz I, Bouché O;Thésaurus National de Cancérologie Digestive (TNCD); Société NationaleFrançaise de Gastroentérologie (SNFGE); Fédération Francophone de CancérologieDigestive (FFCD); Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR);Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); SociétéFrançaise de Chirurgie Digestive (SFCD); Société Française d’EndoscopieDigestive (SFED); Société Française de Radiothérapie Oncologique (SFRO);Association Française pour l’Etude du Foie (AFEF).Clin Res Hepatol Gastroenterol. 2021Mar;45(2):101590. doi: 10.1016/j.clinre.2020.101590. Epub 2021 Mar 26.PMID: 33780876

101. Severe Altered Immune Status After BurnInjury Is Associated With Bacterial Infection and Septic Shock. Moins-Teisserenc H, Cordeiro DJ, Audigier V, Ressaire Q,Benyamina M, Lambert J, Maki G, Homyrda L, Toubert A, Legrand M.FrontImmunol. 2021 Mar 2;12:586195. doi: 10.3389/fimmu.2021.586195. eCollection2021.PMID: 33737924 Free PMCarticle.

102. Endoscopic ultrasound efficacy instaging gastric linitis plastica lesion: a retrospective multicentric Frenchstudy. Morgant S, Artru P, Oudjit A, LourencoN, Pasquer A, Walter T, Gornet JM, Rouquette A, Brezault C, Coriat R.AnnTransl Med. 2021 Jan;9(1):50. doi: 10.21037/atm-20-3474.PMID: 33553343 Free PMCarticle.

103. Endoscopic internal drainage and lownegative-pressure endoscopic vacuum therapy for anastomotic leaks afteroncologic upper gastrointestinal surgery. Jung CFM, Hallit R, Müller-Dornieden A, Calmels M, Goere D, Chaput U, Camus M, Gonzalez JM,Barthet M, Jacques J, Legros R, Barrioz T, Kück F, Seif Amir Hosseini A,Ghadimi M, Kunsch S, Ellenrieder V, Wedi E, Barret M.Endoscopy.2022 Jan;54(1):71-74. doi: 10.1055/a-1375-8151. Epub 2021 Apr 8.PMID: 33506454

104. The Role of Hyperthermic IntraperitonealChemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. Kusamura S, Barretta F, Yonemura Y,Sugarbaker PH, Moran BJ, Levine EA, Goere D, Baratti D, Nizri E, Morris DL, GlehenO, Sardi A, Barrios P, Quénet F, Villeneuve L, Gómez-Portilla A, de Hingh I, CeelenW, Pelz JOW, Piso P, González-Moreno S, Van Der Speeten K, Deraco M; PeritonealSurface Oncology Group International (PSOGI) and the French National Registryof Rare Peritoneal Surface Malignancies (RENAPE).JAMASurg. 2021 Mar 1;156(3):e206363. doi: 10.1001/jamasurg.2020.6363. Epub 2021 Mar10.PMID: 33502455 Free PMCarticle.

105. Cytoreductive surgery plus hyperthermicintraperitoneal chemotherapy versus cytoreductive surgery alone for colorectalperitoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase3 trial. Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, Facy O, Arvieux C,Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, Juzyna B, de Forges H, PaineauJ, Glehen O; UNICANCER-GI Group and BIG Renape Group.LancetOncol. 2021 Feb;22(2):256-266. doi: 10.1016/S1470-2045(20)30599-4. Epub 2021Jan 18.PMID: 33476595 ClinicalTrial.

106. MRI-Based Radiomics Input for Predictionof 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma. GiraudN, Saut O, Aparicio T,Ronchin P, Bazire LA, Barbier E, Lemanski C, Mirabel X, Etienne PL, Lièvre A,Cacheux W, Darut-Jouve A, De la Fouchardière C, Hocquelet A, Trillaud H,Charleux T, Breysacher G, Argo-Leignel D, Tessier A, Magné N, Ben Abdelghani M,Lepage C, Vendrely V.Cancers(Basel). 2021 Jan 7;13(2):193. doi: 10.3390/cancers13020193.PMID: 33430396 Free PMCarticle.

107. Impact of time-varying cumulativebevacizumab exposures on survival: re-analysis of data from randomized clinicaltrial in patients with metastatic colo-rectal cancer. GuilloteauA, Abrahamowicz M, Boussari O, Jooste V, AparicioT, Quantin C, Le MalicotK, Binquet C.BMCMed Res Methodol. 2021 Jan 9;21(1):14. doi:10.1186/s12874-020-01202-9.PMID: 33422006 Free PMCarticle. Clinical Trial.

108. Impact of HIV Infection on the Course ofInflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study. Guillo L, Uzzan M, Beaugerie L, Gornet JM, Amiot A, Pelletier AL, Altwegg R,Laharie D, Abitbol V, Filippi J, Goutorbe F, Nachury M, Nancey S, Viennot S,Reenaers C, Amil M, Caillo L, Buisson A, Collins M, Picon L, Vidon M, BenezechA, Rabaud C, Baumann C, Rousseau H, Dubourg G, Serrero M, Peyrin-Biroulet L.ClinGastroenterol Hepatol. 2022 Apr;20(4):787-797.e2. doi:10.1016/j.cgh.2020.12.023. Epub 2020 Dec 24.PMID: 33359726

109. PRODIGE 59-DURIGAST trial: A randomisedphase II study evaluating FOLFIRI + Durvalumab± Tremelimumab in second-line of patients with advanced gastric cancer. Evrard C, Louvet C, Hajbi FE, Fiore FD,Malicot KL, Aparicio T, Bouché O, Laurent-Puig P, Bibeau F,Lecomte T, Lièvre A, Guimbaud R, Kim S, Zaanan A, Sokol H, Chibaudel B, DesrameJ, Pierre S, Gonzalez D, Lepage C, Tougeron D.DigLiver Dis. 2021 Apr;53(4):420-426. doi: 10.1016/j.dld.2020.11.036. Epub 2021Jan 6.PMID: 33358124 Freearticle. Clinical Trial.

110. Safety of ustekinumab or vedolizumab inpregnant inflammatory bowel disease patients: a multicentre cohort study. Wils P, Seksik P, Stefanescu C, NanceyS, Allez M, Pineton de Chambrun G, Altwegg R,Gilletta C, Vuitton L, Viennot S, Serrero M, Fumery M, Savoye G, Collins M,Goutorbe F, Brixi H, Bouguen G, Tavernier N, Boualit M, Amiot A, Abitbol V,Laharie D, Pariente B; PREGNANCY-GETAID study group.AlimentPharmacol Ther. 2021 Feb;53(4):460-470. doi: 10.1111/apt.16192. Epub 2020 Dec7.PMID: 33345331

111. Management of digestive cancers duringthe COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD,GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). TougeronD, Michel P, Lièvre A, Ducreux M, Gaujoux S, Guiu B, Huguet F, Lecomte T,Lepage C, Louvet C, Maggiori L, Mariani P, AparicioT, Bouché O; ThésaurusNational de Cancérologie Digestive (TNCD); Société Nationale Française deGastroentérologie (SNFGE); Fédération Francophone de Cancérologie Digestive(FFCD); Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR); FédérationNationale des Centres de Lutte Contre le Cancer (UNICANCER); Société Françaisede Chirurgie Digestive (SFCD); Société Française d'Endoscopie Digestive (SFED);Société Française de Radiothérapie Oncologique (SFRO); Association de ChirurgieHépato-Bilio-Pancréatique et Transplantation (ACHBT); Société Française deRadiologie (SFR).DigLiver Dis. 2021 Mar;53(3):306-308. doi: 10.1016/j.dld.2020.11.029. Epub2020 Dec 17.PMID: 33341421 Free PMCarticle.

112. [Early salvage radiotherapy in prostatecancer: A future standard treatment?]. Labidi M, Hennequin C, Quéro L.BullCancer. 2021 Jan;108(1):40-42. doi: 10.1016/j.bulcan.2020.11.002. Epub 2020 Dec3.PMID: 33280838 French. No abstract available.

113. Long-term efficacy of fibrin glueinjection for perianal fistulas in patients with Crohn's disease. Vidon M, Munoz-Bongrand N, Lambert J, MaggioriL, Zeitoun JD, Corte H, Panis Y, Seksik P, Treton X, Abramowitz L, Allez M, Gornet JM.ColorectalDis. 2021 Apr;23(4):894-900. doi: 10.1111/codi.15477. Epub 2020 Dec 29.PMID: 33278859 ClinicalTrial.

114. The IBD-disk Is a Reliable Tool toAssess the Daily-life Burden of Patients with Inflammatory Bowel Disease. Tadbiri S, Nachury M, Bouhnik Y, SerreroM, Hébuterne X, Roblin X, Kirchgesner J, Bouguen G, Franchimont D, Savoye G,Buisson A, Louis E, Nancey S, ABitbol V, Reimund JM, DeWit O, Vuitton L,Matthieu N, Peyrin-Biroulet L, Gilletta C, Allez M, Viennot S, Trang-Poisson C, Dib N,Brixi H, Boualit M, Plastaras L, Boivineau L, Fumery M, Caillo L, Laharie D,Amiot A; GETAID-IBD-disk study group.JCrohns Colitis. 2021 May 4;15(5):766-773. doi: 10.1093/ecco-jcc/jjaa244.PMID: 33246337 Freearticle.

115. Impact of abdominal or pelvicradiotherapy on disease activity in inflammatory bowel disease: a multicentrecohort study from the GETAID. Broussard D, Rivière P, Bonnet J,Fotsing G, Amiot A, Peyrin-Biroulet L, Rajca S, Buisson A, Gilleta C, PelletierAL, Serrero M, Bouguen G, Altwegg R, Hebuterne X, Nancey S, Fumery M, Cadiot G,Nahon S, Rahier JF, Gornet JM, Vendrely V, Laharie D; Groupe d’ÉtudeThérapeutique des Affections Inflammatoires du Tube Digestif (GETAID).AlimentPharmacol Ther. 2021 Feb;53(3):400-409. doi: 10.1111/apt.16176. Epub 2020 Nov26.PMID: 33241906

116. What is the Best Therapeutic Strategyfor Metachronous Resectable Colorectal Liver Metastases After AdjuvantOxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey. Nassar A, Phelip JM, Goéré D, Loriau J, Gallois C, Michel P, PennaC, Taieb J, Brouquet A, Benoist S.WorldJ Surg. 2021 Mar;45(3):822-830. doi: 10.1007/s00268-020-05837-z. Epub 2020 Nov18.PMID: 33210163

117. Safety of Hydrocortisone PremedicationDiscontinuation in Patients with Inflammatory Bowel Disease on MaintenanceTherapy with Infliximab: a Prospective Clinical and Pharmacological Study. Tran-MinhML, Gornet JM,Maillet M, Houze P, Simon M, McLellan P, Hassid D, Vivier-Chicoteau J, BaudryC, Hammoudi N, Allez M.JCrohns Colitis. 2021 May 4;15(5):742-748. doi: 10.1093/ecco-jcc/jjaa231.PMID: 33205193

118. Patients' real-world experience withinflammatory bowel disease: A cross-sectional survey in tertiary care centresfrom the GETAID group. Nachury M, Bouhnik Y, Serrero M, FilippiJ, Roblin X, Kirchgesner J, Bouguen G, Franchimont D, Savoye G, Buisson A,Louis E, Nancey S, Abitbol V, Reimund JM, DeWit O, Vuitton L, Matthieu N,Peyrin-Biroulet L, Gilletta C, Tadbiri S, Allez M, Viennot S, Bourreille A, Laharie D,Amiot A; GETAID-patient experience study group.DigLiver Dis. 2021 Apr;53(4):434-441. doi: 10.1016/j.dld.2020.10.020. Epub 2020Nov 10.PMID: 33187920 Freearticle.

119. Panel gene profiling of small boweladenocarcinoma: Results from the NADEGE prospective cohort. Aparicio T, Svrcek M, Henriques J, Afchain P,Lièvre A, Tougeron D, Gagniere J, Terrebonne E, Piessen G, Legoux JL, LecailleC, Pocard M, Gornet JM, Zaanan A, Lavau-Denes S, Lecomte T,Deutsch D, Vernerey D, Puig PL.IntJ Cancer. 2021 Apr 1;148(7):1731-1742. doi: 10.1002/ijc.33392. Epub 2021 Jan 4.PMID: 33186471 Freearticle.

2020

120. Adult parameningial alveolarrhabdomyosarcoma: Case report and literature review. Barthère X, Guillerm S, Quero L, Le Maignan C, Torossian N, VerillaudB, Itti R, Hennequin C.Cancer Radiother. 2020Dec;24(8):870-875. doi: 10.1016/j.canrad.2020.03.015. Epub 2020 Nov 7.PMID: 33172776

121. Ustekinumab for Perianal Crohn'sDisease: The BioLAP Multicenter Study From the GETAID. Chapuis-Biron C, Kirchgesner J, ParienteB, Bouhnik Y, Amiot A, Viennot S, Serrero M, Fumery M, Allez M, Siproudhis L, Buisson A, Pineton deChambrun G, Abitbol V, Nancey S, Caillo L, Plastaras L, Savoye G, Chanteloup E,Simon M, Dib N, Rajca S, Amil M, Parmentier AL, Peyrin-Biroulet L, Vuitton L; GETAIDBioLAP Study Group.Am J Gastroenterol. 2020Nov;115(11):1812-1820. doi: 10.14309/ajg.0000000000000810.PMID: 33156100

122. Results from the PROPHYLOCHIP-PRODIGE 15trial - Authors' reply.

123. GoéréD, Ducreux M.Lancet Oncol. 2020 Nov;21(11):e498. doi:10.1016/S1470-2045(20)30628-8.PMID: 33152290 No abstract available.

124. Impact of tobacco smoking on thepatient's outcome after (chemo)radiotherapy for anal cancer. Lerman J, Hennequin C, Etienney I,Abramowitz L, Goujon G, Gornet JM, Guillerm S, Aparicio T, Valverde A, Cattan P, Quéro L.EurJ Cancer. 2020 Dec;141:143-151. doi: 10.1016/j.ejca.2020.09.039. Epub 2020 Nov1.PMID: 33137590

125. Risk factors for Coronavirus Disease2019 (COVID-19) severity and mortality among solid cancer patients and impactof the disease on anticancer treatment: A French nationwide cohort study(GCO-002 CACOVID-19). Lièvre A, Turpin A, Ray-Coquard I, LeMalicot K, Thariat J, Ahle G, Neuzillet C, Paoletti X, Bouché O, Aldabbagh K,Michel P, Debieuvre D, Canellas A, Wislez M, Laurent L, Mabro M, Colle R,Hardy-Bessard AC, Mansi L, Colomba E, Bourhis J, Gorphe P, Pointreau Y, IdbaihA, Ursu R, Di Stefano AL, Zalcman G, Aparicio T; GCO-002 CACOVID-19collaborators/investigators.Eur J Cancer. 2020 Dec;141:62-81. doi:10.1016/j.ejca.2020.09.035. Epub 2020 Oct 8.PMID: 33129039 Free PMCarticle.

126. Clinicogenomic factors of biotherapyimmunogenicity in autoimmune disease: A prospective multicohort study of theABIRISK consortium. Hässler S, Bachelet D, Duhaze J, SzelyN, Gleizes A, Hacein-Bey Abina S, Aktas O, Auer M, Avouac J, Birchler M,Bouhnik Y, Brocq O, Buck-Martin D, Cadiot G, Carbonnel F, Chowers Y, ComabellaM, Derfuss T, De Vries N, Donnellan N, Doukani A, Guger M, Hartung HP, KubalaHavrdova E, Hemmer B, Huizinga T, Ingenhoven K, Hyldgaard-Jensen PE, Jury EC,Khalil M, Kieseier B, Laurén A, Lindberg R, Loercher A, Maggi E, Manson J,Mauri C, Mohand Oumoussa B, Montalban X, Nachury M, Nytrova P, Richez C, RynerM, Sellebjerg F, Sievers C, Sikkema D, Soubrier M, Tourdot S, Trang C,Vultaggio A, Warnke C, Spindeldreher S, Dönnes P, Hickling TP, Hincelin Mery A, Allez M, Deisenhammer F, Fogdell-Hahn A,Mariette X, Pallardy M, Broët P; ABIRISK consortium.PLoSMed. 2020 Oct 30;17(10):e1003348. doi: 10.1371/journal.pmed.1003348.eCollection 2020 Oct.PMID: 33125391 Free PMCarticle.

127. [Crohn's disease and autologoushemapoietic cell transplantation: Guidelines from the Francophone Society ofBone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Puyade M, Treton X, Alric L, Badoglio M,Castilla Llorente C, Fotsing G, Marjanovic Z, Rovira M, Terriou L, TorregrosaDíaz Jose M, Tran-Minh ML, Allez M, Pugnet G, Laharie D, Yakoub-Agha I,Farge D.Bull Cancer. 2020 Dec;107(12S):S140-S150. doi:10.1016/j.bulcan.2020.08.009. Epub 2020 Oct 14.PMID: 33066955 Review. French.

128. Letter to the editor with regard to thearticle entitled "Sézary syndrome and mycosis fungoides: An overview,including the role of immunophenotyping". Roelens M, de Masson A, Ram-Wolff C, Bagot M, Moins-TeisserencH.Cytometry B Clin Cytom. 2021 Mar;100(2):139-140. doi:10.1002/cyto.b.21962. Epub 2020 Oct 8.PMID: 33031631 Freearticle. No abstract available.

129. Response to Hanzel. Hammoudi N, Allez M.AmJ Gastroenterol. 2021 Jan 1;116(1):218. doi: 10.14309/ajg.0000000000000991.PMID: 33009056 No abstract available.

130. Personalized four-category staging forpredicting prognosis in patients with small bowel Adenocarcinoma: aninternational development and validation study. Dai ZH, Wang QW, Zhang QW, Yan XL, Aparicio T, Zhou YY, Wang H, Zhang CH, Zaanan A,Afchain P, Zhang Y, Chen HM, Gao YJ, Ge ZZ.EBioMedicine.2020 Oct;60:102979. doi: 10.1016/j.ebiom.2020.102979. Epub 2020 Sep 24.PMID: 32980692 Free PMCarticle.

131. Long-term outcome of Crohn's diseasepatients with upper gastrointestinal stricture: A GETAID study. Lambin T, Amiot A, Stefanescu C, Gornet JM, Seksik P, Laharie D, Reenaers C,Bourreille A, Cadiot G, Carbonnel F, Dib N, Fumery M, Gilletta de St Joseph C,Filippi J, Viennot S, Plastaras L, Coffin B, Serrero M, Nahon S, Pineton deChambrun G, Rahier JF, Roblin X, Boualit M, Bouguen G, Peyrin-Biroulet L,Pariente B; UGT-CD-stricture GETAID study group.DigLiver Dis. 2020 Nov;52(11):1323-1330. doi: 10.1016/j.dld.2020.08.034. Epub 2020Sep 20.PMID: 32962965

132. Aflibercept in Combination With FOLFIRIas First-line Chemotherapy in Patients With Metastatic Colorectal Cancer(mCRC): A Phase II Study (FFCD 1302). Lapeyre-Prost A, Pernot S, Sigrand J, Le Malicot K,Mary F, Aparicio T, Dahan L, Caroli-Bosc FX, Lecomte T,Doat S, Marthey L, Desrame J, Lepage C, Taieb J.ClinColorectal Cancer. 2020 Dec;19(4):285-290. doi: 10.1016/j.clcc.2020.06.003.Epub 2020 Jun 12.PMID: 32921581 ClinicalTrial.

133. Decision-Making Analysis forHyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: A Survey by theExecutive Committee of the Peritoneal Surface Oncology Group International(PSOGI). Steffen T, Häller L, Bijelic L, GlatzerM, Glehen O, Goéré D, de Hingh I, Li Y, Moran BJ, Morris DL,Piso P, Quadros CA, Rau B, Sugarbaker P, Yonemura Y, Putora PM.Oncology.2021;99(1):41-48. doi: 10.1159/000510098. Epub 2020 Sep 11.PMID: 32920557

134. BRAF inhibitor resistance of melanomacells triggers increased susceptibility to natural killer cell-mediated lysis. Frazao A, Rethacker L, Jeudy G, ColomboM, Pasmant E, Avril MF, Toubert A, Moins-TeisserencH, Roelens M, Dalac S, Maubec E, Caignard A.JImmunother Cancer. 2020 Sep;8(2):e000275. doi: 10.1136/jitc-2019-000275.PMID: 32912923 Free PMCarticle.

135. Patient Selection for HyperthermicIntraperitoneal Chemotherapy in Patients With Colorectal Cancer: Consensus onDecision Making Among International Experts. Steffen T, Eden J, Bijelic L, Glatzer M, Glehen O, Goéré D, de Hingh I, Li Y, Moran B, Morris D,Piso P, Quadros C, Rau B, Sugarbaker P, Yonemura Y, Putora PM.ClinColorectal Cancer. 2020 Dec;19(4):277-284. doi: 10.1016/j.clcc.2020.06.010.Epub 2020 Jul 15.PMID: 32912822

136. Serum IgG2 levels predict long-termprotection following pneumococcal vaccination in systemic lupus erythematosus(SLE). GerardAL, Goulenok T, Bahuaud M, Francois C, Aucouturier P, Moins-TeisserencH, Batteux F, Papo T,Sacre K.Vaccine.2020 Oct 14;38(44):6859-6863. doi: 10.1016/j.vaccine.2020.08.065. Epub2020 Sep 4.PMID: 32896468

137. Duration of combination therapy and riskof treatment failure in patients with inflammatory bowel disease. Lambrescak E, Vaysse T, Allez M, Ungar B, Gleizes A, Hacein-Bey S,Chowers Y, Roblin X, Kopylov U, Rachas A, Carbonnel F.ClinRes Hepatol Gastroenterol. 2021 Mar;45(2):101503. doi:10.1016/j.clinre.2020.07.008. Epub 2020 Sep 4.PMID: 32893176

138. Reply to comment on "Sarcopenia: Animportant prognostic factor for males treated for a locally advanced esophagealcarcinoma". Benadon B, Quero L, Hennequin C.DigLiver Dis. 2020 Nov;52(11):1376. doi: 10.1016/j.dld.2020.08.009. Epub 2020 Sep1.PMID: 32883608 No abstract available.

139. Integrated microbiota and metaboliteprofiles link Crohn's disease to sulfur metabolism. Metwaly A, Dunkel A, Waldschmitt N, Raj ACD, LagkouvardosI, Corraliza AM, Mayorgas A, Martinez-Medina M, Reiter S, Schloter M, HofmannT, Allez M, Panes J, Salas A, Haller D.NatCommun. 2020 Aug 28;11(1):4322. doi: 10.1038/s41467-020-17956-1.PMID: 32859898 Free PMCarticle.

140. Evolution of Endoscopic Lesions inSteroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab orCyclosporine. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, SavoyeG, Vuitton L, Moreau J, Amiot A, Beaugerie L, Ricart E, Dewit O, Lopez-SanromanA, Fumery M, Carbonnel F, Buisson A, Coffin B, Roblin X, van Assche G, EsteveM, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Peyrin-Biroulet L,Mary JY.Clin Gastroenterol Hepatol. 2021Jun;19(6):1180-1188.e4. doi: 10.1016/j.cgh.2020.08.001. Epub 2020 Aug 7.PMID: 32777552 ClinicalTrial.

141. Maintenance treatment withfluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after inductionchemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 -(FFCD 1710) phase III study. Manfredi S, Turpin A, Malka D, BarbierE, Laurent-Puig P, Zaanan A, Dahan L, Lièvre A, Phelip JM, Michel P,Hautefeuille V, Legoux JL, Lepage C, Tougeron D, Aparicio T.DigLiver Dis. 2020 Oct;52(10):1143-1147. doi: 10.1016/j.dld.2020.06.034. Epub 2020Jul 31.PMID: 32747302

142. Care of the Patient With IBD RequiringHospitalisation During the COVID-19 Pandemic. Allez M, Fleshner P, Gearry R, Lakatos PL,Rubin DT.J Crohns Colitis. 2020 Oct 21;14(14 Suppl3):S774-S779. doi: 10.1093/ecco-jcc/jjaa150.PMID: 32722757 Free PMCarticle.

143. Second-look surgery plus hyperthermicintraperitoneal chemotherapy versus surveillance in patients at high risk ofdeveloping colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): arandomised, phase 3 study. Goéré D, Glehen O, Quenet F, Guilloit JM,Bereder JM, Lorimier G, Thibaudeau E, Ghouti L, Pinto A, Tuech JJ, KianmaneshR, Carretier M, Marchal F, Arvieux C, Brigand C, Meeus P, Rat P,Durand-Fontanier S, Mariani P, Lakkis Z, Loi V, Pirro N, Sabbagh C, Texier M,Elias D; BIG-RENAPE group.Lancet Oncol. 2020 Sep;21(9):1147-1154.doi: 10.1016/S1470-2045(20)30322-3. Epub 2020 Jul 24.PMID: 32717180 ClinicalTrial.

144. COVID-19-Related IgA Vasculitis. Allez M, Denis B, Bouaziz JD, Battistella M,Zagdanski AM, Bayart J, Lazaridou I, Gatey C, Pillebout E, Chaix Baudier ML,Delaugerre C, Molina JM, Le Goff J.ArthritisRheumatol. 2020 Nov;72(11):1952-1953. doi: 10.1002/art.41428. Epub 2020 Sep 22.PMID: 32633104 Free PMCarticle. No abstract available.

145. Postoperative Endoscopic Recurrence onthe Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-TermOutcomes in Crohn's Disease. Hammoudi N, Auzolle C, Tran Minh ML,Boschetti G, Bezault M, Buisson A, Pariente B, Treton X, Seksik P, Fumery M, Le Bourhis L, Nancey S, Allez M.AmJ Gastroenterol. 2020 Jul;115(7):1084-1093. doi: 10.14309/ajg.0000000000000638.PMID: 32618659

146. Bidirectional chemotherapy combiningintraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patientswith unresectable peritoneal metastasis from gastric cancer: the first study inWestern countries. Lo Dico R, Gornet JM, Guglielmo N, Zaanan A, Taieb J, PocardM.Pleura Peritoneum. 2020 Apr 17;5(2):20190035. doi:10.1515/pp-2019-0035. eCollection 2020 Jun 1.PMID: 32566725 Free PMCarticle.

147. Long-Term Results after SurgicalResection of Peritoneal Metastasis from Neuroendocrine Tumors.

148. Benhaim L, Faron M, Hadoux J, Gelli M, Sourrouille I,Burtin P, Honoré C, Malka D, Leboulleux S, Ducreux M, Scoazec JY, Goere D, Baudin E.Neuroendocrinology.2021;111(6):599-608. doi: 10.1159/000509220. Epub 2020 Jun 8.PMID: 32512564

149. Sarcopenia: An important prognosticfactor for males treated for a locally advanced esophageal carcinoma. BenadonB, Servagi-Vernat S, Quero L,Cattan P, Guillerm S, Hennequin V, AparicioT, Lourenço N, Bouché O,Hennequin C.DigLiver Dis. 2020 Sep;52(9):1047-1052. doi: 10.1016/j.dld.2020.04.009. Epub2020 May 31.PMID: 32493629

150. Baseline Splenic Volume as a PrognosticBiomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation inMetastatic Colorectal Carcinoma. Niogret J, Limagne E, Thibaudin M, Blanc J, Bertaut A, Le Malicot K,Rinaldi Y, Caroli-Bosc FX, Audemar F, Nguyen S, Sarda C, Lombard-Bohas C,Locher C, Carreiro M, Legoux JL, Etienne PL, Baconnier M, Porneuf M, Aparicio T, Ghiringhelli F.Cancers(Basel). 2020 May 31;12(6):1429. doi: 10.3390/cancers12061429.PMID: 32486421 Free PMCarticle.

151. KLRG1 and CD103 Expressions DefineDistinct Intestinal Tissue-Resident Memory CD8 T Cell Subsets Modulated inCrohn's Disease. Bottois H, Ngollo M, Hammoudi N, Courau T, Bonnereau J, ChardinyV, Grand C, Gergaud B, Allez M, LeBourhis L.FrontImmunol. 2020 May 12;11:896. doi: 10.3389/fimmu.2020.00896.eCollection 2020.PMID: 32477365 Free PMCarticle.

152. Human-Derived α1-Antitrypsin is Still Efficacious inHeavily Pretreated Patients with Steroid-Resistant GastrointestinalGraft-versus-Host Disease. Giannoni L, Morin F, Robin M, Peyneau M,Schlageter MH, Desmier D, Pagliuca S, Sutra Del Galy A, Sicre de Fontbrune F,Xhaard A, Dhedin N, Moins-TeisserencH, Peffault de Latour R, Socié G, Michonneau D.BiolBlood Marrow Transplant. 2020 Sep;26(9):1620-1626. doi:10.1016/j.bbmt.2020.05.014. Epub 2020 May 25.PMID: 32454215 Freearticle.

153. COVID-19 epidemic: Proposed alternativesin the management of digestive cancers: A French intergroup clinical point ofview (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). DiFiore F, Bouché O, Lepage C, Sefrioui D, Gangloff A, Schwarz L, Tuech JJ, AparicioT, Lecomte T, Boulagnon-RombiC, Lièvre A, Manfredi S, Phelip JM, Michel P; Thésaurus National deCancérologie Digestive (TNCD); Société Nationale Française de Gastroentérologie(SNFGE); Fédération Francophone de Cancérologie Digestive (FFCD); GroupeCoopérateur multidisciplinaire en Oncologie (GERCOR); Fédération Nationale desCentres de Lutte Contre le Cancer (UNICANCER); Société Française de ChirurgieDigestive (SFCD); Société Française d'Endoscopie Digestive (SFED); SociétéFrançaise de Radiothérapie Oncologique (SFRO) and Société Française deRadiologie (SFR); Association Chirurgie Hepato-Biliaire et Transplantation(ACHBT).DigLiver Dis. 2020 Jun;52(6):597-603. doi: 10.1016/j.dld.2020.03.031. Epub2020 May 14.PMID: 32418773 Free PMCarticle.

154. Efficacy of Anti-EGFR in MicrosatelliteInstability Metastatic Colorectal Cancer Depending on Sporadic or FamilialOrigin. ZaananA, Henriques J, Cohen R, Sefrioui D, Evrard C, de la Fouchardiere C, Lecomte T, AparicioT, Svrcek M, Taieb J,André T, Vernerey D, Tougeron D; Association des Gastro-entérologues Oncologues(AGEO).JNatl Cancer Inst. 2021 Apr 6;113(4):496-500. doi: 10.1093/jnci/djaa072.PMID: 32415973 Free PMC article.

155. Long-term outcome of patients with acutesevere ulcerative colitis responding to intravenous steroids. Salameh R, Kirchgesner J, Allez M, Carbonnel F, Meyer A, Gornet JM, Beaugerie L, Amiot A.AlimentPharmacol Ther. 2020 Jun;51(11):1096-1104. doi: 10.1111/apt.15751. Epub 2020Apr 28.PMID: 32342994

156. Single-arm phase II trial to evaluateefficacy and tolerance of regorafenib monotherapy in patients over 70 withpreviously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD. Aparicio T, Darut-Jouve A, Khemissa Akouz F,Montérymard C, Artru P, Cany L, Romano O, Valenza B, Le Foll C, Delbaldo C,Falandry C, Norguet Monnereau E, Ben Abdelghani M, Smith D, Rinaldi Y, PèreVerge D, Baize N, Maillard E, Dohan A, Des Guetz G, Pamoukdjian F, Lepage C.JGeriatr Oncol. 2020 Nov;11(8):1255-1262. doi: 10.1016/j.jgo.2020.04.001. Epub2020 Apr 22.PMID: 32334940 Freearticle. Clinical Trial.

157. Surgical and regional treatments forcolorectal cancer metastases in older patients: A systematic review andmeta-analysis. de'Angelis N, Baldini C, Brustia R,Pessaux P, Sommacale D, Laurent A, Le Roy B, Tacher V, Kobeiter H, Luciani A,Paillaud E, Aparicio T, Canuï-Poitrine F, Liuu E.PLoSOne. 2020 Apr 22;15(4):e0230914. doi: 10.1371/journal.pone.0230914. eCollection2020.PMID: 32320417 Free PMCarticle.

158. A Machine Learning Approach forHigh-Dimensional Time-to-Event Prediction With Application to Immunogenicity ofBiotherapies in the ABIRISK Cohort. Duhazé J, Hässler S, Bachelet D, Gleizes A,Hacein-Bey-Abina S, Allez M, Deisenhammer F, Fogdell-Hahn A,Mariette X, Pallardy M, Broët P.FrontImmunol. 2020 Apr 7;11:608. doi: 10.3389/fimmu.2020.00608. eCollection 2020.PMID: 32318076 Free PMCarticle.

159. Effectiveness and safety of ustekinumabinduction therapy for 103 patients with ulcerative colitis: a GETAIDmulticentre real-world cohort study. Amiot A, Filippi J, Abitbol V, Cadiot G, Laharie D,Serrero M, Altwegg R, Bouhnik Y, Peyrin-Biroulet L, Gilletta C, Roblin X,Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet JM, Nahon S, Bouguen G, Viennot S,Pariente B, Fumery M; UC-USK-GETAID Study Group.AlimentPharmacol Ther. 2020 Jun;51(11):1039-1046. doi: 10.1111/apt.15717. Epub 2020Apr 14.PMID: 32291786 Freearticle.

160. The effectiveness of either ustekinumabor vedolizumab in 239 patients with Crohn's disease refractory to anti-tumournecrosis factor. Alric H, Amiot A, Kirchgesner J, TrétonX, Allez M, Bouhnik Y, Beaugerie L, Carbonnel F,Meyer A.Aliment Pharmacol Ther. 2020 May;51(10):948-957. doi:10.1111/apt.15706. Epub 2020 Apr 6.PMID: 32249966

161. Assessing the effect of genetic markerson drug immunogenicity from a mechanistic model-based approach. Duhazé J, Caubet M, Hässler S, BacheletD, Allez M, Deisenhammer F, Fogdell-Hahn A,Gleizes A, Hacein-Bey-Abina S, Mariette X, Pallardy M, Broët P; ABIRISKConsortium.BMC Med Res Methodol. 2020 Mar 20;20(1):69. doi:10.1186/s12874-020-00941-z.PMID: 32192445 Free PMCarticle.

162. Guidelines for time-to-event end-pointdefinitions in adjuvant randomised trials for patients with localised coloncancer: Results of the DATECAN initiative. Cohen R, Vernerey D, Bellera C, Meurisse A, HenriquesJ, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM,Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J,Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A,Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S,Yoshino T, Yothers G, de Gramont A, Shi Q, André T; ACCENT Group.EurJ Cancer. 2020 May;130:63-71. doi: 10.1016/j.ejca.2020.02.009. Epub 2020 Mar12.PMID: 32172199 Free PMCarticle.

163. Development, validation and clinicalimpact of a prediction model for 6-month mortality in older cancer patients:the GRADE. Angeli E, Chouahnia K, Canoui-PoitrineF, Duchemann B, Aparicio T, Paillaud E, Zelek L, Bousquet G,Pamoukdjian F.Aging (Albany NY). 2020 Mar10;12(5):4230-4246. doi: 10.18632/aging.102876. Epub 2020 Mar 10.PMID: 32156833 Free PMCarticle.

164. Mitochondrial impairment drivesintestinal stem cell transition into dysfunctional Paneth cells predictingCrohn's disease recurrence. Khaloian S, Rath E, Hammoudi N,Gleisinger E, Blutke A, Giesbertz P, Berger E, Metwaly A, Waldschmitt N, Allez M, Haller D.Gut.2020 Nov;69(11):1939-1951. doi: 10.1136/gutjnl-2019-319514. Epub 2020 Feb 28.PMID: 32111634 Free PMCarticle.

165. [An unusual digestive complication underanti-PD-1 (pembrolizumab)]. Calvani J, Elia R, Battistella M, DelyonJ, Vivier-Chicoteau J, Gornet JM, Lebbé C, Baroudjian B, Bertheau P.AnnPathol. 2020 Jul;40(4):320-323. doi: 10.1016/j.annpat.2020.02.001. Epub 2020Feb 24.PMID: 32107038 French.

166. Development and internal validation of adiagnostic score for gastric linitis plastica. Vivier-Chicoteau J, Lambert J, Coriat R, Bonnot PE,Goere D, Roche B, Dior M, Goujon G, Morgant S, Pocard M, Glehen O, Aparicio T, Gornet JM.GastricCancer. 2020 Jul;23(4):639-647. doi: 10.1007/s10120-020-01051-x. Epub 2020 Feb26.PMID: 32103376

167. [Localized MSI/dMMR gastric cancerpatients, perioperative immunotherapy instead of chemotherapy: The GERCORNEONIPIGA phase II study is opened to recruitment]. Cohen R, Pudlarz T, Garcia-Larnicol ML, Vernerey D,Dray X, Clavel L, Jary M, Piessen G, Zaanan A, Aparicio T, Louvet C, Tournigand C, Chibaudel B,Tougeron D, Guimbaud R, Benouna J, Adenis A, Sokol H, Borg C, Duval A, SvrcekM, André T.Bull Cancer. 2020 Apr;107(4):438-446. doi:10.1016/j.bulcan.2019.11.016. Epub 2020 Feb 10.PMID: 32057467 Freearticle. French.

168. Withholding the Introduction ofAnti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-TypeMetastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). Palmieri LJ, Mineur L, Tougeron D,Rousseau B, Granger V, Gornet JM, Smith D, Lievre A, Galais MP, Doat S,Pernot S, Bignon-Bretagne AL, Metges JP, Baba-Hamed N, Michel P, Obled S,Vitellius C, Bouche O, Saban-Roche L, Buecher B, des Guetz G, Locher C,Trouilloud I, Goujon G, Dior M, Manfredi S, Soularue E, Phelip JM, Henriques J,Vernery D, Coriat R.Oncologist. 2020 Feb;25(2):e266-e275.doi: 10.1634/theoncologist.2019-0328. Epub 2019 Oct 2.PMID: 32043796 Free PMCarticle.

169. Treatment guidelines of metastaticcolorectal cancer in older patients from the French Society of GeriatricOncology (SoFOG). Aparicio T, Canouï-Poitrine F, Caillet P, FrançoisE, Cudennec T, Carola E, Albrand G, Bouvier AM, Petri C, Couturier B, PhelipJM, Bengrine-Lefevre L, Paillaud E.DigLiver Dis. 2020 May;52(5):493-505. doi: 10.1016/j.dld.2019.12.145. Epub 2020Feb 3.PMID: 32029404

170. Predictive factors for early progressionduring induction chemotherapy and chemotherapy-free interval: analysis fromPRODIGE 9 trial. Aparicio T, Bennouna J, Le Malicot K, Boige V,Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, BachetJB, Egreteau J, Kaminsky MC, Gornet JM, Cojocarasu O, Gasmi M, Guerin-Meyer V,Lepage C, Ghiringhelli F; for PRODIGE investigators/collaborators.BrJ Cancer. 2020 Mar;122(7):957-962. doi: 10.1038/s41416-020-0735-8. Epub 2020Feb 4.PMID: 32015513 Free PMCarticle. Clinical Trial.

171. Treatment intensification with hepaticarterial infusion chemotherapy in patients with liver-only colorectalmetastases still unresectable after systemic induction chemotherapy - arandomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- studyprotocol. BoilèveA, Maillard A, Wagner M, Dromain C, Laurent C, Dupont Bierre E, Le Sourd S,Audemar F, Ulusakarya A, Guerin-Meyer V, Smisth D, Pezzella V, De Baere T, GoereD, Gelli M, Taieb J,Boige V.BMCCancer. 2020 Jan 30;20(1):74. doi: 10.1186/s12885-020-6571-7.PMID: 32000724 Free PMCarticle. Clinical Trial.

172. Prognosis and chemosensitivity ofdeficient MMR phenotype in patients with metastatic colorectal cancer: An AGEOretrospective multicenter study. Tougeron D, Sueur B,Zaanan A, de la Fouchardiére C, Sefrioui D, Lecomte T, AparicioT, Des Guetz G, Artru P,Hautefeuille V, Coriat R, Moulin V, Locher C, Touchefeu Y, Lecaille C, GoujonG, Ferru A, Evrard C, Chautard R, Gentilhomme L, Vernerey D, Taieb J, André T,Henriques J, Cohen R; Association des Gastro-entérologues Oncologues (AGEO).Int J Cancer. 2020 Jul 1;147(1):285-296. doi:10.1002/ijc.32879. Epub 2020 Feb 13.PMID: 31970760 Freearticle.

173. Two-dimensional dynamic evaluation ofnatural killer cell-mediated lysis of adherent target cells. Frazao A, Rethacker L, Caignard A.MethodsEnzymol. 2020;631:289-304. doi: 10.1016/bs.mie.2019.07.033. Epub 2019 Aug 13.PMID: 31948553

174. An Unusual Case of Chronic CoughRevealing Ulcerative Colitis. Hammoudi N, Bondeelle L, Gornet JM.Gastroenterology.2020 Apr;158(5):1224-1225. doi: 10.1053/j.gastro.2019.12.036. Epub 2020 Jan 13.PMID: 31945367 No abstract available.

175. Maintenance of Remission Among PatientsWith Inflammatory Bowel Disease After Vedolizumab Discontinuation: AMulticentre Cohort Study. Martin A, Nachury M, Peyrin-Biroulet L,Bouhnik Y, Nancey S, Bourrier A, Serrero M, Fumery M, Buisson A, Laharie D,Gilletta C, Filippi J, Allez M, Bouguen G, Roblin X, Altwegg R, Dib N,Pineton de Chambrun G, Savoye G, Carbonnel F, Viennot S, Amiot A; GETAID-Vedo-STOPStudy Group.J Crohns Colitis. 2020 Jul 30;14(7):896-903. doi:10.1093/ecco-jcc/jjaa005.PMID: 31930285 Freearticle.

176. Real-world use of therapeutic drugmonitoring of CT-P13 in patients with inflammatory bowel disease: A 12-monthprospective observational cohort study. Petitdidier N, Beaugerie L, Carbonnel F, Bourrier A,Treton X, Rajca S, Malamut G, Abitbol V, Allez M, Pelletier AL, Marthey L, Jouet P,Benamouzig R, Amiot X, Bouhnik Y, Amiot A.ClinRes Hepatol Gastroenterol. 2020 Sep;44(4):609-618. doi:10.1016/j.clinre.2019.11.008. Epub 2020 Jan 8.PMID: 31924554

177. Small bowel adenocarcinoma: Results froma nationwide prospective ARCAD-NADEGE cohort study of 347 patients. Aparicio T, Henriques J, Manfredi S, Tougeron D,Bouché O, Pezet D, Piessen G, Coriat R, Zaanan A, Legoux JL, Terrebone E,Pocard M, Gornet JM, Lecomte T, Lombard-Bohas C, Perrier H,Lecaille C, Lavau-Denes S, Vernerey D, Afchain P; NADEGE Investigators.IntJ Cancer. 2020 Aug 15;147(4):967-977. doi: 10.1002/ijc.32860. Epub 2020 Jan 22.PMID: 31912484 Freearticle.

178. Artificial intelligence-guided tissueanalysis combined with immune infiltrate assessment predicts stage III coloncancer outcomes in PETACC08 study. Reichling C, Taieb J, Derangere V, Klopfenstein Q, Le Malicot K, Gornet JM, Becheur H, Fein F, Cojocarasu O,Kaminsky MC, Lagasse JP, Luet D, Nguyen S, Etienne PL, Gasmi M, Vanoli A,Perrier H, Puig PL, Emile JF, Lepage C, Ghiringhelli F.Gut.2020 Apr;69(4):681-690. doi: 10.1136/gutjnl-2019-319292. Epub 2019 Nov 28.PMID: 31780575 Free PMCarticle.

2019

‍

179. Everolimus after hepatic arterialembolisation therapy of metastases from gastrointestinal neuroendocrinetumours: The FFCD 1104-EVACEL-GTE phase II study. Walter T, Lepage C, Coriat R, Barbier E, Cadiot G,Caroli-Bosc FX, Aparicio T, Bouhier-Leporrier K, Hentic-Dhome O,Gay F, Dupont-Gossart AC, Duluc M, Lepere C, Lecomte T, Smith D, Petorin C,Di-Fiore F, Ghiringhelli F, Legoux JL, Guimbaud R, Baudin E, Lombard-Bohas C,de Baère T; FFCD 1104 investigators/investigators.EurJ Cancer. 2019 Dec;123:92-100. doi: 10.1016/j.ejca.2019.09.021. Epub 2019 Oct31.PMID: 31678771 ClinicalTrial.

180. ASO Author Reflections: What is the BestTherapeutic Strategy for Patients with Limited Synchronous PeritonealMetastases of Colorectal Cancer? Mariani A, Goere D.AnnSurg Oncol. 2019 Dec;26(Suppl 3):818. doi: 10.1245/s10434-019-07829-3. Epub2019 Oct 30.PMID: 31667730 No abstract available.

181. Guidelines for the use of flow cytometryand cell sorting in immunological studies (second edition). Cossarizza A, Chang HD, Radbruch A, AcsA, Adam D, Adam-Klages S, Agace WW, Aghaeepour N, Akdis M, Allez M, Almeida LN, Alvisi G, Anderson G,Andrä I, Annunziato F, Anselmo A, Bacher P, Baldari CT, Bari S, Barnaba V,Barros-Martins J, Battistini L, Bauer W, Baumgart S, Baumgarth N, Baumjohann D,Baying B, Bebawy M, Becher B, Beisker W, Benes V, Beyaert R, Blanco A, BoardmanDA, Bogdan C, Borger JG, Borsellino G, Boulais PE, Bradford JA, Brenner D,Brinkman RR, Brooks AES, Busch DH, Büscher M, Bushnell TP, Calzetti F, CameronG, Cammarata I, Cao X, Cardell SL, Casola S, Cassatella MA, Cavani A, Celada A,Chatenoud L, Chattopadhyay PK, Chow S, Christakou E, Čičin-Šain L, Clerici M,Colombo FS, Cook L, Cooke A, Cooper AM, Corbett AJ, Cosma A, Cosmi L, CouliePG, Cumano A, Cvetkovic L, Dang VD, Dang-Heine C, Davey MS, Davies D, De BiasiS, Del Zotto G, Dela Cruz GV, Delacher M, Della Bella S, Dellabona P, Deniz G,Dessing M, Di Santo JP, Diefenbach A, Dieli F, Dolf A, Dörner T, Dress RJ,Dudziak D, Dustin M, Dutertre CA, Ebner F, Eckle SBG, Edinger M, Eede P,Ehrhardt GRA, Eich M, Engel P, Engelhardt B, Erdei A, Esser C, Everts B, EvrardM, Falk CS, Fehniger TA, Felipo-Benavent M, Ferry H, Feuerer M, Filby A, FilkorK, Fillatreau S, Follo M, Förster I, Foster J, Foulds GA, Frehse B, FrenettePS, Frischbutter S, Fritzsche W, Galbraith DW, Gangaev A, Garbi N, GaudilliereB, Gazzinelli RT, Geginat J, Gerner W, Gherardin NA, Ghoreschi K, Gibellini L,Ginhoux F, Goda K, Godfrey DI, Goettlinger C, González-Navajas JM, Goodyear CS,Gori A, Grogan JL, Grummitt D, Grützkau A, Haftmann C, Hahn J, Hammad H,Hämmerling G, Hansmann L, Hansson G, Harpur CM, Hartmann S, Hauser A, HauserAE, Haviland DL, Hedley D, Hernández DC, Herrera G, Herrmann M, Hess C, HöferT, Hoffmann P, Hogquist K, Holland T, Höllt T, Holmdahl R, Hombrink P, HoustonJP, Hoyer BF, Huang B, Huang FP, Huber JE, Huehn J, Hundemer M, Hunter CA,Hwang WYK, Iannone A, Ingelfinger F, Ivison SM, Jäck HM, Jani PK, Jávega B,Jonjic S, Kaiser T, Kalina T, Kamradt T, Kaufmann SHE, Keller B, Ketelaars SLC,Khalilnezhad A, Khan S, Kisielow J, Klenerman P, Knopf J, Koay HF, Kobow K,Kolls JK, Kong WT, Kopf M, Korn T, Kriegsmann K, Kristyanto H, Kroneis T,Krueger A, Kühne J, Kukat C, Kunkel D, Kunze-Schumacher H, Kurosaki T, Kurts C,Kvistborg P, Kwok I, Landry J, Lantz O, Lanuti P, LaRosa F, Lehuen A,LeibundGut-Landmann S, Leipold MD, Leung LYT, Levings MK, Lino AC, Liotta F,Litwin V, Liu Y, Ljunggren HG, Lohoff M, Lombardi G, Lopez L, López-Botet M,Lovett-Racke AE, Lubberts E, Luche H, Ludewig B, Lugli E, Lunemann S, MaeckerHT, Maggi L, Maguire O, Mair F, Mair KH, Mantovani A, Manz RA, Marshall AJ,Martínez-Romero A, Martrus G, Marventano I, Maslinski W, Matarese G, MattioliAV, Maueröder C, Mazzoni A, McCluskey J, McGrath M, McGuire HM, McInnes IB, MeiHE, Melchers F, Melzer S, Mielenz D, Miller SD, Mills KHG, Minderman H,Mjösberg J, Moore J, Moran B, Moretta L, Mosmann TR, Müller S, Multhoff G,Muñoz LE, Münz C, Nakayama T, Nasi M, Neumann K, Ng LG, Niedobitek A,Nourshargh S, Núñez G, O'Connor JE, Ochel A, Oja A, Ordonez D, Orfao A,Orlowski-Oliver E, Ouyang W, Oxenius A, Palankar R, Panse I, Pattanapanyasat K,Paulsen M, Pavlinic D, Penter L, Peterson P, Peth C, Petriz J, Piancone F,Pickl WF, Piconese S, Pinti M, Pockley AG, Podolska MJ, Poon Z, Pracht K, PrinzI, Pucillo CEM, Quataert SA, Quatrini L, Quinn KM, Radbruch H, Radstake TRDJ,Rahmig S, Rahn HP, Rajwa B, Ravichandran G, Raz Y, Rebhahn JA, Recktenwald D,Reimer D, Reis e Sousa C, Remmerswaal EBM, Richter L, Rico LG, Riddell A,Rieger AM, Robinson JP, Romagnani C, Rubartelli A, Ruland J, Saalmüller A,Saeys Y, Saito T, Sakaguchi S, Sala-de-Oyanguren F, Samstag Y, Sanderson S,Sandrock I, Santoni A, Sanz RB, Saresella M, Sautes-Fridman C, Sawitzki B,Schadt L, Scheffold A, Scherer HU, Schiemann M, Schildberg FA, Schimisky E,Schlitzer A, Schlosser J, Schmid S, Schmitt S, Schober K, Schraivogel D, SchuhW, Schüler T, Schulte R, Schulz AR, Schulz SR, Scottá C, Scott-Algara D, SesterDP, Shankey TV, Silva-Santos B, Simon AK, Sitnik KM, Sozzani S, Speiser DE,Spidlen J, Stahlberg A, Stall AM, Stanley N, Stark R, Stehle C, Steinmetz T,Stockinger H, Takahama Y, Takeda K, Tan L, Tárnok A, Tiegs G, Toldi G, TornackJ, Traggiai E, Trebak M, Tree TIM, Trotter J, Trowsdale J, Tsoumakidou M,Ulrich H, Urbanczyk S, van de Veen W, van den Broek M, van der Pol E, VanGassen S, Van Isterdael G, van Lier RAW, Veldhoen M, Vento-Asturias S, VieiraP, Voehringer D, Volk HD, von Borstel A, von Volkmann K, Waisman A, Walker RV,Wallace PK, Wang SA, Wang XM, Ward MD, Ward-Hartstonge KA, Warnatz K, Warnes G,Warth S, Waskow C, Watson JV, Watzl C, Wegener L, Weisenburger T, Wiedemann A,Wienands J, Wilharm A, Wilkinson RJ, Willimsky G, Wing JB, Winkelmann R,Winkler TH, Wirz OF, Wong A, Wurst P, Yang JHM, Yang J, Yazdanbakhsh M, Yu L,Yue A, Zhang H, Zhao Y, Ziegler SM, Zielinski C, Zimmermann J, Zychlinsky A.EurJ Immunol. 2019 Oct;49(10):1457-1973. doi: 10.1002/eji.201970107.PMID: 31633216 Free PMCarticle.

182. Possible Paradoxical PhotosensitivePsoriasis Induced by Tumour Necrosis Factor-alpha Inhibitors. Bataille P, Masson A, Vignon-Pennamen MD,Bouaziz JD, Gornet JM.ActaDerm Venereol. 2019 Dec 1;99(13):1293-1294. doi: 10.2340/00015555-3330.PMID: 31584104 Freearticle. Review. No abstract available.

183. Colorectal cancer fecal screening testcompletion after age 74, sources and outcomes in French program. Koïvogui A, Balamou C, Rymzhanova R,Letrung T, Hadad HA, Brixi Z, Cornelis S, Delattre-Massy H, Aparicio T, Benamouzig R.WorldJ Gastrointest Oncol. 2019 Sep 15;11(9):729-740. doi: 10.4251/wjgo.v11.i9.729.PMID: 31558977 Free PMCarticle.

184. UCP2 Deficiency Increases ColonTumorigenesis by Promoting Lipid Synthesis and Depleting NADPH for AntioxidantDefenses. AguilarE, Esteves P, Sancerni T, Lenoir V, Aparicio T, Bouillaud F, Dentin R, Prip-Buus C, Ricquier D,Pecqueur C, Guilmeau S, Alves-Guerra MC.Cell Rep. 2019 Aug27;28(9):2306-2316.e5. doi: 10.1016/j.celrep.2019.07.097.PMID: 31461648 Free PMC article.

185. The cellular prion protein controls themesenchymal-like molecular subtype and predicts disease outcome in colorectalcancer. Le Corre D, Ghazi A, Balogoun R, PilatiC, Aparicio T, Martin-Lannerée S, Marisa L, DjouadiF, Poindessous V, Crozet C, Emile JF, Mulot C, Le Malicot K, Boige V, Blons H,de Reynies A, Taieb J, Ghiringhelli F, Bennouna J, Launay JM, Laurent-Puig P,Mouillet-Richard S.EBioMedicine. 2019 Aug;46:94-104. doi:10.1016/j.ebiom.2019.07.036. Epub 2019 Jul 31.PMID: 31377347 Free PMCarticle.

186. Inclusion of Older Patients with Cancerin Clinical Trials: The SAGE Prospective Multicenter Cohort Survey. Canouï-Poitrine F, Lièvre A, Dayde F,Lopez-Trabada-Ataz D, Baumgaertner I, Dubreuil O, Brunetti F, Coriat R, MaleyK, Pernot S, Tournigand C, Hagege M, Aparicio T, Paillaud E, Bastuji-Garin S.Oncologist.2019 Dec;24(12):e1351-e1359. doi: 10.1634/theoncologist.2019-0166. Epub 2019Jul 19.PMID: 31324663 Free PMCarticle.

187. BRAF Mutation Status in Circulating Tumor DNA from Patientswith Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEORASANC Study. Mas L, Bachet JB, Taly V, Bouché O,Taieb J, Cohen R, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Thirot-Bidault A,Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, Vernerey D,Laurent-Puig P.Cancers (Basel). 2019 Jul 17;11(7):998.doi: 10.3390/cancers11070998.PMID: 31319569 Free PMCarticle.

188. Impact on health-related quality of lifedeterioration-free survival of a first-line therapy combining nab-paclitaxelplus either gemcitabine or simplified leucovorin and fluorouracil for patientswith metastatic pancreatic cancer: Results of the randomized phase II AFUGEMGERCOR clinical trial. Charton E, Bachet JB, Hammel P, DesraméJ, Chibaudel B, Cohen R, Debourdeau P, Dauba J, Lecomte T, Seitz JF, TournigandC, Aparicio T, Guerin-Meyer V, Taieb J, Volet J,Louvet C, Anota A, Bonnetain F.CancerMed. 2019 Sep;8(11):5079-5088. doi: 10.1002/cam4.2311. Epub 2019 Jul 17.PMID: 31314957 Free PMCarticle. Clinical Trial.

189. Efficacy and Safety of Two NeoadjuvantStrategies With Bevacizumab in MRI-Defined Locally Advanced T3 ResectableRectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVAStudy. Borg C, Mantion G, Boudghène F, MornexF, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet JB,Vendrely V, François Y, Conroy T, Rio E, Roullet B, Spaëth D, Quero L, Lakkis Z, Coudert M, Ionescu-Goga M,Tanang A, André T.Clin Colorectal Cancer. 2019Sep;18(3):200-208.e1. doi: 10.1016/j.clcc.2019.04.006. Epub 2019 May 3.PMID: 31311761 ClinicalTrial.

190. ROCK2 inhibition triggers the collectiveinvasion of colorectal adenocarcinomas. Libanje F, Raingeaud J, Luan R, Thomas Z, Zajac O,Veiga J, Marisa L, Adam J, Boige V, Malka D, Goéré D, Hall A, Soazec JY, Prall F, Gelli M,Dartigues P, Jaulin F.EMBO J. 2019 Jul 15;38(14):e99299. doi:10.15252/embj.201899299. Epub 2019 Jun 18.PMID: 31304629 Free PMCarticle.

191. Carcinoembryonic Antigen Levels andSurvival in Stage III Colon Cancer: Posthoc Analysis of the MOSAIC and PETACC-8Trials. Auclin E, Taieb J, Lepage C, Aparicio T, Faroux R, Mini E, Folprecht G, SalazarR, Benetkiewicz M, Banzi M, Louvet C, Van Laethem JL, Tabernero J, Hickish T,de Gramont A, André T, Vernerey D.CancerEpidemiol Biomarkers Prev. 2019 Jul;28(7):1153-1161. doi:10.1158/1055-9965.EPI-18-0867.PMID: 31263053

192. The role of integrins in thepathogenesis of inflammatory bowel disease: Approved and investigationalanti-integrin therapies. Dotan I, Allez M, Danese S, Keir M, Tole S, McBride J.MedRes Rev. 2020 Jan;40(1):245-262. doi: 10.1002/med.21601. Epub 2019 Jun 19.PMID: 31215680 Free PMCarticle. Review.

193. Survival after complete cytoreductivesurgery and HIPEC for extensive pseudomyxoma peritonei. Benhaim L, Faron M, Gelli M, SourrouilleI, Honoré C, Delhorme JB, Elias D, Goere D.SurgOncol. 2019 Jun;29:78-83. doi: 10.1016/j.suronc.2019.03.004. Epub 2019 Apr 3.PMID: 31196498

194. Anti-epidermal growth factor receptortherapy in combination with chemoradiotherapy for the treatment of locallyadvanced anal canal carcinoma: Results of a phase I dose-escalation study withpanitumumab (FFCD 0904). Vendrely V, Lemanski C, Gnep K, BarbierE, Hajbi FE, Lledo G, Dahan L, Terrebonne E, Manfredi S, Mirabel X, Mammar V,Cowen D, Lepage C, Aparicio T; for FFCD investigators/Collaborators.RadiotherOncol. 2019 Nov;140:84-89. doi: 10.1016/j.radonc.2019.05.018. Epub 2019 Jun 8.PMID: 31185328 ClinicalTrial.

195. Multiple colic intussusceptions. Tzedakis S, Flacs M, Besse B, Goere D.ClinCase Rep. 2019 May 11;7(6):1265-1266. doi: 10.1002/ccr3.2181. eCollection 2019Jun.PMID: 31183109 Free PMCarticle.

196. Three-year effectiveness and safety ofvedolizumab therapy for inflammatory bowel disease: a prospective multi-centrecohort study. Amiot A, Serrero M, Peyrin-Biroulet L,Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C,Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, ViennotS, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y; OBSERV-IBD studygroup, the GETAID.Aliment Pharmacol Ther. 2019Jul;50(1):40-53. doi: 10.1111/apt.15294. Epub 2019 Jun 5.PMID: 31165509

197. Prominence of ileal mucosa-associatedmicrobiota to predict postoperative endoscopic recurrence in Crohn's disease. Sokol H, Brot L, Stefanescu C, Auzolle C,Barnich N, Buisson A, Fumery M, Pariente B, Le Bourhis L, Treton X, Nancey S, Allez M, Seksik P; REMIND Study GroupInvestigators.Gut. 2020 Mar;69(3):462-472. doi:10.1136/gutjnl-2019-318719. Epub 2019 May 29.PMID: 31142586

198. FOLFOX alone or combined withrilotumumab or panitumumab as first-line treatment for patients with advancedgastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised,open-label, three-arm phase II trial. Malka D, François E, Penault-Llorca F, Castan F,Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E,Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A,Laurent-Puig P, Gourgou S, Emile JF, Taïeb J.EurJ Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May23.PMID: 31129386 ClinicalTrial.

199. Early evaluation using a radiomicsignature of unresectable hepatic metastases to predict outcome in patientswith colorectal cancer treated with FOLFIRI and bevacizumab. Dohan A, Gallix B, Guiu B, Le Malicot K,Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J,Bouché O, François E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, BenAbdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F,Texereau P, Suc E, Lepage C, Aparicio T, Hoeffel C; PRODIGE 9 Investigators andPRODIGE 20 Investigators.Gut. 2020 Mar;69(3):531-539. doi:10.1136/gutjnl-2018-316407. Epub 2019 May 17.PMID: 31101691

200. Severe gastrointestinal toxicity of MEKinhibitors. Mourad N, Lourenço N, Delyon J,Eftekhari P, Bertheau P, Allayous C, Ballon A, Pagès C, Allez M, Lebbé C, Baroudjian B; PATIO group.MelanomaRes. 2019 Oct;29(5):556-559. doi: 10.1097/CMR.0000000000000618.PMID: 31095035

201. Cytoreductive Surgery With or WithoutHyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With PeritonealMetastases (CYTO-CHIP study): A Propensity Score Analysis. Bonnot PE, Piessen G, Kepenekian V,Decullier E, Pocard M, Meunier B, Bereder JM, Abboud K, Marchal F, Quenet F, Goere D, Msika S, Arvieux C, Pirro N, WernertR, Rat P, Gagnière J, Lefevre JH, Courvoisier T, Kianmanesh R, Vaudoyer D,Rivoire M, Meeus P, Passot G, Glehen O; FREGAT and BIG-RENAPE Networks.JClin Oncol. 2019 Aug 10;37(23):2028-2040. doi: 10.1200/JCO.18.01688. Epub 2019May 14.PMID: 31084544

202. Association Between Microscopic Lesionsat Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn'sDisease. Hammoudi N, Cazals-Hatem D, Auzolle C,Gardair C, Ngollo M, Bottois H, Nancey S, Pariente B, Buisson A, Treton X,Fumery M, Bezault M, Seksik P, Le Bourhis L; REMIND Study Group Investigators;Flejou JF, Allez M.ClinGastroenterol Hepatol. 2020 Jan;18(1):141-149.e2. doi: 10.1016/j.cgh.2019.04.045.Epub 2019 Apr 28.PMID: 31042575

203. NKG2D/NKG2-Ligand Pathway Offers NewOpportunities in Cancer Treatment. Frazao A, Rethacker L, Messaoudene M, Avril MF, Toubert A, Dulphy N, Caignard A.FrontImmunol. 2019 Mar 29;10:661. doi: 10.3389/fimmu.2019.00661. eCollection 2019.PMID: 30984204 Free PMCarticle. Review.

204. Phase I/II study of oxaliplatin doseescalation via a laparoscopic approach using pressurized aerosolintraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastasesof digestive cancers (stomach, small bowel and colorectal): Rationale anddesign. Dumont F, Senellart H, Pein F, CampionL, Glehen O, Goere D, Pocard M, Thibaudeau E.PleuraPeritoneum. 2018 Sep 15;3(3):20180120. doi: 10.1515/pp-2018-0120. eCollection2018 Sep 1.PMID: 30911664 Free PMCarticle.

205. Safety of CD34⁺ Hematopoietic Stem Cells and CD4⁺ T Lymphocytes Transduced with LVsh5/C46 in HIV-1Infected Patients with High-Risk Lymphoma. Delville M, Touzot F, Couzin C, Hmitou I, Djerroudi L,Ouedrani A, Lefrère F, Tuchman-Durand C, Mollet C, Fabreguettes JR, Ferry N,Laganier L, Magnani A, Magrin E, Jolaine V, Saez-Cirion A, Wolstein O, SymondsG, Frange P, Moins-Teisserenc H, Chaix-Baudier ML, Toubert A, LargheroJ, Parquet N, Brignier AC, Barré-Sinoussi F, Oksenhendler E, Cavazzana M.MolTher Methods Clin Dev. 2019 Feb 26;13:303-309. doi: 10.1016/j.omtm.2019.02.006.eCollection 2019 Jun 14.PMID: 30911587 Free PMCarticle.

206. Cocultures of human colorectal tumorspheroids with immune cells reveal the therapeutic potential of MICA/B andNKG2A targeting for cancer treatment. CourauT, Bonnereau J, Chicoteau J, Bottois H, Remark R, Assante Miranda L, Toubert A,Blery M, Aparicio T, AllezM, LeBourhis L.JImmunother Cancer. 2019 Mar 14;7(1):74. doi:10.1186/s40425-019-0553-9.PMID: 30871626 Free PMCarticle.

207. Occurrence of Extensive Cutaneous HumanPapillomavirus Infection After Initiation of Tofacitinib Therapy. Brunet-PossentiF, Charpentier C, Bouhnik Y, Deschamps L, Descamps D, Moins-TeisserencH, Descamps V.JAMA Dermatol. 2019May 1;155(5):629-631. doi: 10.1001/jamadermatol.2018.5528.PMID: 30865238 No abstract available.

208. Comparison of three lymph node stagingschemes for predicting the outcome in patients with small bowel adenocarcinoma:A population-based cohort and international multicentre cohort study. Zhou YY, Du XJ, Zhang CH, Aparicio T, Zaanan A, Afchain P, Chen LP, Hu SK,Zhang PC, Wu M, Zhang QW, Wang H.EBioMedicine.2019 Mar;41:276-285. doi: 10.1016/j.ebiom.2019.02.043. Epub 2019 Feb 26.PMID: 30824384 Free PMCarticle.

209. Strategies for Managing IntraoperativeDiscovery of Limited Colorectal Peritoneal Metastases. Mariani A, Gelli M, Sourrouille I,Benhaim L, Faron M, Honoré C, Elias D, Goéré D.AnnSurg Oncol. 2019 May;26(5):1437-1444. doi: 10.1245/s10434-019-07225-x. Epub2019 Feb 25.PMID: 30805806 ClinicalTrial.

210. T cell clonal expansions in ilealCrohn's disease are associated with smoking behaviour and postoperativerecurrence. Allez M, Auzolle C, Ngollo M, Bottois H,Chardiny V, Corraliza AM, Salas A, Perez K, Stefanescu C, Nancey S, Buisson A,Pariente B, Fumery M, Sokol H, Tréton X, Barnich N, Seksik P, Le Bourhis L; REMIND Study Group.Gut.2019 Nov;68(11):1961-1970. doi: 10.1136/gutjnl-2018-317878. Epub 2019 Feb 12.PMID: 30792246

211. Reply to: Inflammatory bowel diseasewith peritoneal metastases: A complex and extremely variable disease. HammoudiN, Gornet JM.EurJ Surg Oncol. 2019 Mar;45(3):484. doi: 10.1016/j.ejso.2018.08.033. Epub2018 Oct 11.PMID: 30786963 No abstract available.

212. Unmet Medical Needs in UlcerativeColitis: An Expert Group Consensus. Danese S, Allez M, van Bodegraven AA, Dotan I, GisbertJP, Hart A, Lakatos PL, Magro F, Peyrin-Biroulet L, Schreiber S, Tarabar D,Vavricka S, Halfvarson J, Vermeire S.DigDis. 2019;37(4):266-283. doi: 10.1159/000496739. Epub 2019 Feb 6.PMID: 30726845 Freearticle.

213. Comparison of Mobility Indices forPredicting Early Death in Older Patients With Cancer: The Physical Frailty inElderly Cancer Cohort Study. Pamoukdjian F, Aparicio T, Zebachi S, Zelek L, Paillaud E,Canoui-Poitrine F.J Gerontol A Biol Sci Med Sci. 2020 Jan1;75(1):189-196. doi: 10.1093/gerona/glz024.PMID: 30715144

214. Circulating NKp46⁺ Natural Killer cells have a potential regulatoryproperty and predict distinct survival in Non-Small Cell Lung Cancer. Picard E, Godet Y, Laheurte C, Dosset M,Galaine J, Beziaud L, Loyon R, Boullerot L, Lauret Marie Joseph E, Spehner L,Jacquin M, Eberst G, Gaugler B, Le Pimpec-Barthes F, Fabre E, Westeel V, Caignard A, Borg C, Adotévi O.Oncoimmunology.2018 Oct 19;8(2):e1527498. doi: 10.1080/2162402X.2018.1527498. eCollection2019.PMID: 30713781 Free PMCarticle.

215. Well-Differentiated PapillaryMesothelioma of the Peritoneum: A Retrospective Study from the RENAPEObservational Registry. Vogin G, Hettal L, Vignaud JM, DartiguesP, Goere D, Ferron G, Heyd B, Bereder JM, TuechJJ, Glehen O, de Chaisemartin C, Lherm Y, Villeneuve L, Kepenekian V, MarchalF; RENAPE Network.Ann Surg Oncol. 2019 Mar;26(3):852-860.doi: 10.1245/s10434-018-07153-2. Epub 2019 Jan 11.PMID: 30635798

216. Hiatal hernia after oesophagectomy: alarge European survey. Gust L, Nafteux P, Allemann P, Tuech JJ,El Nakadi I, Collet D, Goere D, Fabre JM, Meunier B, Dumont F, PoncetG, Passot G, Carrere N, Mathonnet M, Lebreton G, Theraux J, Marchal F, BarabinoG, Thomas PA, Piessen G, D'Journo XB.EurJ Cardiothorac Surg. 2019 Jun 1;55(6):1104-1112. doi: 10.1093/ejcts/ezy451.PMID: 30596989

217. Obesity survival paradox in cancerpatients: Results from the Physical Frailty in older adult cancer patients(PF-EC) study. Pamoukdjian F, Aparicio T, Canoui-Poitrine F, Duchemann B, LévyV, Wind P, Ganne N, Sebbane G, Zelek L, Paillaud E.ClinNutr. 2019 Dec;38(6):2806-2812. doi: 10.1016/j.clnu.2018.12.011. Epub 2018 Dec13.PMID: 30583963

218. Efficacy of Ruxolitinib Therapy in aPatient With Severe Enterocolitis Associated With a STAT3 Gain-of-FunctionMutation. Parlato M, Charbit-Henrion F, Abi NaderE, Begue B, Guegan N, Bruneau J, Khater S, Macintyre E, Picard C, Frédéric RL, Le Bourhis L, Allez M, Goulet O, Cellier C, Hermine O,Cerf-Bensussan N, Malamut G.Gastroenterology. 2019Mar;156(4):1206-1210.e1. doi: 10.1053/j.gastro.2018.11.065. Epub 2018 Dec 15.PMID: 30557559 Free PMCarticle. No abstract available.

219. Differences in Peripheral and TissueImmune Cell Populations Following Haematopoietic Stem Cell Transplantation inCrohn's Disease Patients. Corraliza AM, Ricart E, López-García A,Carme Masamunt M, Veny M, Esteller M, Mayorgas A, Le Bourhis L, Allez M, Planell N, Visvanathan S, Baum P,España C, Cabezón-Cabello R, Benítez-Ribas D, Rovira M, Panés J, Salas A.JCrohns Colitis. 2019 Apr 26;13(5):634-647. doi: 10.1093/ecco-jcc/jjy203.PMID: 30521002 Free PMCarticle.

220. Resection of small bowel adenocarcinomametastases: Results of the ARCAD-NADEGE cohort study. Rompteaux P, Gagnière J, Gornet JM, Coriat R, Baumgaertner I, Lecomte T,Afchain P, Zaanan A, Pocard M, Bachet JB, Bonichon-Lamichhane N, Bouché O,Faucheron JL, Forestier J, Lecaille C, Manfredi S, Tougeron D, Terrebonne E,Chehimi M, Villing AL, Sarda C, Legoux JL, Benamouzig R, Aparicio T.EurJ Surg Oncol. 2019 Mar;45(3):331-335. doi: 10.1016/j.ejso.2018.11.012. Epub2018 Nov 22.PMID: 30501999

221. CD16⁺NKG2A^high Natural Killer Cells Infiltrate Breast Cancer-DrainingLymph Nodes. Frazao A, Messaoudene M, Nunez N, DulphyN, Roussin F, Sedlik C, Zitvogel L, Piaggio E, Toubert A, Caignard A.CancerImmunol Res. 2019 Feb;7(2):208-218. doi: 10.1158/2326-6066.CIR-18-0085. Epub2018 Dec 4.PMID: 30514793

222. Well differentiated papillary peritonealmesothelioma treated by cytoreduction and hyperthermic intraperitonealchemotherapy-the experience of the PSOGI registry. Deraco M, Nizri E, Glehen O, Baratti D, Tuech JJ,Bereder JM, Kepenekian V, Kusamura S, Goere D.EurJ Surg Oncol. 2019 Mar;45(3):371-375. doi: 10.1016/j.ejso.2018.10.065. Epub2018 Oct 19.PMID: 30473172

223. ERBB3-Activating Mutations in Small BowelAdenocarcinomas. Cabel L, Aparicio T, Bieche I, Svrcek M, Zaanan A, AfchainP, Di Fiore F, Gornet JM, Le Corre D, Vacher S, Callens C,Bernard V, Laurent-Puig P, Bidard FC.JCOPrecis Oncol. 2018 Nov;2:1-9. doi: 10.1200/PO.17.00243.PMID: 35135114

224. Editorial: predicting recurrence ofCrohn's disease after surgical resection-Close to a crystal ball. Authors'reply. Allez M, Auzolle C, Le Bourhis L, Seksik P.AlimentPharmacol Ther. 2018 Nov;48(10):1157-1158. doi: 10.1111/apt.14998.PMID: 30375683 No abstract available.

225. How Does Chemoradiotherapy FollowingInduction FOLFIRINOX Improve the Results in Resected Borderline or LocallyAdvanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. Pietrasz D, Turrini O, Vendrely V, SimonJM, Hentic O, Coriat R, Portales F, Le Roy B, Taieb J, Regenet N, Goere D, Artru P, Vaillant JC, Huguet F,Laurent C, Sauvanet A, Delpero JR, Bachet JB, Sa Cunha A.AnnSurg Oncol. 2019 Jan;26(1):109-117. doi: 10.1245/s10434-018-6931-6. Epub 2018Oct 25.PMID: 30362063

226. Urinary function and quality of lifeafter radiotherapy for prostate cancer in patients with prior history ofsurgical treatment for benign prostatic hyperplasia. Guilhen M, Hennequin C, Ouzaid I, FumagalliI, Martin V, Guillerm S, Mongiat-Artus P, Ravery V, Desgrandchamps F, Quéro L.RadiatOncol. 2018 Oct 24;13(1):209. doi: 10.1186/s13014-018-1149-0.PMID: 30355359 Free PMCarticle.

227. Reconstitution of HIV-1 reservoirfollowing high-dose chemotherapy/autologous stem cell transplantation forlymphoma. Delagreverie HM, Gerard L, Chaillon A, RoelensM, Djerroudi L, Salmona M, Larghero J, Galicier L, Simon F, Oksenhendler E, Moins-TeisserencH, Delaugerre C.AIDS.2019 Feb 1;33(2):247-257. doi: 10.1097/QAD.0000000000002051.PMID: 30325771

228. Rare cause of rectal stenosis in apatient with long-term use of Infliximab and Mercaptopurine for ulcerativecolitis. HammoudiN, Gardair C, Tran-Minh ML, Allez M, GornetJM.Gut.2019 Jun;68(6):976-995. doi: 10.1136/gutjnl-2018-317069. Epub2018 Oct 9.PMID: 30301770 No abstract available.

229. T-cell bispecific antibodiesin node-positive breast cancer: novel therapeutic avenue for MHC class I lossvariants.Messaoudene M, Mourikis TP,Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A,Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, JacquelotN, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, MarabelleA, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C,Delaloge S, McGranahan N, André F, Zitvogel L.Ann Oncol. 2019 Jun 1;30(6):934-944.doi: 10.1093/annonc/mdz112.PMID: 30924846 Free article.

2018

230. Prevalence of Yersinia Species in the Ileum of Crohn's Disease Patients andControls. Le Baut G, O'Brien C, Pavli P, Roy M,Seksik P, Tréton X, Nancey S, Barnich N, Bezault M, Auzolle C, Cazals-Hatem D,Viala J, Allez M; REMIND GROUP; Hugot JP, Dumay A.FrontCell Infect Microbiol. 2018 Sep 21;8:336. doi: 10.3389/fcimb.2018.00336.eCollection 2018.PMID: 30298122 Free PMCarticle.

231. Computed tomography scan efficacy instaging gastric linitis plastica lesion: a retrospective multicentric Frenchstudy. Morgant S, Artru P, Oudjit A, LourencoN, Pasquer A, Walter T, Gornet JM, Rouquette A, Lledo G, Brezault C,Coriat R.Cancer Manag Res. 2018 Sep 24;10:3825-3831. doi:10.2147/CMAR.S163141. eCollection 2018.PMID: 30288113 Free PMCarticle.

232. EPIGIST: An observational real-lifestudy on patients with metastatic gastrointestinal stromal tumors receivingimatinib. Bouché O, Cesne AL, Rios M, Chaigneau L,Italiano A, Duffaud F, Lecomte T, Arsène D, Manfredi S, Aparicio T, Remy S, Isambert N, Collard O, PriouF, Bertucci F, Sambuc R, Bisot-Locard S, Bourges O, Chabaud S, Blay JY.PLoSOne. 2018 Sep 18;13(9):e0204117. doi: 10.1371/journal.pone.0204117. eCollection2018.PMID: 30226855 Free PMCarticle.

233. Emergence of severespondyloarthropathy-related entheseal pathology following successfulvedolizumab therapy for inflammatory bowel disease. Dubash S, Marianayagam T, Tinazzi I, Al-Araimi T,Pagnoux C, Weizman AV, Richette P, Tran Minh ML, Allez M, Singh A, Ciccia F, Hamlin J, Tan AL, Marzo-OrtegaH, McGonagle D.Rheumatology (Oxford). 2019 Jun1;58(6):963-968. doi: 10.1093/rheumatology/key267.PMID: 30204909 Freearticle.

234. Anti-TNF therapy for genital fistulas infemale patients with Crohn's disease: a nationwide study from the Grouped'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). Le Baut G, Peyrin-Biroulet L, Bouguen G, Gornet JM, Stefanescu C, Amiot A, Laharie D,Altwegg R, Fumery M, Trang C, Vuitton L, Simon M, Gilletta de Saint Joseph C,Nahon S, Caillo L, Del Tedesco E, Plastaras L, Aubourg A, Pineton de ChambrunG, Seksik P, Viennot S.Aliment Pharmacol Ther. 2018Oct;48(8):831-838. doi: 10.1111/apt.14946. Epub 2018 Sep 7.PMID: 30194687

235. Palliative Radiotherapy for DisfiguringMycosis Fungoides Lesion: A Key Treatment to Reduce Psychological and SocialImpact. Egal A, Ram-Wolf C, Quero L, Bagot M, Vignon-Pennamen MD, HennequinC, M'Barek B.Case Rep Dermatol Med. 2018 Jul26;2018:1762050. doi: 10.1155/2018/1762050. eCollection 2018.PMID: 30147966 Free PMCarticle.

236. Male gender, active smoking and previousintestinal resection are risk factors for post-operative endoscopic recurrencein Crohn's disease: results from a prospective cohort study. Auzolle C, Nancey S, Tran-Minh ML,Buisson A, Pariente B, Stefanescu C, Fumery M, Marteau P, Treton X, Hammoudi N;REMIND Study Group Investigators; Jouven X, Seksik P, Allez M.AlimentPharmacol Ther. 2018 Nov;48(9):924-932. doi: 10.1111/apt.14944. Epub 2018 Aug20.PMID: 30126030

237. Postoperative hepatic arterialchemotherapy in high-risk patients as adjuvant treatment after resection ofcolorectal liver metastases - a randomized phase II/III trial - PACHA-01(NCT02494973). Goéré D,Pignon JP, Gelli M, Elias D, Benhaim L, Deschamps F, Caramella C, Boige V,Ducreux M, de Baere T, Malka D.BMC Cancer. 2018 Aug 6;18(1):787. doi:10.1186/s12885-018-4697-7.PMID: 30081865 Free PMCarticle.

238. Risk of serious infection in healthcareworkers with inflammatory bowel disease: a case-control study of the Grouped'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). Gagnière C, Bourrier A, Seksik P, Gornet JM, DeWit O, Nancey S, Altwegg R, AbitbolV, Laharie D, Reenaers C, Buisson A, Pariente B, Viennot S, Vuitton L,Stefanescu C, Marteau P, Bouguen G, Cosnes J, Amiot A; GETAID INFOPRO studygroup.Aliment Pharmacol Ther. 2018 Oct;48(7):713-722. doi:10.1111/apt.14926. Epub 2018 Aug 2.PMID: 30069921 Freearticle.

239. Peritoneal and extraperitoneal relapseafter previous curative treatment of peritoneal metastases from colorectalcancer: What survival can we expect? GelliM, Huguenin JFL, de Baere T, Benhaim L, Mariani A, Boige V, Malka D, SourouilleI, Ducreux M, Elias D, Goéré D.EurJ Cancer. 2018 Sep;100:94-103. doi: 10.1016/j.ejca.2018.04.015.Epub 2018 Jul 5.PMID: 30014885

240. Ustekinumab treatment for neutrophilicdermatoses associated with Crohn's disease: A multicenter retrospective study. de Risi-Pugliese T, Seksik P, BouazizJD, Chasset F, Moguelet P, Gornet JM, Bourrier A, Amiot A, Beaugerie L,Francès C, Guégan S; Ustekinumab–Crohn's Disease–Neutrophilic Dermatosis StudyGroup.J Am Acad Dermatol. 2019 Mar;80(3):781-784. doi:10.1016/j.jaad.2018.06.065. Epub 2018 Jul 10.PMID: 30003991 No abstract available.

241. Postoperative Infectious ComplicationsImpact Long-Term Survival in Patients Who Underwent Hepatectomies for ColorectalLiver Metastases: a Propensity Score Matching Analysis. Memeo R, de Blasi V, Adam R, Goéré D, Laurent A, de'Angelis N, Piardi T,Lermite E, Herrero A, Navarro F, Sa Cunha A, Pessaux P; French colorectal livermetastases working group - Association Française de Chirurgie (AFC).JGastrointest Surg. 2018 Dec;22(12):2045-2054. doi: 10.1007/s11605-018-3854-2.Epub 2018 Jul 10.PMID: 29992519

242. Impact of Combination Chemotherapy inPeritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): TheRENAPE Study. Malgras B, Gayat E, Aoun O, Lo Dico R,Eveno C, Pautrat K, Delhorme JB, Passot G, Marchal F, Sgarbura O, Ferron G, Goéré D, Andre T, Pocard M; RENAPE Network.AnnSurg Oncol. 2018 Oct;25(11):3271-3279. doi: 10.1245/s10434-018-6631-2. Epub2018 Jul 5.PMID: 29978366

243. Methotrexate and BAFF interactionprevents immunization against TNF inhibitors. Bitoun S, Nocturne G, Ly B, Krzysiek R, Roques P,Pruvost A, Paoletti A, Pascaud J, Dönnes P, Florence K, Gleizes A,Hincelin-Mery A, Allez M, Hacein-Bey-Abina S, Mackay F, PallardyM, Le Grand R, Mariette X.Ann Rheum Dis. 2018Oct;77(10):1463-1470. doi: 10.1136/annrheumdis-2018-213403. Epub 2018 Jun 23.PMID: 29936438

244. Peritoneal Metastases from ColorectalCancer: Treatment Principles and Perspectives. Goéré D, Sourrouille I, Gelli M, Benhaim L,Faron M, Honoré C.Surg Oncol Clin N Am. 2018Jul;27(3):563-583. doi: 10.1016/j.soc.2018.02.011.PMID: 29935690 Review.

245. Prognostic Value of Methylator Phenotypein Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. Gallois C, Taieb J, Le Corre D, LeMalicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, VanLaethem JL, Emile JF, Laurent-Puig P; PETACC8 investigators.ClinCancer Res. 2018 Oct 1;24(19):4745-4753. doi: 10.1158/1078-0432.CCR-18-0866.Epub 2018 Jun 19.PMID: 29921730 ClinicalTrial.

246. Is there an oncological interest in thecombination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of amulticenter international study. Mehta S, Schwarz L, Spiliotis J, Hsieh MC, Akaishi EH, Goere D, Sugarbaker PH, Baratti D, Quenet F,Bartlett DL, Villeneuve L, Kepenekian V; PSOGI and BIG-RENAPE Working Groups.EurJ Surg Oncol. 2018 Nov;44(11):1786-1792. doi: 10.1016/j.ejso.2018.05.021. Epub2018 May 28.PMID: 29885982

247. Efficacy of a docetaxel-5FU-oxaliplatinregimen (TEFOX) in first-line treatment of advanced gastric signet ring cellcarcinoma: an AGEO multicentre study. Pernot S, Dubreuil O, Aparicio T, Le Malicot K, Tougeron D, Lepère C,Lecaille C, Marthey L, Palle J, Bachet JB, Zaanan A, Taieb J.BrJ Cancer. 2018 Aug;119(4):424-428. doi: 10.1038/s41416-018-0133-7. Epub 2018Jun 6.PMID: 29872148 Free PMCarticle.

248. Critical Contribution of NK Group 2Member D Expressed on Invariant Natural Killer T Cells in ConcanavalinA-Induced Liver Hepatitis in Mice. Al Dulaimi D, Klibi J, Olivo Pimentel V, Parietti V, Allez M, Toubert A, Benlagha K.FrontImmunol. 2018 May 17;9:1052. doi: 10.3389/fimmu.2018.01052. eCollection 2018.PMID: 29868013 Free PMCarticle.

249. Reply to M. Mo et al. AparicioT, Ghiringhelli F, BoigeV, Le Malicot K, Taieb J, Bennouna J.J Clin Oncol. 2018 Aug 10;36(23):2452-2453. doi:10.1200/JCO.2018.78.9669. Epub 2018 Jun 4.PMID: 29863977 No abstract available.

250. Overweight is associated to a betterprognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. Aparicio T, Ducreux M, Faroux R, Barbier E,Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, FrançoisE, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, LepageC, Bouché O, Seitz JF; for FFCD investigators.EurJ Cancer. 2018 Jul;98:1-9. doi: 10.1016/j.ejca.2018.03.031. Epub 2018 May 26.PMID: 29807237 Freearticle.

251. Personalized therapy based on sequentialmolecular analysis leads to 30 months of survival in a patient with diffuseunresectable gastric linitis plastica. Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A,Bahleda R, Jamme P, Gelli M, Goere D, Lacroix L, Adam J, Heukamp L, TrentaP, Hembrough T, Soria JC, Sternberg C, Ducreux M.Tumori.2018 Dec;104(6):NP38-NP41. doi: 10.1177/0300891618763215. Epub 2018 Mar 21.PMID: 29714649

252. Impact of the addition of bevacizumab,oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment ofmetastatic colorectal cancer in elderly patients. Landre T, Maillard E, Taleb C, Ghebriou D, Guetz GD,Zelek L, Aparicio T.IntJ Colorectal Dis. 2018 Aug;33(8):1125-1130. doi: 10.1007/s00384-018-3053-3.Epub 2018 Apr 21.PMID: 29680896

253. Homeostatic proliferation leads totelomere attrition and increased PD-1 expression after autologous hematopoieticSCT for systemic sclerosis. Arruda LCM, Lima-Júnior JR, Clave E,Moraes DA, Douay C, Fournier I, Moins-TeisserencH, Covas DT, Simões BP, Farge D, Toubert A, MalmegrimKCR, Oliveira MC.Bone Marrow Transplant. 2018Oct;53(10):1319-1327. doi: 10.1038/s41409-018-0162-0. Epub 2018 Apr 18.PMID: 29670207 ClinicalTrial.

254. Major Hepatectomy for Colorectal LiverMetastases in Patients Aged Over 80: A Propensity Score Matching Analysis. De Blasi V, Memeo R, Adam R, Goéré D, Cherqui D, Regimbeau JM, Rivoire M,Perotto LO, Navarro F, Sa Cunha A, PessauxP;on behalf of the French Colorectal Liver Metastases Working Group, Association Française de Chirurgie.DigSurg. 2018;35(4):333-341. doi: 10.1159/000486522. Epub 2018 Apr 17.PMID: 29669343

255. Inflammatory bowel disease drasticallyaffects the prognosis of patients treated for peritoneal metastases withcombined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Amulticenter study. Hammoudi N, Eveno C, Lambert J, MailletM, Glehen O, Goere D, Lourenco N, Allez M, Aparicio T, Pocard M, Gornet JM; BIG-RENAPE working group.EurJ Surg Oncol. 2018 Jun;44(6):799-804. doi: 10.1016/j.ejso.2018.03.006. Epub2018 Mar 17.PMID: 29650418

256. Peritoneal Carcinomatosis of Rare OvarianOrigin Treated by Cytoreductive Surgery and Hyperthermic IntraperitonealChemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE. Mercier F, Bakrin N, Bartlett DL, Goere D, Quenet F, Dumont F, Heyd B, Abboud K,Marolho C, Villeneuve L, Glehen O; PSOGI Working Group; BIG-RENAPE WorkingGroup.Ann Surg Oncol. 2018 Jun;25(6):1668-1675. doi:10.1245/s10434-018-6464-z. Epub 2018 Apr 10.PMID: 29637438

257. Cytoreductive Surgery Plus HyperthermicIntraperitoneal Chemotherapy for Peritoneal Metastases From a Small BowelAdenocarcinoma: Multi-Institutional Experience. Liu Y, Yonemura Y, Levine EA, Glehen O, Goere D, Elias D, Morris DL, Sugarbaker PH,Tuech JJ, Cashin P, Spiliotis JD, de Hingh I, Ceelen W, Baumgartner JM, Piso P,Katayama K, Deraco M, Kusamura S, Pocard M, Quenet F, Fushita S; BIG-RENAPEGroup.Ann Surg Oncol. 2018 May;25(5):1184-1192. doi:10.1245/s10434-018-6369-x. Epub 2018 Feb 26.PMID: 29484565 Free PMCarticle.

258. Efficacy and safety of pasireotide-LARfor the treatment of refractory bleeding due to gastrointestinalangiodysplasias: results of the ANGIOPAS multicenter phase II noncomparativeprospective double-blinded randomized study. Benamouzig R, Benallaoua M, Saurin JC, Boubaya M,Cellier C, Laugier R, Vincent M, Boustière C, Gincul R, Samaha E, Grandval P, Aparicio T, Airinei G, Bejou B, Bon C, Raynaud JJ,Levy V, Sautereau D.Therap Adv Gastroenterol. 2018 Feb16;11:1756283X18756260. doi: 10.1177/1756283X18756260. eCollection 2018.PMID: 29479375 Free PMCarticle.

259. Impaired long-term immune protectionfollowing pneumococcal 13-valent/23-valent polysaccharide vaccine in systemiclupus erythematosus (SLE). Sacre K, Goulenok T, Bahuaud M, FrancoisC, Van der Haegen MC, Alexandra JF, Aucouturier P, Hurtado-Nedelec M, Moins-TeisserencH, Batteux F, Papo T.AnnRheum Dis. 2018 Oct;77(10):1540-1542. doi: 10.1136/annrheumdis-2017-212789.Epub 2018 Feb 14.PMID: 29444908 No abstract available.

260. Phase III randomized trial comparing5-fluorouracil and oxaliplatin with or without docetaxel in first-line advancedgastric cancer chemotherapy (GASTFOX study). ZaananA, Samalin E, Aparicio T,Bouche O, Laurent-Puig P, Manfredi S, Michel P, Monterymard C, Moreau M,Rougier P, Tougeron D, Taieb J, Louvet C.Dig Liver Dis. 2018 Apr;50(4):408-410. doi:10.1016/j.dld.2018.01.119. Epub 2018 Mar 1.PMID: 29409778 ClinicalTrial.

261. Tumour spheres with inverted polaritydrive the formation of peritoneal metastases in patients with hypermethylatedcolorectal carcinomas.ZajacO, Raingeaud J, Libanje F, Lefebvre C, Sabino D, Martins I, Roy P, Benatar C,Canet-Jourdan C, Azorin P, Polrot M, Gonin P, Benbarche S, Souquere S, PierronG, Nowak D, Bigot L, Ducreux M, Malka D, Lobry C, Scoazec JY, Eveno C, PocardM, Perfettini JL, Elias D, Dartigues P, Goéré D, Jaulin F.NatCell Biol. 2018 Mar;20(3):296-306. doi: 10.1038/s41556-017-0027-6. Epub 2018Feb 5.PMID: 29403038

262. Aspirin versus placebo in stage III orhigh-risk stage II colon cancer with PIK3CA mutation: A French randomiseddouble-blind phase III trial (PRODIGE 50-ASPIK). Michel P, Boige V, Andre T, Aparicio T, Bachet JB, Dahan L, Guimbaud R, LepageC, Manfredi S, Tougeron D, Taieb J, Selves J, Le Malicot K, Di Fiore F,Maillard E.Dig Liver Dis. 2018 Mar;50(3):305-307. doi: 10.1016/j.dld.2017.12.023.Epub 2017 Dec 30.PMID: 29402752 ClinicalTrial.

263. Immune rebound associates with afavorable clinical response to autologous HSCT in systemic sclerosis patients. Arruda LCM, Malmegrim KCR, Lima-JúniorJR, Clave E, Dias JBE, Moraes DA, Douay C, Fournier I, Moins-TeisserencH, Alberdi AJ, Covas DT, Simões BP, Lansiaux P, ToubertA, Oliveira MC.Blood Adv. 2018 Jan 23;2(2):126-141.doi: 10.1182/bloodadvances.2017011072.PMID: 29365321 Free PMCarticle.

264. Bevacizumab Maintenance Versus NoMaintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer:A Randomized Phase III Trial (PRODIGE 9). Aparicio T, Ghiringhelli F, Boige V, Le Malicot K,Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, JacquotS, Genet D, Khemissa F, Suc E, Desseigne F, Texereau P, Lepage C, Bennouna J;PRODIGE 9 Investigators.J Clin Oncol. 2018 Mar 1;36(7):674-681.doi: 10.1200/JCO.2017.75.2931. Epub 2018 Jan 18.PMID: 29346040 ClinicalTrial.

265. Autologous Haematopoietic Stem CellTransplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCOand EBMT. Snowden JA, Panés J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J,Hasselblatt P, Hawkey C, Kazmi M, Lindsay JO, Onida F, Salas A, Saccardi R,Vermeire S, Rovira M, Ricart E; European Crohn’s and Colitis Organisation(ECCO); European Society for Blood and Marrow Transplantation (EBMT);Autoimmune Diseases Working Party (ADWP); Joint Accreditation Committee of theInternational Society for Cellular Therapy (ISCT) and EBMT (JACIE).JCrohns Colitis. 2018 Mar 28;12(4):476-488. doi: 10.1093/ecco-jcc/jjx184.PMID: 29325112 Freearticle. Review.

266. Increasing Infliximab Dose Based onSymptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical,Endoscopic, and Corticosteroid-Free Remission in Patients With ActiveLuminal Crohn's Disease. D'Haens G, Vermeire S, Lambrecht G,Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander WoudeJ, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, Mana F,Peyrin-Biroulet L, Brixi H, Allez M, Caenepeel P, Aubourg A, Oldenburg B,Pierik M, Gils A, Chevret S, Laharie D; GETAID.Gastroenterology.2018 Apr;154(5):1343-1351.e1. doi: 10.1053/j.gastro.2018.01.004. Epub 2018 Jan6.PMID: 29317275 Freearticle. Clinical Trial.

267. Peritoneal Carcinomatosis of UrachusOrigin Treated by Cytoreductive Surgery and Hyperthermic IntraperitonealChemotherapy (HIPEC): An International Registry of 36 Patients. Mercier F, Passot G, Villeneuve L,Levine EA, Yonemura Y, Goéré D, Sugarbaker PH, Marolho C, Bartlett DL,Glehen O; BIG-RENAPE Working Group.AnnSurg Oncol. 2018 Apr;25(4):1094-1100. doi: 10.1245/s10434-017-6299-z. Epub 2017Dec 13.PMID: 29238881

268. High Risk of Anal and Rectal Cancer inPatients With Anal and/or Perianal Crohn's Disease. Beaugerie L, Carrat F, Nahon S, Zeitoun JD, Sabaté JM,Peyrin-Biroulet L, Colombel JF, Allez M, Fléjou JF, Kirchgesner J, Svrcek M;Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales En FranceStudy Group.Clin Gastroenterol Hepatol. 2018 Jun;16(6):892-899.e2.doi: 10.1016/j.cgh.2017.11.041. Epub 2017 Dec 2.PMID: 29199142

269. Plesiobrachytherapy for chest wallrecurrences of breast cancer after mastectomy and radiotherapy for breastcancer. Besson N, Hennequin C, Guillerm S,Fumagalli I, Martin V, Michaud S, Texeira L, Quero L.Brachytherapy.2018 Mar-Apr;17(2):425-431. doi: 10.1016/j.brachy.2017.10.005. Epub 2017 Nov23.PMID: 29174938

270. Small bowel adenocarcinoma: Frenchintergroup clinical practice guidelines for diagnosis, treatments and follow-up(SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). LocherC, Batumona B, Afchain P, Carrère N, Samalin E, Cellier C, AparicioT, Becouarn Y, Bedenne L,Michel P, Parc Y, Pocard M, Chibaudel B, Bouché O; Thésaurus National deCancérologie Digestive (TNCD).Dig Liver Dis. 2018 Jan;50(1):15-19. doi:10.1016/j.dld.2017.09.123. Epub 2017 Oct 6.PMID: 29174568 Review.

271. Association of Prognostic Value ofPrimary Tumor Location in Stage III Colon Cancer With RAS and BRAF MutationalStatus. Taieb J, Kourie HR, Emile JF, Le MalicotK, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C,Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, VanCutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P; Pan-European Trialsin Alimentary Tract Cancer (PETACC)-8 Investigators.JAMAOncol. 2018 Jul 12;4(7):e173695. doi: 10.1001/jamaoncol.2017.3695. Epub 2018Jul 12.PMID: 29167892 Free PMCarticle.

272. Hodgkin lymphoma in adolescent and youngadults: insights from an adult tertiary single-center cohort of 349 patients. Bigenwald C, Galimard JE, Quero L, Cabannes-Hamy A, Thieblemont C,Boissel N, Brice P.Oncotarget. 2017 Sep6;8(45):80073-80082. doi: 10.18632/oncotarget.20684. eCollection 2017 Oct 3.PMID: 29108389 Free PMCarticle.

273. Impact of RAS Mutations in MetastaticColorectal Cancer After Potentially Curative Resection: Does Site of MetastasesMatter? Passot G, Kim BJ, Glehen O, Mehran RJ, Kopetz SE, Goere D, Overman MJ, Pocard M, Marchal F,Conrad C, Aloia TA, Vauthey JN, Chun YS; BIG-RENAPE Working Group.AnnSurg Oncol. 2018 Jan;25(1):179-187. doi: 10.1245/s10434-017-6141-7. Epub 2017Oct 25.PMID: 29071660

274. Comparative Safety of Targeted Therapiesfor Metastatic Colorectal Cancer between Elderly and Younger Patients: a StudyUsing the International Pharmacovigilance Database. GouverneurA, Claraz P, Rousset M, Arnaud M, Fourrier-Réglat A, Pariente A, AparicioT, Miremont-Salamé G,Noize P.TargetOncol. 2017 Dec;12(6):805-814. doi:10.1007/s11523-017-0529-y.PMID: 29022151

275. TNFR2/BIRC3-TRAF1 signaling pathway as anovel NK cell immune checkpoint in cancer. Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A,Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C,Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ,Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L.Oncoimmunology.2017 Oct 11;7(12):e1386826. doi: 10.1080/2162402X.2017.1386826. eCollection2018.PMID: 30524877 Free PMCarticle.

276. Outcomes 7 Years After InfliximabWithdrawal for Patients With Crohn's Disease in Sustained Remission. Reenaers C, Mary JY, Nachury M, BouhnikY, Laharie D, Allez M, Fumery M, Amiot A, Savoye G, AltweggR, Devos M, Malamut G, Bourreille A, Flourie B, Marteau P, Vuitton L, Coffin B,Viennot S, Lambert J, Colombel JF, Louis E; Groupe d'Etude Therapeutique desAffections Inflammatoires du tube Digestif.ClinGastroenterol Hepatol. 2018 Feb;16(2):234-243.e2. doi:10.1016/j.cgh.2017.09.061. Epub 2017 Oct 7.PMID: 28993262 Freearticle.

277. European Crohn's and ColitisOrganisation Topical Review on Treatment Withdrawal ['Exit Strategies'] inInflammatory Bowel Disease.DohertyG, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R,Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, LouisE.J Crohns Colitis. 2018 Jan 5;12(1):17-31. doi:10.1093/ecco-jcc/jjx101.PMID: 28981623 Freearticle. Review.

278. Effect of PF-00547659 on Central NervousSystem Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report ofthe TOSCA Study. D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, SandbornWJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R,Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-ZahraeeM, Reinisch W, Stuve O.J Crohns Colitis. 2018 Jan24;12(2):188-196. doi: 10.1093/ecco-jcc/jjx128.PMID: 28961770 Free PMCarticle.

279. Tumor-Derived Mesenchymal Stem Cells UseDistinct Mechanisms to Block the Activity of Natural Killer Cell Subsets. Galland S, Vuille J, Martin P, LetovanecI, Caignard A, Fregni G, Stamenkovic I.CellRep. 2017 Sep 19;20(12):2891-2905. doi: 10.1016/j.celrep.2017.08.089.PMID: 28930684 Freearticle.

280. Margin Status is Still an ImportantPrognostic Factor in Hepatectomies for Colorectal Liver Metastases: APropensity Score Matching Analysis. Memeo R, de Blasi V, Adam R, Goéré D, Piardi T, Lermite E, Turrini O,Navarro F, de'Angelis N, Cunha AS, Pessaux P; French Colorectal LiverMetastases Working Group, Association Française de Chirurgie (AFC).WorldJ Surg. 2018 Mar;42(3):892-901. doi: 10.1007/s00268-017-4229-7.PMID: 28929341

281. Chronological Age and Risk ofChemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or IIIColorectal Cancer Patients Given Adjuvant-modified FOLFOX6. LaurentM, Des Guetz G, Bastuji-Garin S, Culine S, Caillet P, AparicioT, Audureau E,Carvahlo-Verlinde M, Reinald N, Tournigand C, Landre T, LeThuaut A, Paillaud E,Canouï-Poitrine F.AmJ Clin Oncol. 2018 Jan;41(1):73-80. doi: 10.1097/COC.0000000000000233.PMID: 26669742

2017

282. Diagnostic performance of gait speed, G8and G8 modified indices to screen for vulnerability in older cancer patients:the prospective PF-EC cohort study. Pamoukdjian F, Canoui-Poitrine F, Longelin-Lombard C, Aparicio T, Ganne N, Wind P, Martinez-Tapia C,Audureau E, Sebbane G, Zelek L, Paillaud E.Oncotarget.2017 Apr 21;8(31):50393-50402. doi: 10.18632/oncotarget.17361. eCollection 2017Aug 1.PMID: 28881570 Free PMCarticle.

283. Response to Dhoble et al. Fumery M, Allez M.AmJ Gastroenterol. 2017 Sep;112(9):1479-1480. doi: 10.1038/ajg.2017.234.PMID: 28874871 No abstract available.

284. Conversion to Complete CytoreductiveSurgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant PeritonealMesothelioma After Bidirectional Chemotherapy. LeRoy F, Gelli M, Hollebecque A, Honoré C, Boige V, Dartigues P, Benhaim L, MalkaD, Ducreux M, Elias D, Goéré D.AnnSurg Oncol. 2017 Nov;24(12):3640-3646. doi:10.1245/s10434-017-6033-x. Epub 2017 Aug 28.PMID: 28849389

285. Are we reproducible in measurement ofNET liver metastasis? Moalla S, Arfi Rouche J, Foulon S, Caramella C, Ternes N,Planchard D, Goere D,Ducreux M, Scoazec JY, Deschamps F, Dromain C, Baudin E.Dig Liver Dis. 2017 Oct;49(10):1121-1127. doi:10.1016/j.dld.2017.05.015. Epub 2017 Jun 28.PMID: 28844707

286. Docetaxel, Cisplatin, and 5-fluorouracil(DCF) chemotherapy in the treatment of metastatic or unresectable locallyrecurrent anal squamous cell carcinoma: a phase II study of Frenchinterdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). Kim S, Jary M, André T, Vendrely V,Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S,Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C,Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C.BMCCancer. 2017 Aug 25;17(1):574. doi: 10.1186/s12885-017-3566-0.PMID: 28841909 Free PMCarticle. Clinical Trial.

287. Features of Autoimmune PancreatitisAssociated With Inflammatory Bowel Diseases. Lorenzo D, Maire F, Stefanescu C, Gornet JM, Seksik P, Serrero M, Bournet B,Marteau P, Amiot A, Laharie D, Trang C, Coffin B, Bellaiche G, Cadiot G,Reenaers C, Racine A, Viennot S, Pauwels A, Bouguen G, Savoye G, Pelletier AL,Pineton de Chambrun G, Lahmek P, Nahon S, Abitbol V; GETAID-AIP study group.ClinGastroenterol Hepatol. 2018 Jan;16(1):59-67. doi: 10.1016/j.cgh.2017.07.033.Epub 2017 Aug 4.PMID: 28782667

288. Circulating and skin-derived Sézarycells: clonal but with phenotypic plasticity. Roelens M, Delord M, Ram-Wolff C, Marie-Cardine A,Alberdi A, Maki G, Homyrda L, Bensussan A, Bagot M, Toubert A, Moins-TeisserencH.Blood. 2017 Sep 21;130(12):1468-1471. doi:10.1182/blood-2017-03-772996. Epub 2017 Jul 31.PMID: 28760889 Freearticle. No abstract available.

289. Interferon-alpha Treatment for DiseaseControl in Metastatic Pheochromocytoma/Paraganglioma Patients. Hadoux J, Terroir M, Leboulleux S,Deschamps F, Al Ghuzlan A, Hescot S, Tselikas L, Borget I, Caramella C,Déandréis D, Goere D, De Baere T, Schlumberger M, Baudin E.HormCancer. 2017 Dec;8(5-6):330-337. doi: 10.1007/s12672-017-0303-8. Epub 2017 Jul26.PMID: 28748315

290. Laparoscopic Compared to Open RepeatHepatectomy for Colorectal Liver Metastases: a Multi-institutionalPropensity-Matched Analysis of Short- and Long-Term Outcomes. Hallet J, Sa Cunha A, Cherqui D, GayetB, Goéré D, Bachellier P, Laurent A, Fuks D,Navarro F, Pessaux P; French Colorectal Liver Metastases Working Group,Association Française de Chirurgie.WorldJ Surg. 2017 Dec;41(12):3189-3198. doi: 10.1007/s00268-017-4119-z.PMID: 28717911

291. Patient's Natural Killer Cells in theEra of Targeted Therapies: Role for Tumor Killers. Messaoudene M, Frazao A, Gavlovsky PJ, Toubert A,Dulphy N, Caignard A.FrontImmunol. 2017 Jun 12;8:683. doi: 10.3389/fimmu.2017.00683. eCollection 2017.PMID: 28659921 Free PMCarticle.

292. Genomic Profiling of Small-BowelAdenocarcinoma. Schrock AB, Devoe CE, McWilliams R, SunJ, Aparicio T, Stephens PJ, Ross JS, Wilson R, MillerVA, Ali SM, Overman MJ.JAMA Oncol. 2017 Nov 1;3(11):1546-1553.doi: 10.1001/jamaoncol.2017.1051.PMID: 28617917 Free PMCarticle.

293. Anal cancer: French Intergroup ClinicalPractice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD,GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). Moureau-Zabotto L, Vendrely V, Abramowitz L, Borg C,Francois E, Goere D, Huguet F, Peiffert D, Siproudhis L,Ducreux M, Bouché O.Dig Liver Dis. 2017 Aug;49(8):831-840.doi: 10.1016/j.dld.2017.05.011. Epub 2017 May 23.PMID: 28610905 Review.

294. Shifting the Balance of Activating andInhibitory Natural Killer Receptor Ligands on BRAF^V600E Melanoma Lines with Vemurafenib. Frazao A, Colombo M, Fourmentraux-NevesE, Messaoudene M, Rusakiewicz S, Zitvogel L, Vivier E, Vély F, Faure F, DrénoB, Benlalam H, Bouquet F, Savina A, Pasmant E, Toubert A, Avril MF, Caignard A.CancerImmunol Res. 2017 Jul;5(7):582-593. doi: 10.1158/2326-6066.CIR-16-0380. Epub2017 Jun 2.PMID: 28576831

295. Ninety percent of the adverse outcomesoccur in 10% of patients: can we identify the populations at high risk ofdeveloping peritoneal metastases after curative surgery for colorectal cancer? Honoré C, Gelli M, Francoual J, BenhaimL, Elias D, Goéré D.IntJ Hyperthermia. 2017 Aug;33(5):505-510. doi: 10.1080/02656736.2017.1306119.PMID: 28540831 Freearticle. Review.

296. Complete cytoreductive surgery plusHIPEC for peritoneal metastases from unusual cancer sites of origin: resultsfrom a worldwide analysis issue of the Peritoneal Surface Oncology GroupInternational (PSOGI). Goéré D, Passot G, Gelli M, Levine EA, BartlettDL, Sugarbaker PH, Glehen O.Int J Hyperthermia. 2017 Aug;33(5):520-527.doi: 10.1080/02656736.2017.1301576.PMID: 28540827 Freearticle.

297. Hepatic complications induced byimmunosuppressants and biologics in inflammatory bowel disease. Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM.WorldJ Hepatol. 2017 May 8;9(13):613-626. doi: 10.4254/wjh.v9.i13.613.PMID: 28539989 Free PMCarticle. Review.

298. Natural killer-cell counts areassociated with molecular relapse-free survival after imatinib discontinuationin chronic myeloid leukemia: the IMMUNOSTIM study. Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F,Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, Gardembas M, DubruilleV, Guerci-Bresler A, Charbonnier A, Maloisel F, Ianotto JC, Villemagne B, MahonFX, Moins-Teisserenc H, Dulphy N, Toubert A.Haematologica.2017 Aug;102(8):1368-1377. doi: 10.3324/haematol.2017.165001. Epub 2017 May 18.PMID: 28522576 Free PMCarticle. Clinical Trial.

299. Nab-paclitaxel plus either gemcitabineor simplified leucovorin and fluorouracil as first-line therapy for metastaticpancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre,open-label, randomised phase 2 trial. Bachet JB, Hammel P, Desramé J, Meurisse A, ChibaudelB, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A,Bonnetain F, Louvet C.Lancet Gastroenterol Hepatol. 2017May;2(5):337-346. doi: 10.1016/S2468-1253(17)30046-8. Epub 2017 Feb 28.PMID: 28397697 ClinicalTrial.

300. Gastrointestinal emergencies incritically ill cancer patients. Lebon D, Biard L, Buyse S, Schnell D, Lengliné E, Roussel C, Gornet JM, Munoz-Bongrand N, Quéro L, Resche-Rigon M, Azoulay E, Canet E.JCrit Care. 2017 Aug;40:69-75. doi: 10.1016/j.jcrc.2017.03.015. Epub 2017 Mar24.PMID: 28363097

301. Risk of Rectal Neoplasia after Colectomyand Ileorectal Anastomosis for Ulcerative Colitis. Uzzan M, Kirchgesner J, Oubaya N, Amiot A, Gornet JM, Seksik P, Nancey S, Cotte E, Allez M, Boschetti G, Laharie D, de Angelis N,Nachury M, Pelletier AL, Abitbol V, Fumery M, Brouquet A, Buisson A, Altwegg R,Cosnes J, Panis Y, Treton X.J Crohns Colitis. 2017 Aug1;11(8):930-935. doi: 10.1093/ecco-jcc/jjx027.PMID: 28333202

302. Systemic Human ILC Precursors Provide aSubstrate for Tissue ILC Differentiation. Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F,Casrouge A, Serafini N, Puel A, Bustamante J, Surace L, Masse-Ranson G, DavidE, Strick-Marchand H, Le Bourhis L, Cocchi R, Topazio D, Graziano P,Muscarella LA, Rogge L, Norel X, Sallenave JM, Allez M, Graf T, Hendriks RW, Casanova JL, AmitI, Yssel H, Di Santo JP.Cell. 2017 Mar 9;168(6):1086-1100.e10.doi: 10.1016/j.cell.2017.02.021.PMID: 28283063 Freearticle.

303. The role of image-guided therapy in themanagement of colorectal cancer metastatic disease. de Baere T, Tselikas L, Yevich S, Boige V, DeschampsF, Ducreux M, Goere D, Nguyen F, Malka D.EurJ Cancer. 2017 Apr;75:231-242. doi: 10.1016/j.ejca.2017.01.010. Epub 2017 Feb24.PMID: 28237869 Review.

304. Impaired mobility, depressed mood,cognitive impairment and polypharmacy are independently associated withdisability in older cancer outpatients: The prospective Physical Frailty inElderly Cancer patients (PF-EC) cohort study. Pamoukdjian F, Aparicio T, Zelek L, Boubaya M, Caillet P,François V, de Decker L, Lévy V, Sebbane G, Paillaud E.JGeriatr Oncol. 2017 May;8(3):190-195. doi: 10.1016/j.jgo.2017.02.003. Epub 2017Feb 22.PMID: 28236586

305. Successful Treatment With Ustekinumabfor Chronic Refractory Pouchitis. Tran-Minh ML, Allez M, Gornet JM.JCrohns Colitis. 2017 Sep 1;11(9):1156. doi: 10.1093/ecco-jcc/jjx018.PMID: 28199485 No abstract available.

306. Prognostic impact of the expression ofNCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lungcancer. Fend L, Rusakiewicz S, Adam J, BastienB, Caignard A, Messaoudene M, Iribarren C, Cremer I,Marabelle A, Borg C, Semeraro M, Barraud L, Limacher JM, Eggermont A, KroemerG, Zitvogel L.Oncoimmunology. 2016 May13;6(1):e1163456. doi: 10.1080/2162402X.2016.1163456. eCollection 2017.PMID: 28197362 Free PMCarticle.

307. NKp30 isoforms and NKp30 ligands arepredictive biomarkers of response to imatinib mesylate in metastatic GISTpatients. Rusakiewicz S, Perier A, Semeraro M,Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Pipéroglou C, Vély F,Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, PerniceniT, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J,Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, MarabelleA, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A,Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L.Oncoimmunology.2016 Apr 25;6(1):e1137418. doi: 10.1080/2162402X.2015.1137418. eCollection2017.PMID: 28197361 Free PMCarticle.

308. Efficacy of adalimumab in patients withCrohn's disease and symptomatic small bowel stricture: a multicentre,prospective, observational cohort (CREOLE) study. Bouhnik Y, Carbonnel F, Laharie D, Stefanescu C,Hébuterne X, Abitbol V, Nachury M, Brixi H, Bourreille A, Picon L, Bourrier A, Allez M, Peyrin-Biroulet L, Moreau J, Savoye G,Fumery M, Nancey S, Roblin X, Altwegg R, Bouguen G, Bommelaer G, Danese S,Louis E, Zappa M, Mary JY; GETAID CREOLE Study Group.Gut.2018 Jan;67(1):53-60. doi: 10.1136/gutjnl-2016-312581. Epub 2017 Jan 24.PMID: 28119352 Free PMCarticle.

309. Are random biopsies still useful for thedetection of neoplasia in patients with IBD undergoing surveillance colonoscopywith chromoendoscopy? Moussata D, Allez M, Cazals-Hatem D, Treton X, Laharie D,Reimund JM, Bertheau P, Bourreille A, Lavergne-Slove A, Brixi H, Branche J, Gornet JM, Stefanescu C, Moreau J, Marteau P,Pelletier AL, Carbonnel F, Seksik P, Simon M, Fléjou JF, Colombel JF, CharloisAL, Roblin X, Nancey S, Bouhnik Y, Berger F, Flourié B; the GETAID.Gut.2018 Apr;67(4):616-624. doi: 10.1136/gutjnl-2016-311892. Epub 2017 Jan 23.PMID: 28115492 ClinicalTrial.

310. Preferences about information anddecision-making among older patients with and without cancer. PaillaudE, Canoui-Poitrine F, Varnier G, Anfasi-Ebadi N, Guery E, Saint-Jean O, GisselbrechtM, Aparicio T,Bastuji-Garin S, Laurent M, Caillet P.Age Ageing. 2017 Jul 1;46(4):665-671. doi:10.1093/ageing/afw256.PMID: 28104597

311. Long-term immune reconstitution and Tcell repertoire analysis after autologous hematopoietic stem celltransplantation in systemic sclerosis patients. Farge D, Arruda LC, Brigant F, Clave E, Douay C,Marjanovic Z, Deligny C, Maki G, Gluckman E, Toubert A, Moins-TeisserencH.J Hematol Oncol. 2017 Jan 19;10(1):21. doi:10.1186/s13045-016-0388-5.PMID: 28103947 Free PMCarticle.

312. Leukocytosis and neutrophilia predictoutcome in locally advanced esophageal cancer treated with definitivechemoradiation. Schernberg A, Moureau-Zabotto L, RivinDel Campo E, Escande A, Ducreux M, Nguyen F, Goere D, Chargari C, Deutsch E.Oncotarget.2017 Feb 14;8(7):11579-11588. doi: 10.18632/oncotarget.14584.PMID: 28086222 Free PMCarticle.

313. Autoimmune cytopenias associated withinflammatory bowel diseases: Insights from a multicenter retrospective cohort. Uzzan M, Galicier L, Gornet JM, Oksenhendler E, Fieschi C, Allez M, Bouhnik Y, Kirchgesner J, Boutboul D,Treton X, Gérard L, Mahévas M, Cosnes J, Amiot A.DigLiver Dis. 2017 Apr;49(4):397-404. doi: 10.1016/j.dld.2016.12.006. Epub 2016Dec 23.PMID: 28063954

314. Strategies to prevent peritonealcarcinomatosis arising from colorectal cancer. Gelli M, Huguenin JF, Cerebelli C, Benhaim L, HonoréC, Elias D, Goéré D.FutureOncol. 2017 Apr;13(10):907-918. doi: 10.2217/fon-2016-0389. Epub 2017 Jan 5.PMID: 28052691 Review.

315. Immune Modifications in Fetal MembranesOverlying the Cervix Precede Parturition in Humans. Marcellin L, Schmitz T, Messaoudene M, Chader D,Parizot C, Jacques S, Delaire J, Gogusev J, Schmitt A, Lesaffre C,Breuiller-Fouché M, Caignard A, Vaiman D, Goffinet F, Cabrol D,Gorochov G, Méhats C.J Immunol. 2017 Feb 1;198(3):1345-1356.doi: 10.4049/jimmunol.1601482. Epub 2016 Dec 28.PMID: 28031337

316. Leukocytosis and neutrophilia predictsoutcome in anal cancer. Schernberg A, Escande A, Rivin Del CampoE, Ducreux M, Nguyen F, Goere D, Chargari C, Deutsch E.RadiotherOncol. 2017 Jan;122(1):137-145. doi: 10.1016/j.radonc.2016.12.009. Epub 2016Dec 24.PMID: 28024835

317. Prognostic Value of Sterilized LymphNodes After Preoperative Chemoradiotherapy for Patients with ypN0 RectalCancer. Vychnevskaia K, Dumont F, Agostini J,Julié C, Dartigues P, Lazure T, Boige V, Goéré D, Brouquet A, Penna C, Peschaud F,Benoist S.Ann Surg Oncol. 2017 May;24(5):1304-1311. doi:10.1245/s10434-016-5736-8. Epub 2016 Dec 22.PMID: 28008572

318. Intra-arterial therapies for colorectalcancer liver metastases (radioembolization excluded). deBaere T, Tselikas L, Boige V, Ducreux M, Malka D, GoéréD, Benahim E, DeschampsF.Bull Cancer. 2017May;104(5):402-406. doi: 10.1016/j.bulcan.2016.10.025. Epub 2016 Dec 16.PMID: 27993355 Review.

319. Postoperative Complications afterIleocecal Resection in Crohn's Disease: A Prospective Study From the REMINDGroup. FumeryM, Seksik P, Auzolle C, Munoz-Bongrand N, Gornet JM, Boschetti G, Cotte E, Buisson A, Dubois A, Pariente B,Zerbib P, Chafai N, Stefanescu C, Panis Y, Marteau P, Pautrat K, Sabbagh C,Filippi J, Chevrier M, Houze P, Jouven X, Treton X, Allez M; REMIND study group investigators.Am J Gastroenterol.2017 Feb;112(2):337-345. doi: 10.1038/ajg.2016.541. Epub 2016 Dec 13.PMID: 27958285

320. Geriatric factors analyses from FFCD2001-02 phase III study of first-line chemotherapy for elderly metastaticcolorectal cancer patients. Aparicio T, Gargot D, Teillet L, Maillard E, GenetD, Cretin J, Locher C, Bouché O, Breysacher G, Seitz JF, Gasmi M, Stefani L, RamdaniM, Lecomte T, Auby D, Faroux R, Bachet JB, Lepère C, Khemissa F, Sobhani I,Boulat O, Mitry E, Jouve JL; FFCD 2001-02 investigators.EurJ Cancer. 2017 Mar;74:98-108. doi: 10.1016/j.ejca.2016.09.029. Epub 2016 Nov 5.PMID: 27825697 ClinicalTrial.

321. Reply. Simon M, Pariente B, Gornet JM.ClinGastroenterol Hepatol. 2017 Jan;15(1):148-149. doi: 10.1016/j.cgh.2016.09.016.Epub 2016 Sep 17.PMID: 27650327 No abstract available.

322. Long-term Follow-up After IleorectalAnastomosis for Ulcerative Colitis: A GETAID/GETAID Chirurgie MulticenterRetrospective Cohort of 343 Patients. Uzzan M, Cosnes J, Amiot A, Gornet JM, Seksik P, Cotte E, Tiret E, Panis Y,Treton X.Ann Surg. 2017 Dec;266(6):1029-1034. doi:10.1097/SLA.0000000000002022.PMID: 27655238

323. Anti-NKG2D monoclonal antibody(NNC0142-0002) in active Crohn's disease: a randomised controlled trial. Allez M, Skolnick BE, Wisniewska-Jarosinska M,Petryka R, Overgaard RV.Gut. 2017 Nov;66(11):1918-1925. doi:10.1136/gutjnl-2016-311824. Epub 2016 Aug 3.PMID: 27489241 ClinicalTrial.

324. 10-Year follow-up of 621 patientstreated using high-dose rate brachytherapy as ambulatory boost technique inconservative breast cancer treatment. Quéro L, Guillerm S, Taright N, Michaud S,Teixeira L, Cahen-Doidy L, Bourstyn E, Espié M, Hennequin C.RadiotherOncol. 2017 Jan;122(1):11-16. doi: 10.1016/j.radonc.2016.06.014. Epub 2016 Jul26.PMID: 27474504

325. Analyses of patterns-of-failure andprognostic factors according to radiation fields in early-stage Hodgkinlymphoma. Krebs L, Amorin S, Brice P, Guillerm S,Menard J, Hennequin C, Quéro L.StrahlentherOnkol. 2017 Feb;193(2):116-124. doi: 10.1007/s00066-016-0969-9. Epub 2016 Jun17.PMID: 27316376 English.

Communication dans un congrès

2022 :

‍

M. Allez

- National tchek Virtualmeeting Prague, Endoskopie a endoterapie u IBD, “Immunogenicity to anti-drugantibodies in IBD: therapeutic options including desensitization toinfliximab”, march 2022

- Grupo de Estudosda Doença Inflamatoria Intestinal (GEDII) annual meeting, Cascais, Portugal,“Crohn after surgery: resetting?”, april 2022

- Word ofmicrobiome meeting, “The role of the microbiome in post-operative recurrence ofCrohn’s disease”, Vienna, april 2022

- Associationdes maladies chroniques de l’appareil digestif (AMCAD), Marrakech, april 2022

- 25th anniversaryIBD Clinical and Research Center, University of Manitoba, Key topics inGastroenterology, conference on invitation: “The Future of IBD Treatment:Should we Modulate the Microbiota or Host Immunity?”, Winnipeg, Canada, June2022

- 33rd GETECCUNational Meeting, Speaker of the Keynote lecture: “Colonic vs ileal Crohn’sdisease. Are really the same disease?”, Madrid september 2022

- UEG Week,conference on invitation: “IL-13p19 inhibitors”, Vienna, October 2022

- Falk symposium,conference “Cell trafficking in IBD: Mechanisms and therapeutic targets”,Frankfurt, november 2022

- Israeli IBDNational meeting. The IBD society, two conferences on invitation: “Futureparadigms and directions”, “Putting the therapeutic puzzle together”, november2022

- IOIBD,Organization of the IOIBD consensus: “Endpoints of post-operative recurrence inCrohn's Disease”, Napa Valley, november 2022

- Falk symposium,State-of-the-art management of IBD, conference “Cell trafficking in IBD: Mechanismsand therapeutic targets”, Frankfurt, november 2022

L.Le Bourhis.

Société Française d’Immunology. Conférence annuelle. Autologous T cell responses toprimary human colorectal cancer spheroids are enhanced by ectonucleotidaseinhibition

N. Hammoudi.

ECCO2022: 8th Y-ECCO Basic Science Workshop:Autologous organoid co-culture model reveals T cell-driven epithelial celldeath in Crohn’s Disease.

JFHOD 2022: OP49: Autologous organoid co-culture modelreveals T cell-driven epithelial cell death in Crohn’s Disease

H. Moins.

EuropeanOrganisation for. Research and Treatment of Cancer (EORTC). Effect of mogamulizumab on thetumour microenvironment and anti-tumourimmunity

2021 :

M. Allez

- Israeli Gastroenterology meeting, virtual: « Can one(anti-IL23) do things that two (anti-12/23) can't do ? Mechanisticconsiderations and Lessons from head to head trials », July 2021

- The International Organization for the Study ofInflammatory Bowel Diseases (IOIBD): “Molecular and cellular pathways ofpost-operative recurrence”, Bordeaux november 2021

T. Aparcicio

NationalCancer Research Institute event : Small bowel adenocarcinoma at molecular age(distanciel, 23/9/21)

L.Rethacker.

ECI2021: Characterization of Human Innate Lymphoid Cell Subsetsin Healthy Lymph Nodes (selected for oral presentation)

L. Le Bourhis.

Hybrid days. Lympho-epithelial interactions in humanintestinal immunity: Impact on inflammation and cancer.

2020 :

‍

M. Allez

- IBD meeting South Africa (virtual), “A look into the future”, september2020

- UEGW meeting (virtual): Post-graduate course (x2): Early identificationof colon cancer: How to do it best?; How to manage postoperative recurrence? ,october 2020

N Hammoudi.

ECCO 2020: OP04: Long-term outcomes after ileocolonicresection in Crohn’s Disease according to severity of early endoscopicrecurrence. N Hammoudi et al. Young-ECCO Abstract Award 2020

ECCO 2020: DOP35: Monitoring of mucosal T cellssubsets under biotherapies in IBD: Responders exhibit a phenotype similar tohealthy controls.

L. Rethacker.

FOCIS2020: BRAF inhibitorresistance of melanoma cells triggers increased susceptibility to NaturalKiller cell-mediated lysis

2019 :

‍

M. Allez

- Grupo de Estudos da Doença InflamatoriaIntestinal (GEDII) annual meeting, conference on invitation “IL23 blockers inIBD”, Porto, January 2019

- Belgian week of Gastroenterology,conference on invitation (BIRD), conferences on invitation “How T cells harmand protect the intestinal mucosa in IBD” “Hematopoietic Stem Celltransplantation in refractory IBD and primary inflammatory disorders”, Antwerp,February 2019

- Asan Medical Center, “Post-operativerecurrence in Crohn’s disease” “Pathophysiological insights and clinicalimplications of Th17 pathway in IBD”, Seoul, Korea, april 2019

- Campininas, conferences “Modulatingmicrobiota is really influencing IMIDs clinical course?” “What does treatmentoptimization mean?”, Campininas, Brazil, may 2019

- University of Toronto, “The role of T cellsin the pathogenesis of IBD”, may 2019

- Pan Hellenic IBD congress (Greeknnational meeting), “Can we prevent /reverse organ damage in IBD?” “Assessingdisease activity by endoscopy in Crohn’s disease”, Porte Heli, june 2019

- XI National Symposium in InflammatoryBowel Diseases, and 2nd Franco-Romanian meeting, Bucarest, september 2019

- The International Committee ForInsurance Medicine (ICLAM), “Looking into future of Inflammatory BowelDisease”, Mumbai, India, november 2019

T. Aparcicio

Tourd’Europe Sanofi : colorectal cancer at APHP : mCRC in the elderly, a specifictherapeutic approach? (Paris, 11/10/19)

L.Rethacker.

SFI, Nantes : Characterization of Human Innate LymphoidCells in Healthy Lymph Nodes

2018 :

‍

M.Allez

- CHUV, Lausanne, March 2018 : « Commentchoisir le premier biologique dans la maladie de Crohn et la colite ulcéreuse ?»

- Learning from ECCO for Asia Pacific, Beijin, Taiwan,April 2018

- Falk Symposium. “Integrating anti-IL12 and anti-IL23into the IBD algorithm”, Lisbon, april 2018

- ESPGHAN, Genève, Mai 2018. “Are there even more futurebiological options?”

- Symposium Falk, Kyoto, Septembre 2018. “Fecalbiomarkers, potential and limitations”

- Karolinska, Stockholm, Septembre 2018. “Frompersonalized medicine to precision medicine in Crohn’s disease: soon areality?”

- ECCO, Interview Talking Heads, 2018

- IBD “TRILOGY” – advanced course, Naples, October 2018.Lecture: Biologic therapy in IBD: how and when?

- UEGW 2018, October 2018. “Post-operative recurrence ofCrohn’s disease: Pathophysiology”; “Autologous stem cell transplantation as areset option?”

- The Annual meeting Of The Israel Society of Colon andRectal Surgery & The Israeli IBD society. “Follow-Up Post IleocecalResection”; “Stem Cell Therapy in IBD - The Future is Here”

- Italian IBD meeting (IG IBD), “Therapies targetingintegrins in IBD: What’s new?”, Florence, November 2018

T.Aparcicio

UnitedEuropean Gastroenterology Week : New modalities for adjuvant treatment:learning from IDEA trial (Vienne, 20/10/18)

EuropeanSociety of Medical Oncology : Small bowel adenocarcinoma (Munich, 21/10/18)

N. Hammoudi.

UEGW 2018: OP237: Deep Mural Histological Alterationsat Ileal Resection Margins are Associated with a Higher Risk of Post-OperativeEndoscopic Recurrence in Crohn's Disease. N.Hammoudi et al.

JFHOD 2018: OP45: Inflammatory bowel diseasedrastically affects the prognosis of patients treated for peritoneal metastaseswith combined cytoreductive surgery and hyperthermic intraperitonealchemotherapy: a multicenter study. N.Hammoudi et al.

L. Rethacker.

ECI 2018Amsterdam: Interestof NK cells to counteract resistance to target therapies in melanoma (selectedfor oral presentation)

CARD(Congrès Annuel de la Recherche en Dermatologie), Paris : Intérêt desLymphocytes Natural Killer pour palier à la résistance aux thérapies ciblées(selected for oral presentation)

2017 :

‍

M. Allez

- SPG, DOENÇA INFLAMATÓRIA INTESTINAL, Lisbon, February2017. « New drugs, new mechanisms of action »

- Falk symposium, Madrid, March 2017. “Ready to usecells?”

- Cape Town, National congress South Africa, May 2017.“Immune responses and microbiota in inflammatory bowel diseases”; “Malignancyin IBD - focus on thiopurines, methotrexate and biologics”

- IBD today, Amsterdam, Juin 2017. “Which cell populationsfuel IBD?”

- Australian Gastroenterology Week, invité d’honneur dela GESA (Gastroenterological Society of Australia), Aout 2017. “Perianalfistulizing Crohn’s disease” ; “Understanding and targeting gut inflammationand the microbiome – one size fits all?”; “Looking to the future in IBD: NewTherapies and New Opportunities”

- Symposium Falk, Octobre 2017. “Autologous HSCT inrefractory Crohn’s disease”

- Japan Digestive Disease Week, Fukuoka, Octobre 2017.“Spotlight on severity and prognosis in Crohn's Disease: When top-down-whenbottom-up”

- UEGW, Barcelone, Octobre 2017. Session Immunotherapyin cancer: “Manipulation of the immune system: lessons from IBD”; Clinicaltrials in Crohn’s disease: “State-of-the-art introduction”

- Annual Congress of the Lebanese Society ofGastroenterology (16th), Beyrouth, Novembre 2017. “Biologic therapy in IBD: howand when?”

- Curso “Miquel Angel Gassull” sobreEnfermedades Inflamatorias Intestinales, Barcelone, Novembre 2017. “Hematopoieticvs. mesenchymal stem cell transplantation: Mechanisms of action and futureprospects”

- ECCO, 7th S-ECCO IBD Masterclass: Cutting edge IBDsurgery. “Advanced endoscopy will solve - dilatation and stenting”

L. Le Bourhis.

InternationalCongress of Mucosal Immunology (oral presentation). T Cell Receptor RepertoireAnalysis Predicts Post-Operative Recurrence in Crohn's Disease: A Study fromthe REMIND Group. Washington, DC, USA.

Poster

2022 :

‍

S. Hamoudi. Société Française d’Immunology. Conférence annuelle. Nice, France.

L. Le Bourhis. Gordon ResearchConference. Immunochemistry and Immunobiology. Castelldefels, Spain. Intestinallymphoepithelial interactions in human diseases and its modulations inautologous co-cultures.

J. Bonnereau. Immuneresponses in Cancer and Infection. Lyon,France. Autologous T cell responses to primary human colorectal cancerspheroids are enhanced by ectonucleotidase inhibition

2020 :

‍

L. Rethacker. FOCIS2020: BRAF inhibitorresistance of melanoma cells triggers increased susceptibility to NaturalKiller cell-mediated lysis

2018 :

‍

H. Bottois. Mucosal immunologycourse and symposium Congress. Oxford, UK. KLRG1 and CD103 Expressions DefineDistinct Intestinal Tissue-Resident Memory CD8 T Cell Subsets Modulated inCrohn's Disease.

T. Courau. Keystone symposium:Cancer Immunotherapy: Combinations. Montreal, Canada. Cocultures of humancolorectal tumor spheroids with immune cells reveal the therapeutic potentialof MICA/B and NKG2A targeting for cancer treatment.

A. Frazao. ECI 2018Amsterdam: CD16⁺NKG2A^highNK cells from Tumor draining lymph nodes correlate with stage in Breast Cancerpatients

2017:

‍

T.Courau. Société Française d’Immunology. Conférenceannuelle. Reims. France. Cocultures of human colorectal tumor spheroids withimmune cells reveal the therapeutic potential of MICA/B and NKG2A targeting forcancer treatment.

K.Perez. UEGW. Vienna, Austria. Acomprehensive molecular classification of crohn’s disease using gene expressiondata.

Chapitred'ouvrage

Rethacker L., Dulphy N., and A. Caignard. (2021).Challenges for NK cell-based therapies: What can we learn from lymph nodes? “SuccessesAnd Challenges Of NK Immunotherapy. Breaking Tolerance To Cancer Resistance”.Ed. Elsevier Academic Press (ISBN 978-0-12-824375-6)

Travauxuniversitaires

Thèses

Julie Bonnereau : 2022. « The T cellanti-tumor response in human colorectal cancer : Autologous cocultures betweentumor spheroids and lymphocytes ». Université de Paris Cité

Nassim Hammoudi : 2021. « Study oflymphoepithelial interactions and their modulation as a therapeutic strategy inCrohn's disease ». Université de Paris Cité

LouiseRethacker : 2021 « Lescellules lymphocytaires innées dans l’immunosurveillance des tumeursmétastatiques ». Université de Paris Cité

KevinPerez : 2021. « Multi-omics characterization ofInflammatory Bowel Diseases ». Université de Paris Cité

MarieRoelens: 2020. « Caractérisation de l'hétérogénéitétumorale et du compartiment lymphocytaire T bénin dans les lymphomes T cutanés,de type Mycosis Fongoïde et syndrome de Sézary ». Université de Paris Cité

Hugo Bottois : 2019. « Acquisition andregulation of effector T cell functions in Crohn’s disease. » Universitéde Paris Cité

AlexandraFrazao : 2018. « Etude fonctionnelle de l'immunitéanti-tumorale des lymphocytes natural killer : De l'immunosurveillance autraitement. Paris Sorbonne Université

‍